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Abstract 
Meq is a viral c-Jun analog and member of the AP-1 transcription factor family that 
acts as the primary oncoprotein encoded by Marek’s disease virus. Previous studies have 
shown that Meq interacts with a variety of proteins as part of its pivotal function in the 
development of Marek’s disease virus-induced lymphoma.  
The primary focus of this study was to identify the global interactome of the Meq 
oncoprotein. This was initially carried out by review of the Meq sequence and the subsequent 
identification of BATF and BATF3 as potential analogous partners. Interactions with novel 
proteins were also predicted based on the nature of charged interactions that mediate a 
leucine zipper dimerisation event. Furthermore, the Meq protein was used as bait in a yeast 
two-hybrid screen to produce a large data set of both known and novel interacting proteins. 
Interactions with JunB, JunD and CtBP1 were confirmed along with a set of novel proteins 
including Par-4, ATF3, RACK1, N4BP1 and Pin1. The chicken Par-4 and ATF3 genes were 
cloned and expressed to confirm co-localisation with Meq in the cell nucleus while further 
biochemical investigations for each interaction were carried out by co-immunoprecipitation.  
The Par-4 and ATF3 proteins have been shown to play a variety of key roles in 
cellular mechanisms such as apoptosis, cell cycle regulation and transformation but we failed 
to see expression of these proteins in either normal or transformed lymphocytes. However, 
Par-4 and ATF3 are expressed in the feather follicle epithelium of infected birds providing 
the potential for a role during lytic infection in the skin. It is clear that more work is required 
in order to explore this hypothesis further but this thesis describes a number of novel 
interactions made by Meq and in doing so we have contributed to the greater understanding 
of Marek’s disease virology. 
  
3 
 
Table of Contents 
Abstract ...................................................................................................................................... 2 
Table of Contents ....................................................................................................................... 3 
Table of Figures ......................................................................................................................... 8 
Table of Tables ........................................................................................................................ 10 
Abbreviations ........................................................................................................................... 11 
Acknowledgements .................................................................................................................. 15 
Declaration ............................................................................................................................... 16 
1 Introduction ...................................................................................................................... 17 
1.1 Introduction to oncogenesis ...................................................................................... 17 
1.2 Viral oncogenesis ...................................................................................................... 19 
1.3 Introduction to Marek’s disease virus ....................................................................... 21 
1.4 History of Marek’s disease virus ............................................................................... 22 
1.5 Classification and genome structure ......................................................................... 22 
1.6  Marek’s disease virus infection, life cycle and pathology ....................................... 26 
1.6.1 Infection ................................................................................................................. 26 
1.6.2 Early cytolytic phase ............................................................................................. 26 
1.6.3 Latency .................................................................................................................. 27 
1.6.4 Late cytolytic phase and productive infection ....................................................... 28 
1.6.5 Cell transformation ................................................................................................ 28 
1.7 Immunity to Marek’s disease .................................................................................... 30 
1.8 Vaccination................................................................................................................ 30 
1.9 Marek’s disease virus-encoded proteins of interest .................................................. 31 
1.10 Marek’s Disease virus-encoded microRNAs ............................................................ 33 
1.11 Marek’s disease virus-encoded EcoRI-Q fragment (Meq) gene ............................... 33 
1.11.1 The Meq protein .................................................................................................... 36 
1.11.2 Meq protein function ............................................................................................. 40 
1.11.3 Meq as a transcription factor ................................................................................. 41 
1.11.4 Meq during apoptosis ............................................................................................ 45 
1.11.5 Meq interacts with CtBP1...................................................................................... 45 
1.12 Prostate apoptosis response-4 ................................................................................... 46 
1.13 Activating transcription factor 3 ............................................................................... 55 
4 
 
1.14 Yeast two-hybrid screen ............................................................................................ 57 
1.15 Aim of this thesis....................................................................................................... 59 
2 Methods ............................................................................................................................ 60 
2.1 Solutions and buffers in appendix I........................................................................... 60 
2.2 Plasmids in appendix II ............................................................................................. 60 
2.3 Antibodies ................................................................................................................. 60 
2.4 Oligonucleotides........................................................................................................ 61 
2.5 Methods ..................................................................................................................... 62 
2.5.1 Leucine zipper interaction prediction .................................................................... 62 
2.5.2 Phylogenetic analysis ............................................................................................ 62 
2.5.3 Plasmid DNA extraction – miniprep ..................................................................... 63 
2.5.4 Plasmid DNA extraction – maxiprep..................................................................... 63 
2.5.5 Glycerol stock production ..................................................................................... 64 
2.5.6 Molecular cloning .................................................................................................. 64 
2.5.7 Polymerase chain reaction ..................................................................................... 65 
2.5.8 Reverse transcription polymerase chain reaction .................................................. 66 
2.5.9 Transformation of chemically competent E. coli .................................................. 66 
2.5.10 Transformation of electro-competent E. coli ......................................................... 67 
2.5.11 Nucleic acid electrophoresis .................................................................................. 67 
2.5.12 SDS protein electrophoresis .................................................................................. 67 
2.5.13 Transfection of DF-1 cells ..................................................................................... 68 
2.5.14 Transfection of HeLa cells .................................................................................... 68 
2.5.15 Transfection of PC-3 cells ..................................................................................... 69 
2.5.16 Transfection of CEF cells ...................................................................................... 69 
2.5.17 Coomassie brilliant blue staining .......................................................................... 70 
2.5.18 Silver staining ........................................................................................................ 70 
2.5.19 Western blot ........................................................................................................... 70 
2.5.20 Immunofluorescent staining of cells ...................................................................... 71 
2.5.21 Immunofluorescent staining of tissues .................................................................. 71 
2.5.22 GST protein purification ........................................................................................ 72 
2.5.23 GST pull-down ...................................................................................................... 73 
2.5.24 Co-immunoprecipitation ........................................................................................ 73 
2.5.25 Luciferase reporter assay ....................................................................................... 74 
5 
 
2.5.26 Yeast competent cell production ........................................................................... 75 
2.5.27 Yeast cell transformation ....................................................................................... 75 
2.5.28 Yeast cell mating ................................................................................................... 76 
2.5.29 Annexin-V apoptosis assay ................................................................................... 77 
2.5.30 Poly ADP ribose polymerase (PARP-1) cleavage assay ....................................... 77 
3 Global Meq interactome ................................................................................................... 78 
3.1 Introduction ............................................................................................................... 78 
3.2 Meq phylogenetic analysis ........................................................................................ 80 
3.3 Predicted interactions mediated by the Meq leucine zipper ...................................... 88 
3.4 Yeast two-hybrid library screen ................................................................................ 90 
3.4.1 Protein expression.................................................................................................. 90 
3.4.2 Autoactivation assay .............................................................................................. 91 
3.4.3 Toxicity assay ........................................................................................................ 92 
3.4.4 Yeast mating .......................................................................................................... 92 
3.4.5 Yeast two-hybrid clone analysis ............................................................................ 96 
3.4.6 Yeast two-hybrid back screen ................................................................................ 99 
3.5 Meq interactions by LC-MS/MS analysis ............................................................... 101 
3.6 Discussion ............................................................................................................... 103 
3.6.1 Meq phylogenetic analysis .................................................................................. 103 
3.6.2 Predicted Meq interactions mediated by the leucine zipper ................................ 104 
3.6.3 Yeast two-hybrid screen ...................................................................................... 106 
4 Meq interacts with Prostate apoptosis response 4 .......................................................... 115 
4.1 Introduction ............................................................................................................. 115 
4.2 Prostate apoptosis response-4 ................................................................................. 116 
4.3 Chicken Par-4 cloning ............................................................................................. 118 
4.4 Par-4 expression in chicken cells ............................................................................ 122 
4.5 Par-4 protein expression in tissue ........................................................................... 124 
4.6 Par-4 protein expression in splenocytes .................................................................. 125 
4.7 Par-4 cellular localisation ........................................................................................ 128 
4.8 Meq and Par-4 co-localise in the cell nucleus ......................................................... 130 
4.9 Meq interacts with Par-4 ......................................................................................... 132 
4.10 Meq reduces Par-4 mediated apoptosis ................................................................... 136 
4.11 Discussion ............................................................................................................... 141 
6 
 
4.11.1 Prostate apoptosis response-4 .............................................................................. 141 
4.11.2 Chicken Par-4 cloning ......................................................................................... 142 
4.11.3 Par-4 expression in chicken cells......................................................................... 144 
4.11.4 Par-4 expression in chicken tissue ....................................................................... 145 
4.11.5 Par-4 cellular localisation .................................................................................... 146 
4.11.6 Par-4 leucine zipper ............................................................................................. 147 
4.11.7 Meq and Par-4 interact via the leucine zipper ..................................................... 148 
4.11.8 Meq and Par-4 during apoptosis .......................................................................... 148 
5 Meq interacts with Activating Transcription Factor 3 .................................................... 150 
5.1  Introduction ............................................................................................................. 150 
5.2 Cloning chicken ATF3 ............................................................................................ 151 
5.3 ATF3 expression in chicken cells ........................................................................... 154 
5.4 MDV infection results in increased ATF3 gene expression ................................... 156 
5.5 ATF3 expression in feather follicle epithelium....................................................... 158 
5.6 Chicken ATF3 co-localises with Meq ..................................................................... 160 
5.7 Meq interacts with ATF3 via the Meq leucine zipper domain ................................ 163 
5.8 Identification of ATF3 binding sites in the MDV genome ..................................... 165 
5.9 MDV-encoded and host gene regulation by Meq and ATF3 .................................. 165 
5.10 Discussion ............................................................................................................... 171 
5.10.1 Chicken ATF3 ..................................................................................................... 171 
5.10.2 ATF3 expression in chicken cells ........................................................................ 171 
5.10.3 ATF3 in the feather follicle epithelium ............................................................... 172 
5.10.4 Chicken ATF3 co-localises with Meq ................................................................. 173 
5.10.5 Meq interacts with chicken ATF3 ....................................................................... 173 
5.10.6 ATF3 in the MDV genome .................................................................................. 174 
5.10.7 ATF3 and the host genome .................................................................................. 175 
6 General Discussion, further work, and conclusions ....................................................... 176 
6.1 Discussion and further work ................................................................................... 176 
6.2 Summary of results.................................................................................................. 187 
6.2.1 Chapter 3 Global Meq interactome ..................................................................... 187 
6.2.2 Chapter 4 Meq interacts with Prostate apoptosis response-4 .............................. 187 
6.2.3 Chapter 5 Meq interacts with Activating transcription factor-3 .......................... 188 
6.3 Concluding remarks ................................................................................................ 188 
7 
 
References .............................................................................................................................. 189 
Appendix I ............................................................................................................................. 200 
Tissue culture ..................................................................................................................... 200 
Yeast cell culture ................................................................................................................ 202 
Bacterial cell culture........................................................................................................... 206 
Protein analysis .................................................................................................................. 207 
Appendix II ............................................................................................................................ 212 
 
  
8 
 
Table of Figures 
Figure 1.1 MDV genome map and herpesvirus family members …………………….. 25 
Figure 1.2 MDV life cycle and pathogenesis………………………………………….. 29 
Figure 1.3 Meq gene and protein sequence……………………………………………. 35 
Figure 1.4 The Meq gene and splice variations………………………………………... 39 
Figure 1.5 Schematic representation of the basic leucine zipper………………………. 43 
Figure 1.6 Leucine zipper dimerisation and specificity………………………………... 44 
Figure 1.7 Par-4 interacts with WT1 to bind the Bcl-2 promoter……………………… 48 
Figure 1.8 Par-4 interacts with PKCζ to regulate NFκB activation and apoptosis…….. 49 
Figure 1.9 Protein kinase A activates Par-4 and promotes apoptosis by NFκB activation 
……………………………………………………………………………………………… 52 
Figure 1.10 Par-4 extrinsic apoptosis pathway………………………………………….. 53 
Figure 1.11 Yeast two-hybrid screen for interacting protein partners…………………... 58 
Figure 3.1 Phylogenetic analysis of Meq and cellular leucine zipper containing proteins 
……………………………………………………………………………………............... 84 
Figure 3.2 Phylogenetic analysis of Meq and cellular functional leucine zipper residues 
……………………………………………………………………………………………… 85 
Figure 3.3 Phylogenetic analysis of Meq and cellular DNA binding domains………... 86 
Figure 3.4 Yeast two-hybrid bait protein expression and yeast strain mating…………. 94 
Figure 3.5 Yeast two-hybrid back screening analysis of positive interactions………… 100 
Figure 3.6 Meq and L-Meq co-immunoprecipitation for LC-MS/MS interactions analysis 
……………………………………………………………………………………............... 102 
Figure 3.7 The Meq interaction with N4BP1 functional hypothesis…………………... 109 
Figure 3.8 Pin1 cis-trans isomerase binding sites in the Meq c-Jun amino acid sequence 
……………………………………………………………………………………………… 113 
Figure 4.1 Yeast two-hybrid clone 25 corresponds to the Par-4 open reading frame…. 117 
Figure 4.2 Chicken Par-4 PCR amplification and cloning…………………………….. 120 
Figure 4.3 Chicken Par-4 amino acid sequence and alignment………………………... 121 
Figure 4.4 Par-4 protein and mRNA expression in chicken cell lines…......................... 123 
Figure 4.5 Par-4 protein expression in a chicken tissue panel…………………………. 126 
Figure 4.6 Par-4 protein expression in chicken splenic lymphocytes…………………..127 
9 
 
Figure 4.7 The partial chicken Par-4 protein localises to the cell nucleus and induces 
apoptosis…………………………………………………………………………………….129 
Figure 4.8 Meq and Par-4 co-localise in the cell nucleus……………………………… 131 
Figure 4.9 Meq helical wheel leucine zipper interaction………………………………. 133 
Figure 4.10 Par-4 interacts with Meq but not the Meq
BZIP
 mutant……………………… 135 
Figure 4.11 Meq decreases Par-4 mediated apoptosis in DF-1 cells……………………. 138 
Figure 4.12 Meq decreases Par-4 mediated apoptosis in PC-3 cells……………………. 139 
Figure 4.13 Par-4 mediated PARP-1 cleavage in PC-3 cells……………………………. 140 
Figure 5.1 Alignment of ATF3 protein homologs……………………………………... 153 
Figure 5.2 ATF3 antibody test and expression profile in MDV-transformed cell lines.. 155 
Figure 5.3 ATF3 transcript levels increase upon MDV infection…............................... 157 
Figure 5.4 Chicken ATF3 is expressed at the feather follicle epithelium……………... 159 
Figure 5.5 ATF3 co-localises with Meq in the cell nucleus…........................................ 161 
Figure 5.6 ATF3 localisation in DF-1 cells……………………………………………. 162 
Figure 5.7 ATF3 interacts with Meq but not the Meq
BZIP
 mutant…………………….. 164 
Figure 5.8 ATF3 binding sites in the MDV genome….................................................. 167 
Figure 5.9 Meq and ATF3 up-regulate the MDV glycoprotein I promoter region……. 168 
Figure 5.10 Host and MDV-encoded gene transcript expression after MDV infection… 169 
Figure 5.11 qRT-PCR analysis of cellular ATF3 targets……………………………….. 170 
Figure 6.1 Par-4 and apoptosis pathway analysis……………………………………… 181 
  
10 
 
Table of Tables 
Table 2.1 Antibodies………………………………………………………………….. 60 
Table 2.2 Oligonucleotides………………………………………………………….... 61 
Table 3.1 Meq and chicken leucine zipper protein alignment………………………... 83 
Table 3.2 BATF and BATF3 leucine zipper mediated interactions………………….. 87 
Table 3.3 Meq known and predicted leucine zipper interactions…………………….. 89 
Table 3.4 Meq
(1-129)
 and Meq
(130-339)
 yeast two-hybrid screen………………………. 95 
Table 3.5 Meq
(1-129)
 yeast two-hybrid positive interacting clones……………………. 97 
Table 3.6 Meq
(130-339)
 yeast two-hybrid positive interacting clones……………..... 98 
  
11 
 
Abbreviations 
aa  Amino acid 
AATF  Apoptosis antagonising transcription factor 
-Ade  Adenine dropout 
Akt  v-akt murine thymoma viral oncogene homolog 
ALV  Avian leukosis virus 
AP-1  Activating protein 1 
ATF  Activating transcription factor 
BATF  Basic activating transcription factor 
Bcl-2  B-cell lymphoma 2 
BR1  Basic region 1 
BR2  Basic region 2 
bZIP  Basic leucine zipper 
CD4+  Cluster of differentiation 4 positive 
CD8+  Cluster of differentiation 8 positive 
CDK  Cyclin D kinase 
cDNA  Complementary DNA 
CEBPβ CCAAT/enhancer binding protein 
CEF  Chicken embryo fibroblasts 
CKC  Chicken kidney cells 
CMV  Cytomegalovirus 
CRE  Cyclic AMP response element 
CREB  Cyclic AMP response element binding protein 
CtBP1  C-terminal binding protein 1 
DDO  Double dropout 
DNA  Deoxyribose nucleic acid 
dsDNA Double stranded DNA 
EBV  Epstein Barr-virus 
12 
 
FADD  Fas (TNFRSF6)-associated via death domain 
FFE  Feather follicle epithelium 
G1  Growth phase 1 
G2  Growth phase 2 
HA  Haemagglutinin  
HeLa  Henrietta Lacks cells 
HSV  Herpes Simplex virus 
HVT  Herpes virus of turkeys 
ICP4  Infected cell peptide 4 
IFN-γ  Interferon gamma 
IKKB  Inhibitor of kappa light polypeptide enhancer in B-cells, kinase beta 
IL  Interleukin 
IRS  Internal repeat short 
KSHV  Kaposi’s sarcoma virus 
LANA2 latency associated nuclear antigen 2 
LAT  Latency associated transcript 
LC  Liquid chromatography 
-Leu  Leucine dropout 
LL  Lymphoid leucosis 
L-Meq  Large Meq 
LRF-1  Liver regenerative factor 1 
LZ  Leucine zipper 
M  Mitosis 
MD  Marek’s Disease 
MDV  Marek’s disease virus 
MEQ  Marek’s disease virus EcoRI-Q fragment 
Meq
(1-129)
 Meq amino acid residues 1 – 129 
Meq
(130-330)
 Meq amino acid residues 130 – 339 
MERE  Meq response element 
13 
 
MHC  Major histocompatibility complex 
miRNA Micro RNA 
mRNA  Messenger RNA 
MS  Mass spectrometry 
N4BP1 Nedd-4 binding protein1 
NFκB  Nuclear factor of kappa light polypeptide gene enhancer in B-cells  
NLS  Nuclear localisation signal 
NoLS  Nucleolar localisation signal 
Ø  Macrophage 
OD  Optical density 
Par-4  Prostate apoptosis response 4 
Par-4
(125-340)
 Par-4 amino acids from ~125 – 340 
PC-3  Prostate cancer 3 cells 
PCR  Polymerase chain reaction 
Pin1  Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 
PKA  Protein kinase A 
PKC  Protein kinase C 
Pp38  Phosphoprotein 38 
pRB  Retinoblastoma protein 
QDO  Quadruple dropout 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RACE  Rapid amplification of cDNA ends 
RACK1 Receptor of activated protein kinase C 1 
RNA  Ribonucleic acid 
RT-PCR Reverse transcription polymerase chain reaction 
S  Synthesis 
SAC  Selective for apoptosis in cancer cells domain 
SD  Selective dropout 
S-Meq  Small Meq 
14 
 
TCR  T-cell receptor 
TDO  Triple dropout 
TH-2  T-helper 2 
THABS THAP binding sequence 
THAP  Thanatos associated protein 
TLR  Toll like receptor 
TRE  Tetradecanoylphorbol acetate response element 
TRL  Terminal repeat long 
-Trp  Tryptophan dropout 
UL  Unique long 
US  Unique short 
UTR  Untranslated region 
UV  Ultraviolet 
VS-Meq Very small Meq 
VV+  Very virulent plus 
VZV  varicella-zoster virus 
Wt  Wild type 
WT1  Wilm’s tumour protein 1 
X-α-Gal X-alpha galactosidase 
Y2H  Yeast two-hybrid 
YPD  Yeast Extract Peptone Dextrose 
ZAD  Zinc finger associated domain 
  
15 
 
Acknowledgements 
 This research was funded by the Biotechnology and Biological Science Research 
Council and without their financial support it would not have been possible. I would firstly 
like to thank Venugopal Nair and Martin Allday for their support and continued enthusiasm 
for me and my work. This research could not have been completed without the daily 
supervision of Sue Baigent and for that I am tremendously grateful. I would also like to thank 
past and present members of the Viral Oncogenesis laboratory at Compton. Lorraine Smith 
was instrumental in teaching me the art of cell culture and the guys (you know who you 
are…..) were a source of unrelenting entertainment. Finally, I would like to thank and 
dedicate this thesis to my loving wife Gabrielle because without her it would not have been 
possible. 
  
16 
 
Declaration  
The research presented in this thesis is my own work except where indicated 
otherwise. The study was carried out at the Institute for Animal Health and registered at 
Imperial College London under the supervision of Professor Venugopal Nair and Professor 
Martin Allday. 
 
James S. Green   
  
17 
 
1 Introduction 
1.1 Introduction to oncogenesis 
 Oncogenesis is a broad term that is used to describe the development of cancer within 
an affected organism. Also known as carcinogenesis or tumourigenesis the term encapsulates 
the process by which a cell undergoes neoplastic transformation in order to become a cancer 
cell and also the subsequent development of neoplastic lesions. This process is regulated by a 
huge variety of events within the cell from oncogene expression to genetic mutation. 
However, ultimately it is the reprogramming of a normal cell so that it will undergo rapid and 
uncontrolled cell division.  
 A key controlling mechanism of oncogenesis is the delicate balancing act played out 
by the expression of tumour suppressor molecules and oncogenes. As their names suggest, 
tumour suppressors act to prevent the formation of cancer cells. This may be through protein-
protein interactions, transcription factor activity, transcription repression activity or 
otherwise. These mechanisms then halt the development of cancer by a variety of pathways 
including apoptosis, cell cycle regulation or proliferation regulation. Oncogenes on the other 
hand work against tumour suppressors in order to promote the formation of a cancer cell. 
They, like tumour suppressors have the ability to regulate the cell through a variety of 
processes but with the opposing outcome. 
 The first tumour suppressor molecule to be identified was retinoblastoma protein 
(pRB) (Knudson 1971). pRB is a major contributing factor to cell cycle regulation and has 
been shown to be pivotal in the controlled progression through G1 phase by binding and thus 
inactivating transcription factors involved in cell cycler progression (Korenjak & Brehm 
2005). In effect, pRB acts as a barrier against a potentially cancerous cell diving. However, 
with such a vital function this leaves the cell exposed if pRB is missing or non-functional. 
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This is particularly evident in the double pRB mutation that leads to the development of 
retinoblastoma and contributed to the further understanding of the two-hit hypothesis.  
 Although pRB was the first tumour suppressor molecule to be described in the 
literature it is perhaps overshadowed by another member of the family. p53 is another cell 
cycle regulatory protein that has the ability to initiate DNA repair and apoptosis and due to its 
role in cancer suppression has been coined the guardian of the genome (Efeyan & Serrano 
2007).  
 A huge varity of oncogenes have been identified over the last century. Perhaps the 
most widely studied are the proto-oncogenes RAS and MYC. As proto-oncogenes they are 
normal genes expressed by the cell that have the ability to act as oncogenes due to high 
expression levels or mutations in the amino acid sequence. As proto-oncogenes RAS and 
MYC act in different ways but ultimately their over expression results in the regulation of 
pro-proliforatory proteins such as RAF, MAPKK and MAPK (Pylayeva-Gupta et al 2011). 
However, oncogenes may not only be expressed by the host genome. The first 
observations of a transforming retrovirus were made in 1911 by Payton Rous (Rous 1911) but 
it was only later linked to infection by a microbiological agent.  The oncogene encoded by 
Rous sarcoma virus is known as v-Src and it was first cloned over half a century after the 
initial observations by Rous (Duesberg at al 1976). The Src protein is a tyrosine kinase that 
was hijacked from the host in order to regulate cell signalling events that in turn lead to 
increased proliferation and oncogenesis.  
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1.2 Viral oncogenesis 
 A large variety of viruses harbour the ability to induce oncogenesis. The centenary of 
the identification of the retroviral Rous Sarcoma virus (RSV) has recently passed but since its 
discovery, increased interest in the subject has resulted in the identification of a startling 
number of cancer inducing viruses.  
Cancer causing retroviruses such as RSV and Human T-lymphotropic virus 1 (HTLV-
1) enter the host cell by recognition of surface antigens (Jones et al 2011) and use the host’s 
transcription machinery to transcribe their genomes. The virus genome is then integrated into 
the host genome where it may become latent or begin expression of pro-virally encoded 
transcripts. In the case of HTLV-1 the Tax oncoprotein is expressed and subsequently 
interacts with CDK4 and Cyclin D in order to force the cell through G1/S phase of the cell 
cycle (Haller 2002). This in turn results in the uncontrolled proliferation of infected cells that 
ultimately become cancerous as a result.  
 However, it is not only RNA viruses that have been implicated in the development of 
cancer. Hepatitis B and Hepatitis C infection has long been linked to the development of 
hepatocellular carcinoma (McGivern & Lemon 2011). Each of which encode several 
oncogenes that have been shown to be pivotal in the progression of liver carcinoma (Koike 
2009).  
 Perhaps the most widely recognised oncogenic virus is Human Papilloma virus (HPV) 
and its relationship with the development of cervical cancer. Infection is through the basal 
membrane and persists in keratinocytes before resulting in warts, and in a small proportion of 
cases, cancer of the cervix (Munger 2002). As with all cancer viruses HPV encodes several 
genes that are linked to the development of oncogenesis. E6 and E7 work to supress the 
tumour suppressor activity of p53 and pRB respectively (Yugawa & Kiyono 2009) and 
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having discussed the importance of p53 and pRB earlier in this chapter, it is perhaps not 
surprising that the suppression of these proteins by the HPV oncogenes can lead to 
oncogenesis. 
 Finally, herpesviruses have long been implicated in the development of many 
different cancers. Kaposi’s Sarcoma-associated herpesvirus (KSHV) and Eptein barr-virus 
(EBV) are well known oncoviruses that act in different ways and in different target cell types 
to promote oncogenesis. KSHV encodes the vFLIP and LANA oncoproteins that are 
expressed during latency and act to prevent apoptosis and regulate cellular gene expression 
respectively (Nicholas 2007) whereas the EBV encoded latent membrane protein 1 (LMP1) 
utilises another mechanism. It interacts with members of the tumour necrosis factor receptor 
family in order to mediate NFκB activation and subsequently increases cellular proliferation 
(Mosialos et al 1995). More recent observations highlight the opportunistic nature of 
herpesvirses in the expression of non-coding RNA molecules. In the case of KSHV the 
oncogenic microRNA or oncomiR miR-K12-11 is a human miR-155 homologue that has 
been shown to target PU.1 and members of the Bcl-2 family.  
 Herpesviruses are large double stranded DNA viruses that encoded a huge number of 
genes and non-coding RNA molecules. It is clear that many of these genes interact with the 
host in order to regulate cell cycle progression, apoptosis and cell proliferation with the 
ultimate goal of oncogenesis. It is also the case that infection by many of the herpesvirus 
family results in the development of cancer in model organisms and the further understanding 
of these viruses will aid us in grasping the extremely complex story of herpesviral 
oncogenesis. 
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1.3 Introduction to Marek’s disease virus  
Marek’s disease (MD) was first described by Jόzsef Marek in 1907 as general 
polyneuritis in the domestic chicken (Marek 1907). Later observations by Pappenheimer et al 
reported the formation of lesions in the kidneys, liver, muscles, lymphoid organs and iris of 
affected chickens (Pappenheimer et al 1926). It was not until the late 1960’s, over a decade 
after the death of Jόzsef Marek, that the disease was differentiated from avian leukosis and 
subsequently shown to be the result of infection by a member of the herpesvirus family 
(Churchill 1968; Churchill & Biggs 1968). Marek’s disease virus (MDV) was originally 
thought to be a member of the γ-herpesvirus sub-family due to pathological similarities to 
disease caused by Epstein-Barr virus (EBV) (Kato 1972) but was later re-classified in the α-
herpesvirus sub-family (Cebrian et al 1982) with Herpes Simplex virus (HSV). The isolation 
of MDV and subsequent attenuation in cell culture resulted in the loss of oncogenicity 
(Churchill et al 1969a) which in turn led to the production of the first widely used vaccine 
against a neoplastic disease (Churchill et al 1969b), a feat that has only recently been 
paralleled with the production of the human papilloma virus vaccine. Although MDV 
vaccines have been used successfully during the previous 40 years, the continuous evolution 
of the virus and the resulting increase in virulence has necessitated the introduction of more 
effective vaccines (Witter 1997). This and the phenotypic similarities of MD tumours to those 
caused by EBV have prompted the increased study of the virus and the resulting natural 
disease model.  
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1.4 History of Marek’s disease virus 
Early descriptions of MD suggested it was a condition that only affected the nervous 
system, hence the attributed names polyneuritis and neuromyelitis (Kaup 1921; Marek 1907). 
The first report of lymphoma directly resulting from infection was a leap in understanding but 
subsequently made differentiation between MD and lymphoid leukosis (LL) particularly 
difficult. The pathology of MD lymphoma is comparable to the lymphocyte infiltration seen 
in the nerves after infection by avain leukosis virus (ALV) (Pappenheimer et al 1926) and 
differentiation between the two disorders remained  problematic. The similarities led to 
mixed terminology and even some groups around the world being unaware of which disease 
and virus they were actually working with. An international committee was assembled to 
rectify the confusion. It proposed the blanket term of lymphomatosis in relation to all fowl 
paralysis with sub-groups designated ocular, neural and visceral lymphomatosis. This 
however, did not resolve the situation as lymphoid leukosis was still classified in the same 
sub-group as an MDV infection that presents with visceral lymphoma. In 1960 the problem 
became so severe that it threatened to compromise all further research into the increasingly 
more confused subject of lymphomatosis. This prompted the first world veterinary poultry 
association to request Biggs and Campbell to present papers on classification of 
lymphomatosis (Biggs 1961; Campbell 1961). They both concluded that the disease 
identified by the early work of Ellerman was to be termed leukosis and that described by 
Jόzsef Marek and further studied by Pappenheimer would from then on be known as MD . 
 
1.5 Classification and genome structure 
The first evidence that MD was caused by viral infection came from studies by 
Churchill and Biggs in the late 1960’s. They incubated whole blood of infected birds with 
chicken kidney cells (CKC) and monitored the resulting cytopathic effect. They concluded 
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that this effect was due to infection by a herpesvirus (Churchill & Biggs 1967). The 
lymphoproliferative nature of the disease suggested that it grouped with viruses such as the 
more recently discovered Kaposi’s Sarcoma-associated herpesvirus (KSHV) and EBV in the 
γ-herpesvirus sub-family. However, with the later application of restriction enzyme fragment 
mapping and electron microscopy, this proved contrary to the hypothesis. The MDV genome 
structure was shown to more closely resemble that of Herpes Simplex virus (HSV) and so 
was re-classified in the α-herpesvirus family of the Mardivirus genus (Cebrian et al 1982; Lee 
et al 1982). 
The MDV genome is approximately 174kb in size and codes for upwards of 100 
genes (Osterrieder et al 2006) and 13 microRNAs (Yao et al 2008). The diagrammatic 
structure of the MDV genome shown in Figure 1.1A consists of a unique long region (UL) 
flanked by a terminal repeat long region (TRL) and an internal repeat long region (IRL), and a 
unique short region (US) flanked by a terminal repeat short region (TRS) and an internal 
repeat short region (IRS) (Fukuchi et al 1984; Fukuchi et al 1985). The unique regions contain 
single copies of each gene but all genes encoded in the repeat regions are replicated in the 
corresponding repeat region. As previously mentioned, the genomic organisation of MDV is 
similar to that of Herpes Simplex virus (HSV) (Figure 1.1B) but there is a high level of 
homology at the genomic level with varicella-zoster virus (VZV) (Buckmaster et al 1988). 
This comparison extends to the life cycle of VZV and its relationship with the nervous 
system and skin of the infected host. 
It is not only gene organisation and structure that MDV has in common with other 
members of the herpesvirus family. The expression of non-coding RNAs is a well-studied 
trait associated with a number of herpesviruses and it is one that is shared by MDV [reviewed 
in (Burnside & Morgan 2007)]. In humans a diverse set of microRNAs are thought to target 
as much as 30% of the genes encoded by the human genome (Lewis et al 2005) which 
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suggests a huge and as yet mostly unexplored method of post transcriptional regulation.  
MDV encodes two clusters of microRNAs that contain a total of 13 microRNAs. The Meq 
cluster, so called because of its proximity to the Meq gene, encodes 6 microRNAs while the 
remaining 7 are found in the latency associated transcript (LAT) cluster (Burnside et al 
2006). These microRNAs have been shown to have a diverse and in some cases vital 
oncogenic function while new targets are being described on a regular basis.  
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Figure 1.1 MDV genome map and herpesvirus family members. A. MDV dsDNA 
genome is ~174kb in size. It consists of a unique long region (UL) that is flanked by a 
terminal repeat long region (TRL) and an internal repeat long region (IRL), and a unique short 
region (US) that is flanked by a terminal repeat short region (TRS) and an internal repeat short 
region (IRS). Genes are encoded by both positive and negative strands (direction indicated by 
arrows). B. The genomic organisation of the herpesvirus family members for comparison (not 
to scale).  
A. 
B. 
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1.6  Marek’s disease virus infection, life cycle and pathology 
  MDV infection leads to the development of gross lesions in lymphatic organs, 
polyneuritis and lymphocyte infiltration through the blood-brain barrier. The characteristic 
lymphoma observed after MDV infection consist of an aggregation of transformed CD4
+
 T-
cells. These lymphatic lesions are the most widely studied of the MDV associated pathologies 
but transformed T-cells have also been observed in the brain of chickens infected with very 
virulent plus (VV+) strains. Although the pathology of MD has been investigated by many 
groups around the world for nearly half a century, little is still known about the events 
leading to T-cell transformation. 
 
1.6.1 Infection 
 Dust and dander shed by infected bird is the underlying cause of MDV infection and 
spread. Chickens infected with MDV shed dust into the poultry house environment and this 
dust harbours what appears to be viable cell-free MDV. Natural infection caused by this dust 
is by uptake into the respiratory system.  
 
1.6.2 Early cytolytic phase 
 Infected dust is taken up into the lungs were macrophages are thought to phagocytose 
the infected dust particles. These cells can then act as transporter cells that enter the blood 
stream and allow the virus to infect cells in primary lymphatic tissues such as the spleen. 
Macrophages have also been shown to be a target for cytolytic infection by expression of the 
early MDV antigens ICP4 and pp38 (Barrow et al 2003). These macrophages also exhibit a 
high death rate which suggests they are resident in early cytolytic infection.  
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 It is thought that the primary targets in the spleen are the B-cells present around the 
ellipsoid-associated reticular cells (Jeurissen et al 1989). This is due to their proximity to the 
splenic blood supply which would provide an efficient target. When infected, these cells 
progress into an acute cytolytic infection that results in T-cell activation. As resting T-cells 
are resistant to infection, it is this activation that is thought to render them susceptible to 
MDV infection. It is not known how the virus is passed between cell types during these early 
stages of infection but it is thought that the close proximity of infected cells during cytolytic 
infection may play a crucial role. This is something currently under investigation in our group 
using live cell imaging. 
 
1.6.3 Latency 
 Based on the current model, MDV infection progresses into the latency stage at 
roughly 7 days post infection depending on the virulence of the specific strain. As with all 
members of the herpesvirus family, this results in a halt to viral antigen expression in order to 
avoid detection by the host immune system. It is thought that latently infected T-cells are 
those that later undergo transformation but the mechanisms and dynamics of such 
transformation events are not fully understood. Control of latency is also under debate as 
there seems to be many factors involved in the maintenance of this stage of viral infection. It 
has been suggested that a latency maintaining factor may be responsible (Buscaglia & Calnek 
1988) but recent studies also implicate cytokines such as IL-6 and IFN-γ in establishment and 
maintenance (Xing & Schat 2000a; b). The viral genome is maintained during latency but 
transcription is limited to the latency associated transcripts (LAT). These genes are thought to 
be pivotal to the link between latency and lytic infection. The LAT genes that map antisense 
to the infected cell peptide 4 (ICP4) gene have been shown to suppress translation of ICP4 
that in turn prevents progress into the late lytic phase (Cantello et al 1997). 
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1.6.4 Late cytolytic phase and productive infection 
 Late cytolytic infection is characterised by a second wave of productive infection 
termed reactivation. With this comes full immunosuppression and can results in the 
development of lesions in all lymphatic tissues. During productive stages of MD, the 
infection spreads to the feather follicle epithelium which in turn allows shedding of cell-free 
virus into the environment. It is thought that MDV glycoprotein D is important for the 
production of cell-free viral particles as it is found expressed at high levels in the feather 
follicle epithelium. However, this is something that required further investigation. 
 
1.6.5 Cell transformation 
 Transformation is the process by which a normal cell is turned into an immortalised 
cancer cell. In the case of MDV infection the mechanism of T-cell transformation is not fully 
understood. It was originally thought that the spleen was the organ of proliferation but this 
has since been disproved as birds lacking a spleen still develop tumours, although at later 
time points (Schat 1981).  
  MDV transformed T-cells have several characteristics that are important in 
understanding the disease as a whole and when relating it to human disease. Perhaps the most 
significant of which is the gross over-expression of the Hodgkin’s disease antigen CD30 in 
MDV-transformed T-cells (Burgess et al 2004). This shared phenotype with Hodgkin’s 
disease lymphoma initially paved the way for the application of MD as a natural disease 
model but little work has been carried out in this regard.  MDV-transformed T-cells exhibit 
the phenotype of CD4
+
, CD30
hi
, MHCI
hi
, MHCII
hi
, IL2 receptor-α+, CD28lo/- and T-cell 
receptor αβ+ which is consistent with a transformed activated memory TH-2 cell (Burgess & 
Davison 2002).  
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Figure 1.2 MDV life cycle and pathogenesis. Cell-free virus is taken up via the respiratory 
route and phagocytosed by macrophages in the lungs. These phagocytic cells then act as 
carrier cells by entering the blood stream and delivering virus to B-cells in secondary 
lymphatic tissues. These cells become lytically infected and die but not before triggering an 
activated T-cell response. These cells then become infected and latency follows. Cell 
transformation is a result of latent infection and lesions develop in all lymphatic tissues. 
Productive infection is characterised by viral particles in the feather follicle epithelium and 
the shedding of cell-free virus into the environment (adapted from Davidson & Nair 2004).  
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1.7 Immunity to Marek’s disease 
Immunity to MDV is thought to be complex and involves multiple pathways. Cell-
mediated responses to MDV and all herpesvirus infections are governed by CD8
+
 cytotoxic 
T-cells that secrete cytokines. This was ascertained by the application of classical depletion 
assays whereby in vitro depletion of CD4
+, TCRγδ+ and TCRαβ2+ all resulted in no effect 
(Omar & Schat 1996). The same authors described an increase in IFN-γ at 3 days post 
infection (Xing & Schat 2000a; b) which was later confirmed by several other groups (Kaiser 
et al 2003). The cell mediated response was also shown to result in the increase of several 
other cytokines including IL-6 and IL-18 (Kaiser et al 2003). However, the targets and 
mechanisms by which this cytokine repertoire acts are not fully understood and require 
further investigation.  
 Antibodies have also been shown to play a key role in immunity to MDV. We have 
shown recently that maternal antibodies from vaccinated and infected hens clearly play a role 
in the delay of classical MD pathology while also reducing mortality (S. Baigent personal 
communication). However, an antibody response against MDV is also mounted after 
vaccination with HVT and subsequent challenge (Lee & Witter 1991). Although it is clear 
that the production of antibodies against MDV is advantageous to the infected host, the 
mechanism by which they act is yet to be fully elucidated. 
 
1.8 Vaccination 
 Vaccination against MDV was the first such preventative measure against a cancer 
causing agent. The first vaccine to be produced against MDV was attenuated by serial 
passage of the oncogenic HPRS-16 strain (Churchill & Chubb 1969). However, this vaccine 
was soon superseded by herpesvirus of Turkeys (HVT) (Witter et al 1970). HVT is a non-
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oncogeneic serotype 3 strain that confers full protection from MD pathology and mortality. 
HVT vaccines are still used, but often as bivalent vaccines with other strains such as SB-1, a 
non-oncogenic serotype 2 Mardivirus (Schat & Calnek 1978). As suggested above, SB-1 is 
often used with HVT as a bivalent vaccine to confer a higher level of protection from 
increasingly more virulent field strains (Calnek et al 1983). The naturally attenuated strain 
named CVI988 or Rispen’s vaccine was first used in the poultry industry in the Netherlands 
(Rispens et al 1972). This serotype 1 strain is still used to this day and is recognised as the 
gold standard for MD vaccination. However, current groups are working in order to ever 
increase vaccine efficiency by the generation of new strategies. One such new generation 
vaccine came with the identification of Meq as the primary oncogene encoded by MDV. It 
was shown that deletion of the Meq gene interferes with the lymphoma formation, and the 
virus was attenuated (Lupiani et al 2004). Further investigation prompted the hypothesis that 
such Meq-deleted (ΔMeq) viruses could be used as a vaccine strain. This was later confirmed 
(Lee et al 2008) but this vaccine is yet to be utilised in a commercial environment. 
 
1.9 Marek’s disease virus-encoded proteins of interest 
Several genes encoded by the MDV genome have been implicated in oncogenesis. 
The pp38 protein was first identified as an MDV specific antigen expressed by tumour cell 
lines (Cui et al 1990). However, the pp38 protein is only expressed in the lytic stages of 
infection and so is not thought to play a central role in transformation. This was further 
confirmed by the deletion of pp38 from the MDV genome to result in a virus that was 
restricted during in vivo lytic replication (Reddy et al 2002). Also, the deletion of pp38 did 
not affect tumour formation and so is not thought to be involved in tumourigenesis. 
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 Early gene transcription is thought to be regulated by expression of the infected cell 
peptide 4 protein (ICP4). The exact role of ICP4 during MDV-induced transformation is not 
yet known but it is clear that high levels of these transcripts are produced in latently infected 
cells. Also, it has been shown that a group of LAT that maps antisense to the ICP4 open 
reading frame can act as a molecular switch when regulating the transcription of ICP4 
demonstrating its importance to the virus (Cantello et al 1994). 
 The MDV-encoded telomerase RNA (vTR) was also identified as a potentially 
important transcript due to its high levels of expression in peripheral blood leukocytes of 
infected chickens (Fragnet et al 2003) and the pivotal role of the telomeric repeat regions 
(TMRs) during viral integration (Kaufer et al 2011b). It is only present in the oncogenic 
serotype 1 strains which suggest that it may be involved in the tumourigenic nature of these 
strains. Evidence also suggests that MDV encoded vTR is translocated to the nucleus by 
interaction with the cellular factor RPL22 but furthermore, this expression was shown to 
result in oncognesis in the absence of telomerase activity (Kaufer et al 2010). More recently, 
elegant mutational analysis of the vTR template sequence was carried out in order to 
demonstrate that this region is necessary for virus-induced tumourigenesis and furthermore, 
the authors suggest potential for the development of a new generation vaccine (Kaufer et al 
2011a). 
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1.10 Marek’s Disease virus-encoded microRNAs 
With the application of new technologies such as deep sequencing recent observations 
have identified a new class of non-coding RNA molecules present in most of the herpesvirus 
family (Pfeffer et al 2005). microRNAs are a group of short 22bp sequences that interact by 
complementary base pairing to the 3’ UTR of the target gene (Winter et al 2009). This 
targeting can either result in the destabilisation and subsequent degradation of the target or 
simply its reduced translation (Winter et al 2009). As described previously,  MDV serotype 1 
strains have been shown to encode 13 microRNA molecules in 2 distinct clusters (Burnside et 
al 2006). These microRNAs have been the subject of great interest in recent studies. In 
particular the MDV-miR-4 molecule was shown to be functionally homologous to the human 
miR-155 oncomir (Zhao et al 2009). This viral homolog is also shared with the KSHV miR-
K12-11. The full repertoire of miR-4 targets is yet to be investigated but it has been shown to 
target transcripts such as PU.1, Bcl2L13, CEBPβ and PDCD6 by complementary base pairing 
and subsequent degradation by the RNA induced silencing complex (RISC) (Zhao et al 
2009). It is clear that further investigation is required in order to identify a more complete list 
of MDV-encoded microRNA targets. 
 
1.11 Marek’s disease virus-encoded EcoRI-Q fragment (Meq) gene 
Among all the MDV-encoded transcripts the Meq gene is of particular importance. 
The Meq gene encodes the only basic leucine zipper (bZIP) protein present in the MDV 
genome and is found exclusively in serotype 1 strains (Jones et al 1992a), the vast majority of 
which are oncogenic. The Meq gene has been shown to be involved in lymphocyte 
transformation (Lupiani et al 2004) and anti-apoptotic activity (Liu et al 1998) which suggest 
that it is the major oncogene encoded by MDV. 
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The Meq promoter contains an Activator Protein 1-like (AP1-like) pseudopalindrome 
sequence of two 4 base pair half sites that overlap at the central guanine-cytosine base pair. 
The AP1-like region contains a tetradecanoylphorbol acetate response element (TRE) that is 
preferentially recognised by c-Jun/c-Fos dimers (Bohmann et al 1987) and a cyclic AMP 
response element (CRE) that is preferentially recognised by CREB/ATF dimers (Hai et al 
1988). Meq/c-Jun dimers have been shown to bind this TRE/CRE-like sequence (Qian et al 
1996) and up-regulate Meq gene expression in chicken embryo fibroblasts (CEF) as well as 
F9 rat cells (Qian et al 1995a). This AP-1 site is termed a Meq response element I (MEREI) 
and provided the first indication of Meq mediated transactivation. The presence of an SP1 
enhancer element as well as the AP1-like site suggests the Meq promoter may respond to a 
variety of regulatory proteins. Little is known about the untranslated regions in the Meq 
transcript but this certainly warrants further study. As mentioned above the 5’ UTR contains 
a predicted SP-1 binding site that could potentially play a role in transcriptional control. The 
3’ UTR has not been fully investigated and as such the regulation of Meq protein expression 
has not been linked to microRNA control. The Meq gene sequence and its protein product are 
seen in Figure 1.3 with the untranslated regions shown in green and the open reading frame in 
red. The promoter region is characterised by the presence of the highlighted AP-1 site and the 
TATA box. 
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Figure 1.3 Meq gene and protein sequence. The Meq coding sequence is 1017 bp long. 
It results in the expression of a 339 amino acid residue wild-type Meq protein. The promoter 
contains a Meq binding site to allow self regulation (palindrome sequence underlined), a 
TATA box (underlined) and an SP-1 binding site (underlined in green). The Meq protein is 
made of several domains. The translational start codon is shown in green, the CtBP1 biding 
domain shown in light grey, the basic DNA binding domains shown in red, the core leucine 
residues in the leucine zipper domain in light blue, the predicted RB binding domain in dark 
grey, the proline repeat regions in dark blue and the predicted THAP domain in black. 
Coding DNA sequence is in red while untranslated regions are shown in green. 
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1.11.1 The Meq protein 
The Meq gene classically encodes a 339 amino acid peptide that resembles the c-
Jun/c-Fos oncoprotein family (Jones et al 1992a). The N-terminus contains a region of basic 
residues and a leucine zipper domain which collectively make up the bZIP domain. The C-
terminus contains a set of proline rich repeats that make up the transactivation domain.  
A schematic of the 339 amino acid form of the Meq protein can be seen in Figure 1.3. 
In recent years the identification of alternatively spliced forms of Meq and changes in gene 
length has revealed a large number of variations in Meq protein structure. The first indication 
of this came with the identification of a larger Meq gene in the CVI988 and CVI988/R6 
strains (Lee et al 2000). The Meq gene present in these strains contains an insertion of 180bp 
and was termed L-Meq because of its larger size. The insertion was originally thought to 
result in a frame shift and the subsequent translation of a truncated Meq protein but 
subsequent studies show that this is not the case (Petherbridge et al 2003). The L-Meq protein 
was later identified in very virulent (vv)MDV stains 2-6 weeks post infection (Chang et al 
2002a) and MDV transformed cell lines (own observations) which suggests that it may be 
involved in MDV latency maintenance. 
A classical bZIP domain is comprised of two distinct regions in a single α-helix 
configuration (Vinson et al 1989). The basic region of the Meq protein bZIP domain contains 
two groups of basic amino acids which are responsible for cellular localisation and DNA 
binding. Basic region 1 (BR1) contains a nuclear localisation signal (NLS). Basic region 2 
(BR2) is split into BR2N and BR2C. Individually these two basic regions also act as NLS’s 
but together they are thought to act as a nucleolar localisation signal (NoLS) (Liu et al 1997). 
These regions are also responsible for the interaction with the acidic major groove of the 
DNA binding site. The leucine zipper sequence that essentially contains a leucine residue 
every seventh amino acid and ends with a histidine is often vital for protein-protein 
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interaction stability. The primary function of the bZIP domain is to mediate dimerisation with 
other bZIP proteins in order to provide variation in DNA sequence recognition and binding. 
The Meq N-terminus also contains a PxDLS CtBP binding sequence (Brown et al 2006) that 
has been shown to be vital for Meq mediated oncogenesis and an LxCxE retinoblastoma 
protein (pRB) binding sequence that is yet to be investigated fully. 
The C-terminal transactivation domain of the Meq protein is characterised by the 
presence of proline-rich repeat sequences. It is these regions of repeat sequences that are 
thought to be the driving force for gene transactivation by the Meq protein. These proline 
repeat regions have been investigated in both the oncogenic Meq as well as the variations 
discussed previously. It is interesting to note that alterations in the Meq gene structure and 
resulting protein composition affect the C-terminus most often. In turn, these alterations can 
drastically affect the proteins ability to transactivate target genes and function as an 
oncoprotein. However, although it is clear that the C-terminus contains a transactivation 
domain that is vital to the oncogenic process, the mechanism by which it functions is not yet 
understood. It is likely that understanding all protein-protein interactions made via the C-
terminus will help shed further light on the mechanisms by which Meq can act as an 
oncoprotein.  
A predicted Thanatos associated protein (THAP) domain with the C-x24-C-x35-53-C-
x2-H consensus sequence is found within these proline rich repeats. THAP domains have 
been shown to interact with DNA in a similar manner to the zinc finger-associated domain 
(ZAD) from Drosophila Grauzone (Liew et al 2007) as well as being important in the pro-
apoptotic activity of the THAP1 protein.  
With the identification of Meq protein variations highlighted in Figure 1.4, it is clear 
that the physiological functions of Meq may not be as simple as first thought. The classical 
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339 amino acid Meq protein has been shown to interact not only with itself and other host 
proteins but also truncated, extended and spliced forms of itself. This suggests that we have 
only scratched the surface of uncovering the complete functional story of Meq. 
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Figure 1.4 The Meq gene and splice variation. The Meq gene is expressed as a variety 
of protein products resulting from either gene alterations or alternative splicing events (all 
regions of conserved wild-type Meq protein are shown in dark blue). The large Meq (L-Meq) 
protein product contains a 60 amino acid residue insertion at the 190 amino acid position. 
This results in a C-terminal extension of the wild-type protein and increases the residual 
composition to 399 amino acids. The wild-type Meq protein is translated as a 339 amino acid 
residue peptide chain. Short Meq (S-Meq) and very short Meq (VS-Meq) are produced by the 
transcription of a Meq gene missing regions of the C-terminus. S-Meq has a 41 amino acid 
deletion at the 190
th
 residue and VS-Meq has a 92 amino acid deletion at the 174
th
 residue. 
This produces protein products with a final size of 298 and 247 residues respectively. 
Meq/vIL8 is a protein product that results from the alternative splicing of the wild-type Meq 
gene and the viral IL8 gene (red). The Meq splice donor site is located at the 100
th
 amino acid 
residue and results in the productions of a chimeric protein of 212 amino acids in length.  
L-Meq 
Meq 
S-Meq 
VS-Meq 
Meq/vIL8 
190 250 399 1 
1 339 
190 191 1 298 
1 174 175 247 
1 100 212 
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1.11.2 Meq protein function 
The first indication that Meq is an oncoprotein came with over-expression studies. It 
was found that the over-expression of Meq in Rat-2 cells resulted in serum-independent 
growth, a reduced G-phase and resistance to apoptosis (Liu et al 1998). Further evidence for 
the involvement of Meq in oncogenesis came from using the Meq (-/-) virus rMd5ΔMeq. It 
was discovered that while Meq is dispensable for virus lytic replication it is essential for 
MDV-induced lymphoma formation (Lee et al 2008; Lupiani et al 2004). This was also 
definitively shown by the use of point mutation analysis to abolish lymphomagenesis (Brown 
et al 2006). 
The Meq protein also has the capacity to transactivate which is due to the presence of 
two and one half proline rich sequences in the C-terminus. These proline rich sequences have 
been shown to be important in transcriptional activation by fusing the last 130 amino acids to 
the yeast Gal4 DNA binding domain in order to up-regulate a reporter system (Qian et al 
1995a). It has already been mentioned that Meq can interact with c-Jun to up-regulate its own 
expression by binding an AP1-like site in the Meq gene promoter (Qian et al 1996) but it is 
also possible that Meq interacts with a huge variety of leucine zipper proteins in order to 
regulate a range of different genes. Binding to AP1-like sequences is also seen in Meq/Meq 
and c-Jun/c-Jun homodimers but with reduced affinity compared with that of Meq/c-Jun 
heterodimers which begs the question as to which other bZIP combinations can interact with 
the highly conserved AP-1 site. However, Meq/Meq homodimers bind to Meq response 
element II (MEREII) with a greater affinity than Meq/c-Jun heterodimers. It is not thought 
that the MEREII consensus sequence (RACACACAY) is bound by other bZIP proteins.  
The MEREII sequence is found at the MDV origin of lytic replication (Bradley et al 
1989) which suggests that Meq/Meq homodimers may be involved in the process of 
replication or general regulation of the MDV genome (Qian et al 1996). The MEREII 
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sequence at the MDV origin of lytic replication is also within the enhancer regions for pp38 
and pp14 (Peng et al 1992; Xie et al 1996) which may link Meq to the expression or 
repression of these genes. It has been shown that Meq DNA binding capacity to the AP1-like 
sequence is reduced by CDK phosphorylation and increased by PKC phosphorylation (Liu et 
al 1999). This suggests that Meq can activate a number of genes according to its 
phosphorylation state as well as the proteins it is partnered with and the cell cycle stage of the 
infected cell. 
 
1.11.3 Meq as a transcription factor 
 Meq is regarded as a member of the AP-1 transcription factor family (Liu & Kung 
2000). From this, we can hypothesise that Meq is able to interact with a variety of different 
transcription factors in order to regulate a large repertoire of genes. The leucine zipper 
domain in the bZIP region is crucial in mediating these interactions and is pivotal to the 
function of Meq as an AP-1 family transcription factor. 
A classical bZIP domain consists of a 60-80 amino acid long α-helix made up from 
two distinct regions (Vinson et al 1989) (Figure 1.5). The N-terminus of the bZIP α-helix 
contains two groups of basic amino acids which are responsible for binding to the acidic 
DNA molecule. The basic N-terminus interacts with DNA through the major groove allowing 
for easy access to the base sequence. The C-terminus contains the leucine zipper sequence 
that essentially contains a leucine residue every seventh amino acid. Amino acid positions in 
a leucine zipper domain are registered sequentially as ‘gabcdef’. In dimer formation the 
majority of ‘e’ and ‘g’ pairs are charged, long side-chain amino acids such as glutamic acid 
or lysine (Alber 1992; Cohen & Parry 1990). It is this arrangement of charged residues that 
determine whether the leucine zipper will form a homodimer, heterodimer or have the ability 
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to form both. Figure 1.6 shows a schematic representation of residues in the ‘e’ and ‘g’ 
positions and what effect a change in charge has on the leucine zipper dimerisation.  
The ‘a’ and ‘d’ positions are vital in dimer formation and stability (Thompson et al 
1993). The majority of leucine zippers contain a leucine at the ‘d’ position and another 
hydrophobic residue at the ‘a’ position. This forms a hydrophobic core and mediates leucine 
zipper dimerisation stability. An exception to this rule is the presence of an asparagine at the 
‘a’ position of the second heptad in almost all human leucine zippers. We go on to show that 
this is also the case for most chicken leucine zipper proteins and even the viral Meq 
oncoprotein itself contains this asparagines residue.  
The Meq leucine zipper has been shown to regulate interactions with a variety of 
different cellular bZIP proteins. The Meq/c-Jun interaction is the most widely studied 
interaction but Meq has also been shown to dimerise with human Fos, human JunB and 
CREB, as well as the bZIP domains of human ATF1, ATF2 and ATF3 (Levy et al 2003). 
However, interactions with chicken homologs of these proteins have not been confirmed and 
it is also expected that Meq will interact with several other members of the bZIP transcription 
factor family but these observations are yet to be described in the literature. 
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Figure 1.5 Schematic representation of the basic leucine zipper domain. Alpha-helical 
basic leucine zipper domain is shown in blue with hydrophobic interactions between leucine 
core residues in red. The basic region is shown to interact with the major groove of the acidic 
DNA molecule (green/purple). 
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Figure 1.6 Helical wheel diagram showing leucine zipper dimerisation and 
specificity. Hydrophobic residues shown in red, positively charged residues in green and 
negatively charged residues in yellow (other resides in black). Green arrows indicate 
favourable electrostatic interactions; red dashed arrows indicate un-favourable electrostatic 
interactions. Intra-helical arrows indicate the direction of the register sequence and α-helices.  
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1.11.4 Meq during apoptosis 
The regulation of apoptosis is a mechanism by which many herpesviruses have been 
shown to exert their oncogenic activity (Lagunoff & Carroll 2003). Furthermore, these 
viruses have been shown to regulate apoptosis by the expression of anti-apoptotic proteins 
such as LANA2 encoded by KSHV (Esteban et al 2003) and LMP1 encoded by EBV 
(Schneider et al 2008). MDV infection has long been implicated in the observed anti-
apoptotic phenotypes of infected cells (Ewert & Duhadaway 1999). This proves to be an 
invaluable trait especially regarding the atrophic nature of MDV infection in the spleen 
(Morimura et al 1996) and thymus (Morimura et al 1997). The anti-apoptotic nature of MDV 
is not fully understood but the expression of the Meq oncoprotein has also long been 
implicated in this function. This is highlighted by the ability of Meq to regulate 
transformation, serum independent growth and anchorage independent growth (Liu et al 
1998). Although Meq has been implicated in the anti-apoptotic effect conferred by MDV 
infection the molecular mechanisms by which this takes place are yet to be investigated. 
 
1.11.5 Meq interacts with CtBP1 
 Perhaps the most important interaction made by the Meq oncoprotein is that with the 
transcriptional co-repressor CtBP1 (Brown et al 2006). The CtBP1 protein is known to 
interact with the C-terminus of the adenovirus E1A protein (Boyd et al 1993). It has been 
shown to have transcriptional co-repressor activity toward multiple targets (Chinnadurai 
2009) and is involved in many different cellular processes from cell cycle regulation to 
apoptosis. Meq was first hypothesised to interact with CtBP due to the presence of a CtBP 
binding domain characterised by the putative PxDLS sequence. This domain was later 
confirmed to be pivotal in mediating the Meq interaction with CtBP1 as mutation of this 
domain not only resulted in the abolition of the interaction but also attenuated the oncogenic 
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nature of the virus (Brown et al 2006). However, the molecular mechanism behind this 
phenotype is not fully understood and requires further investigation.  
 
1.12 Prostate apoptosis response-4 
In this study we identify Prostate apoptosis response-4 (Par-4) as a novel Meq interacting 
protein. It was first identified as one of five novel ionomycin-inducible genes in the 
androgen-independent AT-3 prostate cancer cell line (Sells et al 1994). The study went on to 
confirm that Par-4 levels were also induced in the rat prostate following castration and this 
effect was downstream to Ca
+
 elevation. This led to apoptosis of androgen dependent prostate 
cells which indicates a role for Par-4 up-regulation in both androgen-independent and 
androgen-dependent prostate cell apoptosis (Sells et al 1994).  The Par-4 or PAWR (PRKC 
apoptosis WT1 regulator) gene encodes a 340 amino acid protein in humans that contains a 
leucine zipper domain (Sells et al 1997) and a selective for apoptosis (SAC) domain (El-
Guendy et al 2003). The Par-4 leucine zipper domain is located at the C-terminus of the 
peptide chain. This domain was first identified to be pivotal to the apoptotic nature of the 
protein in transfection studies that utilised a leucine zipper deletion mutant. The wild type 
Par-4 molecule was able to induced increased levels of apoptosis but the Par-4 leucine zipper 
mutant had no effect (Sells et al 1997). This was the first study to highlight the functional 
importance of the Par-4 leucine zipper domain.  
The importance of the leucine zipper domain was highlighted in a previous study that 
confirmed an interaction with the WT1 tumour suppressor protein (Johnstone et al 1996). 
This interaction was shown to be mediated by the leucine zipper domain of Par-4 and the zinc 
finger domain of WT1. Furthermore, the interaction was shown to result in the rescue from 
WT1 mediated growth suppression in A375-C6 cells. Later studies observed the in vivo and 
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in vitro binding of Par-4 and WT1 to the pro-survival Bcl-2 promoter region (Cheema et al 
2003). Specifically, the dimer binds to the putative WT1 domain and furthermore, this 
interaction results in decreased Bcl-2 expression. This was first identified by a decrease in 
Bcl-2 correlating to the change in localisation of Par-4 from the cytoplasm to the nucleus. 
This also correlated with an increase in WT1 levels that were subsequently experimentally 
blocked to resolve Bcl-2 levels (Cheema et al 2003). Ultimately this study shows that the Par-
4 leucine zipper interaction with WT1 has the potential to down-regulate expression of the 
vital pro-survival protein Bcl-2 (Figure 1.7).  
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Figure 1.7 Par-4 interacts with WT1 to bind the Bcl-2 promoter and regulate gene 
expression. WT1 up-regulates the pro-survival Bcl-2 protein by binding the putative WT1 
binding sequence in the Bcl-2 promoter. The WT1/Par-4 dimer also recognises this sequence 
and binding results in suppression of Bcl-2 expression.  
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Figure 1.8 Par-4 interacts with PKCζ to regulate NFκB activation and apoptosis. 
PKCζ phosphorylates IKKB in order to activate and release NFκB from the IKKB complex. 
Par-4 interacts with PKCζ to prevent IKKB phosphorylation and NFκB activation. p62 
overexpression leads to binding to the PKCζ complex to reactivate PKCζ and allow 
phosphorylation of IKKB and activation of NKκB. 
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Par-4 physically interacts with a large array of proteins in order to regulate many 
different processes. After the identification of WT1 as a Par-4 interacting protein the Dlk/ZIP 
kinase was shown to interact with Par-4 by the application of yeast two-hybrid screen (Page 
et al 1999). The Dlk/ZIP kinase contains a leucine zipper domain but surprisingly this was 
dispensable for the interaction to take place. It was shown to be mediated by an arginine rich 
region comprising almost 100 residues. Furthermore, co-expression of Par-4 and Dlk/Zip led 
to the translocalisation of Dlk/ZIP to the cytoplasm whereby massive cytoskeleton 
rearrangement indicated the morphological characteristics of apoptosis (Page et al 1999). 
This interaction is also maintained in DaOy, D341, MHH-MED-1 and D283 
medulloblastoma cell lines where this apoptotic effect was further confirmed (Kogel et al 
2001). Further investigation revealed that endogenous Par-4 is localised to F-actin filaments 
in rat fibroblast cells and it is this localisation that allows increased phosphorylation of 
myosin 2 and subsequent apoptotic events (Vetterkind et al 2005). Recent observations 
confirm the functional significance of the Par-4 interaction with Dlk/ ZIP. Phosphorylation of 
Par-4 at T
155
 takes place and is essential for the induction of apoptosis mediated by this 
dimer. This was elegantly demonstrated with the use of mutational analysis whereby the 
incorporation of a T
155
 alanine mutant abrogated Par-4 mediated apoptosis (Boosen et al 
2009). 
 Par-4 interactions are almost exclusively made via the leucine zipper domain. 
Apoptosis antagonising transcription factor (AATF) was shown to interact with Par-4 by 
utilising this domain (Guo & Xie 2004). AATF also contains a leucine zipper and this 
dimerisation was confirmed by co-localisation in the nucleus and the cytoplasm of neural 
cells as well as biochemical experimentation. It was shown that the over-expression of Par-4 
induced the secretion of the neurotoxic amyloid beta peptide 1-42 in neuroblastoma. 
However, this was abrogated by the co-expression and subsequent interaction with AATF. 
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This confirms AATF as a regulatory protein that harbours antagonistic properties when 
bound to Par-4 (Guo & Xie 2004). Further investigation regarding the Par-4 interaction with 
AATF seems warranted due to the potential significance of this interaction in a variety of 
cellular processes.  
 Par-4 is known to targeted and be targeted by several kinase molecules. The 
interaction with atypical isoforms of protein kinase C is highlighted by interactions with 
PKCζ and PKCλ (Diaz-Meco et al 1996). Furthermore, this interaction was shown to inhibit 
this family of PKCs in their ability to regulate the NFκB pathway by specific targeting of the 
IκB kinase and inhibition of tumour necrosis factor induced translocation of p62 (Diaz-Meco 
et al 1999). However, more recent studies suggest that p62 and Par-4 do not compete for the 
PKCζ interaction but in fact regulate a ternary complex containing all three proteins (Chang 
et al 2002b). It was found that p62 bound in order to activate PCKζ and thus resulted in 
increased IκB phosphorylation. This was further highlighted with the over-expression of p62 
in order to halt Par-4 mediated inactivation of PKCζ and thus Par-4 mediated apoptosis. This 
is described diagrammatically in Figure 1.8. 
 Cancer cells often exhibit elevated levels of protein kinase A (PKA) and it has even 
been identified as a cancer marker (Cho et al 2000). This is a well studied characteristic of 
cancer cells and one that Par-4 is thought to utilise. The phosphorylation of Par-4 by PKA 
takes place at T
155
 and was shown to be pivotal in the ability of Par-4 to induce apoptosis 
(Gurumurthy et al 2005). Furthermore, this phosphorylation was shown to regulate the 
translocalisation of Par-4 into the nucleus of sensitive cancer cells in order to induce 
apoptosis by negative regulation of NFκB. This is shown in Figure 1.9 adapted from 
(Gurumurthy et al 2005) and was confirmed with the application of peptide treatment to 
reduce PKA activity which resulted in abrogated Par-4 phosphorylation and subsequent 
apoptosis. 
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Figure 1.9 Protein kinase A activates Par-4 and promotes apoptosis by NFκB 
regulation. Protein kinase A mediates phosphorylation of Par-4 at T
155
. This phophorylation 
is proposed to activate Par-4 by mediating nuclear translocalisation and subsequent negative 
regulation of NFκB (Gurumurthy et al 2005). 
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Figure 1.10 Par-4 extrinsic apoptosis pathway. Stress signals result in the release of 
GRP78 and Par-4 dimers from the endoplasmic reticulum and translocalisation to the plasma 
membrane. Par-4 is then released by GRP78 as a secreted apoptotic signal. A feedback loop 
is activated whereby Par-4 then binds GRP78 on the cell surface which both acts to increase 
endoplasmic reticulum stress and initiate the FADD death cascade to ultimately induce 
apoptosis. 
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The PI3K-Akt pathway is well studied in terms of oncogenesis and particularly the 
loss of the PTEN tumour suppressor during cancer (Cantley & Neel 1999). Akt is 
overexpressed in many different cancers and as the pivotal member in this cascade an 
interaction with Par-4 has further highlighted its importance to the survival of cancer cells. A 
physical interaction was first identified to be mediated by the leucine zipper of Par-4. This 
interaction resulted in the phosphorylation of Par-4 at S
294
 which subsequently resulted in the 
loss of pro-apoptotic function (Goswami et al 2005). This was elegantly shown by inhibiting 
Akt in order to induce apoptosis. However, this was rescued by blocking Par-4 which 
suggests that Par-4 is required for PTEN inducible apoptosis (Goswami et al 2005). 
Par-4 is expressed in many normal cell types where it is found mainly in the 
cytoplasm (Sells et al 1997). However, in numerous cancer cells undergoing apoptosis Par-4 
translocates to the nucleus (El-Guendy et al 2003). This led to the discovery that ectopic 
expression of Par-4 is sufficient to induce apoptosis in most cancer cells but not normal cells. 
The presence of a nuclear localisation signal was the key in identification of the SAC domain 
that was shown to be essential for the up-regulation of apoptosis by NFκB regulation (El-
Guendy et al 2003). When transfected alone the SAC domain not only mirrored the apoptotic 
effect exhibited by the full length protein but it also extended this function to previously 
resistant cell lines. Furthermore, SAC expressing transgenic mice were found to be resistant 
to oncogene induced and spontaneous tumour formation (Zhao et al 2007).  
Recent evidence has uncovered a new role for Par-4 in apoptosis. An exhaustive study 
identified Par-4 as a molecule secreted by both normal and cancer cells (Burikhanov et al 
2009). Furthermore, this secretion of Par-4 was shown to mediate the up-regulation of 
apoptosis by binding the glucose regulated protein-78 (GPR78) that is specifically expressed 
at the surface of cancer cells. It was also shown that TRAIL induced apoptosis not only 
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utilised this function but Par-4 is essential in this extrinsic apoptotic mechanism. Figure 1.10 
is adapted from (Burikhanov et al 2009). 
The role of Par-4 during apoptosis is still not yet fully understood but it is clear that 
numerous protein-protein interactions are implicated in the process. The majority of known 
interactions with Par-4 are mediated by the leucine zipper domain and this, along with the 
SAC domain, has been shown to be pivotal in Par-4 mediated apoptosis. It is also clear that 
Par-4 is secreted as an extracellular apoptotic signal and is able to hijack many cellular 
pathways to carry out its apoptotic function. Moreover, several proteins such as p62 have 
been shown to interact with Par-4 in order to abrogate its apoptotic effects. This begs the 
question whether other protein-protein interactions play a role in Par-4 mediated apoptosis 
and this certainly warrants further investigation. 
 
1.13 Activating transcription factor 3 
When first identified, ATF3 was given the name liver regenerative factor 1 (LRF-1). 
It was shown to be highly up-regulated during liver regeneration and homodimeric 
interactions as well as heterodimeric interactions with Jun but not Fos were observed (Hsu et 
al 1991). This was further confirmed in later observations that suggested interactions with 
JunB and c-Jun (Hsu et al 1992). Moreover, those interactions were thought to play a key role 
in the G1 phase of liver regeneration (Hsu et al 1992). The first indication that LRF-1 was 
involved in cancer came with the identification of higher levels of transcription during 
progression of hepatocellular carcinoma and the surrounding tissue of the liver (Liao et al 
1996). 
LRF-1 was later termed ATF3 in humans due to similarities with the activating 
transcription factor family. Most notable of which is the presence of a highly conserved bZIP 
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domain that mediates the majority of protein-protein interactions made by ATF3. One such 
interaction is made with NFκB in order to bind and regulate the E-selectin promoter region 
(Kaszubska et al 1993) while later observations indicate that the ATF3 interaction with NFκB 
may play a key role in TLR4 dependant gene expression (Kim et al 2010). However, the 
majority of interactions made by ATF3 are with other members of the bZIP transcription 
factor family. 
ATF3 is primarily a stress associated protein product of the ATF3 gene in humans. It 
has been shown to target a huge number of genes in the human genome to potentially play 
major and diverse roles in a variety of cellular processes including apoptosis, cell cycle 
regulation and differentiation (Tanaka et al 2011). Although the ATF3 protein is a member of 
the activating transcription factor family it is more commonly associated with the suppression 
of its target genes. This is most notably due to the lack of a transactivation domain that many 
other bZIP transcription factors harbour. ATF3 is able to target genes by binding conserved 
DNA sequences such as CRE, TRE and AP-1 sites (Hai et al 1999). These sequences are 
extremely common in the genome which increases the number of potential ATF3 targets to 
almost 10,000 genes. Although it is extremely unlikely that the ATF3 protein targets the 
entire repertoire of ATF3 binding sites a recent study showed that cancer associated ATF3 is 
recruited to 5,984 promoter regions in LNCaP prostate cancer cells (Tanaka et al 2011).  
Known targets of ATF3 include the ATF3 inhibitor gadd153 (Chen et al 1996; 
Wolfgang et al 1997), Cyclin D1 (Allan et al 2001), Snai2, Wnt7b and Jun (Xi et al 2011). 
The mechanism by which ATF3 activates and represses genes is not fully understood but the 
presence of a conserved domain at the N-terminus is thought to play a key role in this 
mechanism. Moreover, the action of ATF3 is not only confined to transcription regulatory 
functions but it also acts as a putative oncoprotein in mouse mammary tumouragenesis 
(Wang et al 2008) and aids in the stability of the tumour suppressor p53 (Yan & Boyd 2006). 
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It is clear that ATF3 exerts its functional effect by interacting with a variety of different 
proteins and further study into these interactions would only aid in the greater understanding 
of this stress inducible protein. 
 
1.14 Yeast two-hybrid screen 
 The classical yeast two-hybrid assay was developed as a high throughput screen for 
the identification of novel protein-protein interactions (Fields & Song 1989). Although the 
underlying theory of the reporter gene and its use in molecular biology has fundamentally 
remained unchanged for almost a quarter of a century the technical aspect of the system has 
become much more robust in terms of accuracy and efficiency. With the development and 
identification of novel yeast strains, reporter genes and selective media the yeast two-hybrid 
assay is still considered the gold standard in identification of novel direct protein-protein 
interactions.  
 As mentioned above, the theory behind the yeast two-hybrid assay has remained 
unchanged for many years. It is based on a reporter gene methodology first described by 
Fields and Song by taking advantage of the Gal4 transcriptional activator found in yeast 
strains (Fields & Song 1989). The yeast two-hybrid assay utilises this mechanism by 
expression of a fusion protein of interest (bait) and the Gal4 DNA binding domain. This 
chimeric protein is then expressed in a yeast strain that harbours a fusion of the Gal4 DNA 
activation domain and a gene expressed from a cDNA library (prey). If a direct interaction 
takes place between the bait and prey proteins the Gal4 DNA binding domain and Gal4 DNA 
activation domain are brought into close enough proximity to allow transactivation of the 
reporter gene. The Clontech Matchmaker 3 yeast two-hybrid system is generally considered 
to be the gold standard in yeast two-hybrid analysis and is depicted in Figure 1.11. 
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1.11 Yeast two-hybrid screen for interacting protein partners. The gene of interest is 
cloned in frame with the GAL4 DNA binding domain present in the pGBKT7-BAIT vector 
and transformed into the yeast strain of choice to produce the bait stain. This strain is then 
mated with a compatible stain containing the cDNA library of choice and incubated on 
selective media. Clones expressing a positive interacting protein partner complete the 
transcriptional machinery and allow activation of the reporter system. Blue colony formation 
is an indication of a positive interaction. These colonies are then screened by PCR and 
sequencing to identify novel protein partners.  
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1.15 Aim of this thesis 
 The aim of this thesis is to identify and shed further light on the global 
interactome of the Meq oncoprotein. It is hypothesised that Meq interacts with a variety of 
novel proteins that potentially mediate the function of this bZIP transcription factor during 
oncogenesis. This investigation will be carried out with the application of a variety of 
biochemical, molecular biological and bioinformatics techniques. Primarily, the Meq protein 
will be dissected in silico in order to provide further understanding of the functional 
properties of this complex oncoprotein. This will also be linked to a predicted bZIP protein-
protein interaction study that will aim to confirm known interactions and uncover a panel of 
novel interactions that will later be screened for biochemically. With the greater 
understanding of the Meq oncoprotein provided by this extensive in silico investigation the 
project will then progress into a global protein-protein interaction study carried out by yeast 
two-hybrid screening and LC-MS/MS analysis. This will provide insight into both direct and 
indirect protein-protein interactions with the ultimate aim of identifying novel protein-protein 
interactions made by the Meq oncoprotein. Novel protein-protein interactions identified by 
the global interaction studies will be further investigated by a range of biochemical 
techniques in order to not only confirm these interactions but also shed further light on their 
biological significance. It is the aim of this thesis to explore and identify these novel protein-
protein interactions and in doing so make a significant step forward in the understanding of 
this surprisingly complex viral oncoprotein.  
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2 Methods 
2.1 Solutions and buffers in appendix I 
2.2 Plasmids in appendix II 
2.3 Antibodies 
Antibody Antigen Isotype Dilution Manufacturer 
   WB IF IP  
FD7 MDV-Meq Mouse IgG1 1:100 1:100  IAH 
Meq MDV-Meq Rabbit IgG 1:500 1:500 1:20 IAH 
Par-4 Rat-Par-4 Goat IgG 1:100   Santa Cruz 
ATF3 Mouse-ATF3 Rabbit IgG 1:100 1:100  Cell signalling 
CtBP1 Mouse-CtBP1 Rabbit IgG 1:1000   Sigma 
Keratin Human-Keratin Mouse IgG1  1:500  Millipore 
PARP Human-Parp1 Rabbit IgG 1:500 1:500  Roche 
BD1 MDV-pp38 Mouse IgG1 1:100 1:100  IAH 
Tubulin Chick-Tubulin Mouse IgG1 1:10000  1:5000 Sigma 
HA Influenza-
Haemagglutinin 
Mouse IgG1 1:1000 1:1000  Covance 
GAL4 Saccharomyces 
cerevisiae-Gal4 
DNA BD 
Mouse IgG1 1:500   Santa Cruz 
Table 2.1 
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2.4 Oligonucleotides 
Name Sequence NCBI or ENSEMBL 46 
Meq_NcoI_Gal4_For 5’CATATGGCCATGGAGATGTCTCAGGAGCCAGAGCC3’ HM488349 
Meq_BamHI_Gal4-Rev 5’GTAGACGGATCCGCAAACTGGCTCATGACAAG3’ HM488349 
Par-4(125-340)HA_For 5’ATAATAAAGCTTGCCACCATGGCATACCCATACGATGTTCCAGATTACGCTGGCG
AGGAGAAGCCGGCGGGCAGGGGAAG3’ 
N/A 
Par-4(125-340)_For 5’ATAATAAAGCTTGCCACCATGGGCGAGGAGAAGCCGGCGGGCAAGGGGAAG3’ N/A 
Par-4(125-340)_Rev 5’ATAATAGGATCCCTACCTTGTCAGCTGTCCAAC3’ N/A 
Meq_HindIII_For 5’ATATATAAAGCTTGCCACCATGTCTCAGGAGCCAGAGCCGGGGCGCT3’ HM488349 
Meq_EcoRI_Rev 5’ATAATAGAATTCCTCAGGGTCTCCCGTCACCTG3’ HM488349 
Par-4(125-340)HABamHI_For 5’GGATCCATGGCATACCCATACGATGT3’ N/A 
Par-4(125-340)HAEcoRI_Rev 5’GAATTCCTACCTTGTCAGCTGTCCAA3’ N/A 
ATF3HA_HindIII_For 5’ATAATAAAGCTTGCCACCATGGCATACCCATACGATGTTCCAGATTACGCTATGA
TGGTCCAACACACCGG3’ 
XM_419429 
ATF3_HindIII_For 5’ATAATAAAGCTTGCCACCATGATGGTCCAACACACCGG3’ XM_419429 
ATF3_BamHI_Rev 5’ATAATAGGATCCTTAACCTTGTAATGTTCCTT3’ XM_419429 
Par-4RACEouter_Rev 5’CCTGTCTCTCCTTTGCAAGTTCC3’ N/A 
Par-4RACEinner_Rev 5’CTGCTGTAAGTTGTCCTCTCCGT3’ N/A 
Par-4(125-340)SEQ1_Rev 5’GAGAGTTCCAGTGCAGATTCCACT3’ N/A 
Par-4(125-340)SEQ2_Rev 5’ATCTGCTTGAAACCATCCTGGAGG3’ N/A 
ChickIFNG_For 5’ATAATACTCGAGCACTTTTAGTCCCTTCTGTT3’ ENSGALT00000016105 
ChickIFNG_Rev 5’ATAATAAAGCTTCTTCTTGGTGATGGCTCAGT3’ ENSGALT00000016105 
MeqGal4AD_For 5’ATAATAGCCATGGAGCAGTTTGCCCTATGGCGGTA3’ HM488349 
MeqGal4AD_Rev 5’ATAATACTGCAGTCAGGGTCTCCCGTCACCTG3’ HM488349 
MDVGI_For 5’ATAATACTCGAGTTTGTCAATGGTACAACACG3’ EF523390 
MDVGI_Rev 
Pin1HA_For 
 
Pin1_Rev 
5’ATAATAAAGCTTCGCAATCACACACGCCGTCT3’ 
5’ATAATAAAGCTTGCCACCATGGCATACCCATACGATGTTCCAGATTACGCTATGG
GAGAGGCCGAGCGGCG3’ 
5’ATAATAGAATTCTCACTCCGTGCGCAGCATGA3’ 
EF523390 
BX950453 
 
BX950453 
Table 2.2 
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2.5 Methods 
2.5.1 Leucine zipper interaction prediction 
Chicken leucine zipper protein sequences were mined using the Biomart Ensembl 
genome browser. Duplicates and redundant sequences were removed and the Meq leucine 
zipper amino acid sequence was aligned in order to predict possible dimerisation events using 
the base optimised weights method. This method is a computational optimization of 
electrostatic weights and experimental coupling energy weights. The seven interactions that 
determine leucine zipper dimerisation specificity are shown in [1]. 
 
[1] aid'i, dia'i+1, die'i, gia'i+1, gie'i+1, aia'i, did'i. 
 
The prime differentiates the two strands and the subscript denotes the relative heptad number 
(e.g. aid'i, is the interaction between the a position in the i-th heptad of one helix and the d 
position in the same heptad of the other helix). Interactions between strands are symmetric 
(e.g. both aid'i and a'idi are included). For each of these interactions a weight is given to 
denote how favourable that interaction is. The example of w(p,q),I,j shows how favourable an 
interaction is between amino acid i at position p and amino acid j at position q. This weight 
score is provided by optimizing data from electrostatic weight scores and experimentally 
obtained coupling energies. 
 
2.5.2 Phylogenetic analysis 
 Amino acid sequences for full length chicken bZIP protein, leucine zipper regions 
only, functional leucine zipper residues only and basic DNA binding regions only were 
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aligned computationally. Alignments and phylogenetic analyses were carried out using 
ClustalX to produce phylogenetic trees and percentage relationships. Protein sequences were 
taken from Ensembl gene build 46 unless stated otherwise. 
 
2.5.3 Plasmid DNA extraction – miniprep 
 A single bacterial clone was picked from selective solid agar medium using a sterile 
loop and used to inoculate 2-5mL selective liquid medium. The culture was incubated at 37ºC 
overnight (a glycerol stock was prepared at this point) and spun at 4,000xg for 10 minutes at 
4ºC. DNA was prepared using the Qiagen miniprep according the manufacturer’s instructions   
Briefly, supernatant was removed and the pellet resuspended in 250µl P1 buffer and 250µl P2 
buffer in a 0.5mL tube. The tube was inverted 4-6 times before adding 350µl neutralizing 
reagent (N3 buffer) and inverting a further 4-6 times. Tubes were then spun at 13,000xg in a 
microfuge for 10 minutes at room temperature and supernatant removed to a disposable 
column and collection tube. Tubes were spun at 13,000xg for 1 minute before evacuating the 
flow through and replacing the supernatant with 500µl PB buffer. Samples were spun as 
above and flow through evacuated before washing was carried out by addition of 1mL PE 
buffer. Tubes were then spun at top speed and flow through was evacuated. This was 
repeated and 20µl elution buffer (EB) was added to the membrane before incubation at room 
temperature for 2 minutes and spinning at 13,000xg to elute. 
 
2.5.4 Plasmid DNA extraction – maxiprep 
 A single bacterial clone was picked from selective solid agar medium using a sterile 
loop and used to inoculate between 100-500mL selective liquid medium depending on the 
copy number of the plasmid. Cultures were incubated at 37ºC overnight and pelleted at 
64 
 
4,000xg for 10 minutes at 4ºC. DNA was prepared using the maxiprep kit (Qiagen) according 
the manufacturer’s instructions.  Briefly, the pellet was resuspended in 10mL P1 buffer and 
P2 buffer before mixing by inversion 4-6 times and incubating at room temperature for 5 
minutes. Neutralising solution (P3 buffer) was added and incubated on wet ice for 20 minutes 
before clearing the lysate. Clearing was carried out by centrifugation at 20,000xg for 20 
minutes and removal of floating contaminants. This was repeated and the supernatant was 
added to the supplied gravity flow columns. Columns were washed by the addition of 30mL 
QC solution and DNA eluted by addition of 10mL QF buffer and gravity flow. DNA was 
precipitated by the addition of 7mL ice cold isopropanol and subject to centrifugation at 
15,000xg for 10 minutes at 4ºC. The visible pellet was then washed by the addition of 10mL 
70% ethanol and repeating the previous step. The pellet was then air dried and resuspended in 
EB or dH20. 
 
2.5.5 Glycerol stock production 
 A single bacterial clone was picked from selective solid agar medium using a sterile 
loop and used to inoculate 2-5mL selective liquid medium. Cultures were incubated 
overnight at 37ºC before removing 500µl for glycerol stock production (the remaining sample 
was used for plasmid DNA isolation). The removed fraction was added to 500µl 50% 
glycerol and stored at -80ºC. 
 
2.5.6 Molecular cloning 
Cloning into a vector backbone was carried out either by the amplification of a target 
DNA sequence by PCR or the manipulation of an existing construct. The target was then 
digested as per manufacturer’s instructions and ligated at 4ºC overnight into the vector of 
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choice using complementary restriction sites. The resulting vector was then transformed into 
the E. coli strain of choice and incubated at 37°C on antibiotic selection media overnight. 
Colonies were screened by colony PCR, restriction digest and sequencing to ensure the 
correct cloning. 
 
2.5.7 Polymerase chain reaction 
PCR was carried out using classical thermocycler protocol as per the Taq polymerase 
manufacturer’s protocol. GoTaq (Promega) was used unless otherwise stated. A typical 
recipe for the PCR master mix is given below: 
 
  GoTaq        1unit 
  MgCl2 (25mM)      1.6µl 
  dNTP’s (10mM)      0.5µl 
Loading buffer (X5)      4µl 
  Forward primer (10 p/mol)     1µl 
  Reverse primer (10 p/mol)     1µl 
  dH20        10.8µl 
 
Template DNA (10ng) was added. 
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2.5.8 Reverse transcription polymerase chain reaction 
Total RNA was extracted using Trizol reagent and the concentration measured by 
NanoDrop. RT-PCR was carried out using 1μg of total RNA as a template for random 
hexamer amplification of cDNA. RT-PCR comprises of 1μl random hexamers (50ng), 1μl 
dNTP (10mM), 1μg total RNA and made up to 10μl with dH20. Samples were incubated at 
65°C for 5 minutes and placed on ice of a further 1 min. 5xRT buffer, 4μl MgCl (25mM), 2μl 
DTT (0.1M) and 1μl RNase out inhibitor was then added to each reaction before mixing 
gently and collecting by centrifugation. Samples were incubated at 25°C for 2 minutes before 
the addition of 1μl Superscripts II reverse transcriptase to positive reactions and 1μl water for 
negative control samples. Samples were incubated at 25°C for a further 2 minutes before 50 
minutes incubation at 42°C and 15 minutes incubation at 70°C to terminate the reaction. 
Samples were then chilled on wet ice before centrifugation to collect and adding 1μl RNaseH 
to degrade any remaining RNA. Samples were incubated at 37°C for 20 minutes before 
storing at -80°C. Specific amplification of target transcripts was then carried out using 
conventional PCR. 
 
2.5.9 Transformation of chemically competent E. coli  
 1-5µl of total ligation reaction was added to 50µl thawed chemically competent E. 
coli cells. Cells were mixed and stored at 4ºC for 20 minutes on wet ice with occasional 
inversion. 950µl pre-warmed super optimum broth was added and cells were allowed to 
recover at 37 ºC for at least 45 minutes. Transformation mix was then titrated onto selective 
LB agar and incubated for 12 hours at 37 ºC. Resulting colonies were screened by colony 
PCR, digestion or sequencing depending on the construct and downstream application. 
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2.5.10 Transformation of electro-competent E. coli  
1-2µl or ~10ng of total ligation reaction was added to 20µl thawed electro-competent 
E. coli cells. Cells were mixed and stored at 4ºC for 20 minutes on wet ice with occasional 
inversion. Shock transformation was carried out as per manufacturer’s instructions with 
varying current and voltage depending on the strain. 980µl pre-warmed super optimum broth 
was added and cells were allowed to recover at 37 ºC for at least 1 hour. Transformation mix 
was then titrated onto selective LB agar and incubated for 12 hours at 37 ºC. Resulting 
colonies were screened by colony PCR, digestion or sequencing depending on the construct 
and downstream application. 
   
2.5.11 Nucleic acid electrophoresis 
 Nucleic acid loading buffer was first added to the sample before loading onto 0.2-2% 
agarose gel (depending on resolution required) in 10X TBE buffer. Ethidium bromide was 
added to the cooled gel at 0.005% before pouring and setting. Agarose gel was then 
immersed in 10X TBE buffer and run at 150 volts and 100 mAmps for 30-45 minutes. DNA 
was visualised under ultraviolet light. DNA samples were always run alongside a DNA 
ladder typically 2-Log ladder (New England Biolabs). 
 
2.5.12 SDS protein electrophoresis 
 Protein samples were boiled in 2X SDS loading buffer before loading into NuPage 
BIS-TRIS pre-cast gels from Invitrogen. BIS-TRIS percentage and well size was varied 
depending on the requirements of the sample and downstream process.  Gels were typically 
run at 150 volts in NuPage running buffer for 45 minutes and removed for downstream 
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process. Samples were always run alongside a molecular weight marker typically the broad 
range molecular weight marker from Biorad. 
  
2.5.13 Transfection of DF-1 cells  
DF-1 cells were seeded at 2.45x10
6
mL
-1 
in a T-75 flask containing 20mL DF-1 
growth medium and incubated at 38.5˚C with 5% CO2 for 24 hours. When DF-1 cells were 
70% confluent transfection was carried out. 500μl OptiMEM and 60μl Lipofectamine 2000 
(Invitrogen) was mixed in a clean tube. 500μl OptiMEM containing 10μg of DNA was then 
added gently and the transfection mix was incubated at room temperature for 20 minutes. The 
transfection mix was then added to the DF-1 cells and incubated for 12 hours at 38.5˚C and 
5% CO2. The transfection mix was then removed and fresh DF-1 growth medium added. Cells 
were incubated for a further 12 hours at 38.5˚C and 5% CO2 before harvesting. 
 
2.5.14 Transfection of HeLa cells 
HeLa cells were seeded at 2.45x10
6
mL
-1 
in a T-75 flask containing 20mL DF-1 
growth medium and incubated at 37˚C with 5% CO2 for 24 hours. When HeLa cells were 
70% confluent transfection was carried out. 500μl OptiMEM and 60μl Lipofectamine 2000 
(Invitrogen) was mixed in a clean tube. 500μl OptiMEM containing 10μg of DNA was then 
added gently and the transfection mix was incubated at room temperature for 20 minutes. The 
transfection mix was then added to the HeLa cells and incubated for 12 hours at 37˚C and 5% 
CO2. The transfection mix was then removed and fresh DF-1 growth medium added. Cells 
were incubated for a further 12 hours at 37˚C and 5% CO2 before harvesting. 
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2.5.15 Transfection of PC-3 cells 
 PC-3 cells were seeded at 6x10
6
 cells
 
in a T-75 flask, 4x10
6 
cells in a T-25 flask, 
2x10
6 
cells in a 6 well plate and 5x10
5 
cells in a 24 well plate containing PC-3 growth 
medium and incubated at 37˚C with 5% CO2 for 24 hours. When PC-3 cells were 90% 
confluent transfection was carried out.  For a T-75 flask 500μl Opti-mem and 40μl 
Lipofectamine 2000 were mixed in a clean tube. 500μl OptiMEM containing 10μg of DNA 
was then added gently and the transfection mix was incubated at room temperature for 20 
minutes. The transfection mix was then added to the PC-3 cells and incubated for 12 hours at 
37˚C and 5% CO2. The transfection mix was then removed and fresh PC-3 growth medium 
added. Cells were incubated for a further 12 hours at 37˚C and 5% CO2 before harvesting. 
Transfection mix was scaled down for reduced size transfections. 
 
2.5.16 Transfection of CEF cells 
CEF cells were seeded at 3x10
6
 cells
 
in a 6 well plate containing CEF growth medium 
and incubated at 38.5˚C with 5% CO2 for 24 hours. When CEF cells were 70%-80% 
confluent transfection was carried out. Growth medium was replaced with 800μl OptiMEM 
and 200μl Lipofectamine (Invitrogen) containing 5μg of DNA. Cells were incubated for 1 
hour at 38.5˚C and 5% CO2 before adding 2mL OptiMEM and incubating for a further 12 
hours. Transfection mix was replaced with CEF maintenance medium and incubated for 24-
48 hours at 38.5˚C and 5% CO2. Transfection mix was scaled up or down for different cell 
numbers. 
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2.5.17 Coomassie brilliant blue staining 
 NuPage SDS protein gel was removed and washed in 100mL dH20 for 20 minutes and 
this process repeated twice. Gels were then immersed in Coomassie brilliant blue G-250 
(Pierce) for at least 1 hour at room temperature. The gel was then washed in dH20 for 20 
minutes to remove excess Coomassie blue stain before de-staining in Coomassie brilliant blue 
de-stain solution. De-staining was carried out until bands were clearly visible and the gel was 
dried, scanned or re-hydrated depending on the downstream process.  
 
2.5.18 Silver staining 
 As carried out by Invitrogen protocol. Briefly, after NuPage SDS page electrophoresis 
the gel was removed and washed in dH20 before incubating in fixative solution for 20 
minutes at room temperature with gentle rotation. The gel was then washed in 30% ethanol 
for 10 minutes before removing and incubating in sensitising solution for a further 10 
minutes. The gel was washed in dH20 for 10 minutes before adding staining solution and 
incubating with gentle rotation for 15 minutes. This was followed by washing in dH20 for 45 
seconds before adding developing solution for 8 minutes. Finally, stopper solution was added 
and incubated for 10 minutes before washing in dH20 and further downstream analysis. 
 
2.5.19 Western blot 
Protein samples were resuspended in 2X SDS loading buffer and boiled for 10 
minutes before running on a 4-12% BIS-TRIS gel. Protein was transferred onto a 
nitrocellulose membrane using the iBlot system (Invitrogen) and blocked in PBS-Tween 
(0.05%) containing 5% skimmed milk powder for 1 hour with rocking. The membrane was 
then incubated with the primary antibody of choice (in blocking solution) at a concentration 
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specified by the manufacturer for 1 hour with rocking. The membrane was then washed 3 
times in PBS-Tween for 5 minutes before the addition of the secondary antibody (in blocking 
solution) at the concentration specified by the manufacturer. The membrane was then washed 
a further 3 times in PBS-Tween for 10 minutes and incubated with ECL developing solution 
for 1 min. Film was exposed to the membrane for varying times and developed using the 
Xograph system. 
 
2.5.20 Immunofluorescent staining of cells 
Cells that grow in a monolayer were grown on coverslips and fixed for 30 minutes in 
4% paraformaldehyde before treating with 0.1% Triton X-100 in PBSa for 15 minutes. Cells 
were then washed in PBSa and blocked in 0.5% bovine serum albumin in PBSa for 30 
minutes. Blocking solution was removed and the primary antibody was added at the 
concentration recommended by the manufacturer (in blocking solution). Primary antibody 
incubation was carried out for 60 minutes with rocking before washing 3 times in PBSa. 
AlexaFluor (Invitrogen) species-specific fluorescent conjugate was then diluted at 1:200 in 
blocking solution and incubated with the cells for a further 60 minutes with rocking. Cells 
were washed 3 times in PBSa and stained with DAPI at 1:15000 (in water) for a further 10 
minutes before dipping in water and mounting on slides using Vectashield (Vector Labs). 
Coverslips were then sealed with nail varnish and visualised by confocal microscopy. 
 
2.5.21 Immunofluorescent staining of tissues 
Tissue sections isolated in optimum cutting temperature compound were affixed to 
microscope slides and incubated for 30 minutes in methanol and acetone fixing buffer before 
washing in PBSa for 15 minutes. Tissue sections were then washed with PBSa and blocked in 
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0.5% bovine serum albumin in PBSa for 30 minutes. Blocking solution was removed and the 
primary antibody was added at the concentration recommended by the manufacturer (in 
blocking solution). Primary antibody incubation was carried out for 60 minutes with rocking 
before washing 3 times in PBSa. AlexaFluor species-specific fluorescent conjugate was then 
diluted at 1:200 in blocking solution and incubated with the tissue section for a further 60 
minutes with rocking. Tissue samples were washed 3 times in PBSa and stained with DAPI at 
1:15000 (in water) for a further 10 minutes before dipping in water and mounting on slides 
using Vectashield. Coverslips were then sealed with nail varnish and visualised by confocal 
microscopy. 
 
2.5.22 GST protein purification   
GST protein expression vector of choice was stored in BL21 (DE3) E.coli at -80°C as 
a glycerol stock. This stock was used to inoculate 50mL LB medium (containing ampicillin at 
100μg/mL) and incubated for 18 hours at 37°C with shaking. 10mL of the culture was then 
diluted in 90mL fresh selection medium and incubated for a further 2 hours before inducing 
protein expression by the addition of IPTG to a final concentration of 1mM. Protein induction 
was carried out at 27°C for 3 hours before cells were harvested by centrifugation at 4000xg 
for 10 minutes (4°C). Cell pellets were resuspended in 10mL PBSa containing lysozyme at a 
final concentration of 0.5μg/mL and PMSF at a final concentration of 1mM. Cell suspension 
was incubated on ice for 10 minutes (cells can be stored at -20°C at this point) before 
sonicating to lyse the cells. The soluble fraction was isolated by centrifugation at 4000xg for 
25 minutes (supernatant should be cloudy).  
GST sepharose beads (1mL of 50% slurry per 10mL supernatant) were loaded into a 
column and washed by the addition of 30mL water and 30mL PBSa. Finally, beads were 
73 
 
washed by the addition of PBSa containing 0.1% Triton X-100. The stopper was placed on 
the column and the supernatant from the GST cell lysate was added and incubated for 1 hour 
at 4°C (pipetting up and down occasionally). The supernatant was then allowed to run 
through the column and the beads were washed a further 3 times by the addition of PBSa. 
The beads were resuspended in 1mL PBSa and stored at -80°C. 
 
2.5.23 GST pull-down 
Cells were lysed in GST lysis buffer for 20 minutes on an orbital rotor at 4°C. The 
cell lysate was then centrifuged at 12,000xg for 10 minutes. The supernatant was incubated 
with 250μl GST fusion protein conjugated beads overnight on an orbital rotor at 4°C. The 
beads were then washed by the addition of 1mL NETN buffer followed by centrifugation for 
30 sec at 700xg and removal of supernatant. This was carried out 4 times to remove any un-
bound proteins. Protein was then eluted in 30μl 2X SDS loading buffer and analysed by 
Coomassie brilliant blue staining, silver staining or western blot. 
 
2.5.24 Co-immunoprecipitation 
 DF-1 cells were seeded at 3x10
6
 per T-75 flask and incubated at 38.5ºC for 24 hours 
or until 70-80% confluent. Cells were co-transfected with 10µg of each construct and 
incubated for a further 48 hours. Cells were harvested by scraping and resuspended in 5mL 
ice cold PBSa. Cells were spun at 500xg for 5 minutes and the pellet resuspended in 600µl 
ice cold co-immunoprecipitation lysis buffer. Cell lysis was carried out for 20 minutes at 4ºC 
on a rotor. Lysate was then spun at 13,000xg for 10 minutes at 4ºC and the supernatant 
removed to a clean 0.5mL tube on ice. 150µl was used for each co-immunoprecipitation 
reaction with 150µl remaining for loading controls.  
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 Protein G sepharose beads were prepared by washing in ice cold co-
immunoprecipitation lysis buffer. 15µl of 50% beads:ethanol slurry (7.5µl bed volume) were 
washed in 1mL of ice cold co-immunoprecipitation lysis buffer before spinning at 1000xg for 
2 minutes and removing the supernatant. This was carried out two further times before adding 
200µl total cell lysate and incubating for 1 hour at 4ºC to pre-clear the lysate. Cell lysate was 
then spun at 1000xg for 2 minutes and the supernatant removed for further co-
immunoprecipitation steps. 20µl of rabbit anti-Meq (or antibody of choice at manufacturer’s 
recommended concentration) was added to the pre-cleared lysate and incubated at 4ºC 
overnight. 20µl (bed volume) of protein G sepharose was added to the lysate and incubated 
for a further 2-4 hours at 4ºC before spinning at 1000xg for 2 minutes. Beads were then 
washed by the addition of 1mL ice cold co-immunoprecipitation lysis buffer and spinning at 
1000xg for 2 minutes. Supernatant was removed and washing was repeated a further two 
times. Finally, supernatant was removed and 15µl 2X SDS loading buffer was added to the 
beads before boiling at 100ºC for 10 minutes and loading on 4-12% BIS-TRIS gel for 
western blot analysis. Remaining 200µl samples were used to carry out reverse co-
immunoprecipitation and negative control IgG (α-Tubulin) control. 20µl of the remaining 
sample was used for each co-immunoprecipitation as 10% loading control to confirm the 
presence of each protein of interest. 
 
2.5.25 Luciferase reporter assay 
 DF-1 cells were seeded at 1.5x10
4
 in a 96 well flat bottomed cell culture plate and 
incubated at 38.5ºC overnight. Transfection of firefly luciferase reporter construct was carried 
out along with renilla luciferase control vector and the protein expression construct of choice. 
Cells were incubated for at least 24 hours after transfection and washed in Opti-mem before 
adding the prediluted renilla firefly substrate. Cells were incubated for 20 minutes with 
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shaking at room temperature before harvesting into a white or black opaque 96 well cell 
culture plate. Luminescence was measured using an illuminometer before the prediluted 
firefly substrate was added and recorded as before to acquire the relative luminescence. 
 
2.5.26 Yeast competent cell production 
A single YPDA agar plate was streaked with AH109 cells from a frozen yeast stock 
before incubating at 30°C until colonies appear (~3 days). One colony (diameter 2–3mm and 
< 4 weeks old) was used to inoculate 3mL YPDA medium and incubated at 30°C with 
shaking at 200 rpm for 12 hours. 5μl of the culture was transferred to a 250mL flask 
containing 50mL of YPDA and incubated with shaking until the OD600 reached 0.15-0.3 (16–
20 hours). The yeast cells were centrifuged at 700xg for 5 minutes at room temperature, the 
supernatant discarded and the pellet resuspended in 100mL of fresh YPDA medium. This was 
incubated at 30°C until the OD600 reached 0.4–0.5 (3–5 hours) and the culture divided into 
two 50mL sterile Falcon conical tubes. The cells were centrifuged at 700xg for 5 minutes at 
room temperature, the supernatant discarded and each pellet resuspended in 30mL dH2O. The 
cells were centrifuged at 700xg for 5 minutes at room temperature, the supernatant discarded 
and each pellet resuspended in 1.5mL of 1.1xTE/LiAc. The cell suspensions were transferred 
to two 1.5mL microcentrifuge tubes and centrifuged at 13,000xg for 15 seconds. The 
supernatant was discarded and each pellet resuspended in 600μl of 1.1xTE/LiAc. The 
competent cells were used within 6 hours of production.   
 
2.5.27 Yeast cell transformation 
Plasmid DNA (100ng) and 5μl denatured Herring Testes Carrier DNA (10μg/μl) was 
combined in a prechilled 1.5mL microfuge tube. Competent cells (50μl) were added and 
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gently mixed before the addition of 0.5mL PEG/LiAc. Cells were gently mixed and incubate 
at 30°C for 30 minutes. 20μl DMSO was added and gently mixed before incubating at 42°C 
for 15 minutes. Centrifugation was carried out at 13,000xg for 15 seconds to pellet yeast 
cells, supernatant discarded and cells resuspended in 1mL YPD medium before incubating 
with shaking for 90 minutes. Sample was centrifuged at 13,000xg for 15 seconds to pellet 
yeast cells, supernatant discarded and cells resuspended in 1mL of 0.9% (w/v) NaCl. 
 
2.5.28 Yeast cell mating  
A single fresh, large (2–3 mm) colony of the bait strain was inoculated into 50mL of 
SD/-Trp liquid medium before incubating with shaking (250rpm) at 30°C until the OD600 
reached 0.8 (16–20 hours). The culture was centrifuged at 1000xg for 5 minutes, supernatant 
discarded and cells resuspended in 5mL SD/-Trp. 
 A single aliquot of the library strain was thawed at room temperature in a water bath 
and 10μl removed for titering on SD/-Leu agar plates. The library strain was combined with 
the 5mL bait strain in a 2L flask before the addition of 45mL of 2X YPDA liquid medium 
with 50μg/mL kanamycin. Cells were rinsed from the library vial twice with 1mL 2X YPDA 
and added to the 2L flask before incubating at 30°C for 20–24 hours shaking at 50 rpm. After 
20 hours, a drop of the culture was analysed under a microscope (40X). Zygotes were visible 
as a three lobed structure. Culture was centrifuged at 1000xg for 10 minutes and the 
supernatant discarded. Cells were resuspended in 10mL of 0.5X YPDA/Kan liquid medium 
and the total volume was measured. From the mated culture 100μl of 1/10, 1/100, 1/1,000, 
1/10,000 dilutions were spread on SD/-Trp,SD/-Leu, SD/-Leu/-Trp (DDO) agar  plates and 
incubated at 30°C for 3–5 days. The remainder of the culture was plated, 200μl per 150 mm 
on SD/-Ade/-His/-Leu/-Trp/X-a-Gal (QDO+X-a-Gal) agar plate (50–55 plates). Cultures 
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were incubated at 30°C for 3–8 days. All yeast protocols followed the Clontech matchmaker 
III manual. 
 
2.5.29 Annexin-V apoptosis assay 
 DF-1 or PC-3 cells were seeded for transfection and incubated overnight in growth 
medium. After transfection the cells were incubated for 24 hours and washed in PBSa. 
Annexin-V Fluos reagent (Roche) was diluted in incubation buffer as per manufacturer’s 
instructions and added to the cell monolayer. Cells were incubated at room temperature in the 
dark for 20 minutes before viewing under fluorescent light microscope as per manufacturer’s 
instruction. Annexin-V positive cells were characterised by excitation at 455nm and represent 
early to mid-stages of apoptosis. All transfections and cell counts were carried out in 
triplicate. 
 
 2.5.30 Poly ADP ribose polymerase (PARP-1) cleavage assay 
DF-1 and PC-3 cells were seeded for transfection and incubated overnight in growth 
medium. Transfections were carried out and cells were incubated for 24 hours before 
removing transfection reagent and harvesting total cell protein by lysis in 2X SDS loading 
buffer. Samples were boiled for 10 minutes and spun at 13,000xg for 10 minutes before 
running on NuPage SDS gel. Samples were then subject to western blot analysis with an 
antibody to the apoptotic indicator protein PARP-1. 
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3 Global Meq interactome 
3.1 Introduction 
Meq is an MDV-encoded oncoprotein that is primarily considered to be responsible 
for T-cell transformation and ultimately the rapid onset of Marek’s disease (Kung et al 2001; 
Liu & Kung 2000; Liu et al 1998). Recently, several groups have shown that deletion of the 
Meq gene from the MDV genome results in the abolition of neoplastic transformation and 
also reduced levels of virus replication (Lee et al 2008). These data provide substantial 
evidence for the confirmation of Meq protein as the major contributing factor to 
lymphomagenesis, but the mechanisms by which it acts are still not clear.  
We recently demonstrated that Meq interacts directly with CtBP via a conserved 
PxDLS motif found adjacent to the Meq bZIP domain (Brown et al 2006). Markerless 
replacement BAC mutagenesis was used to abolish this interaction which in turn prevented 
the induction of lymphoma formation in vivo. Although we have shown the interaction with 
CtBP to be vital for Meq mediated oncogenesis, the molecular mechanisms responsible for 
this phenotype are yet to be fully elucidated. However, due to essential interactions with both 
CtBP and c-Jun it is reasonable to assume that as yet undetermined protein-protein 
interactions also play a potentially pivotal role in the function of Meq during viral infection 
and transformation.  
As described earlier, Meq contains two distinct domains that may mediate a number 
of significant protein-protein interactions (Levy et al 2003; Qian et al 1995a). The N-terminus 
(amino acid residues 1-129) is made up of a basic DNA binding domain primarily comprising 
two repeat sequences of basic arginine residues that interact specifically with the acidic major 
groove of a conserved Meq DNA binding domain (Qian et al 1996). This interaction with 
DNA is only viable when Meq is present as a bZIP dimer. These interactions can either be 
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homodimeric or heterodimeric with a change in protein partner potentially mediating the 
specificity of target DNA sequences (Levy et al 2003). A coiled-coil leucine zipper domain is 
found directly adjacent to the basic region to make up the bZIP domain. This leucine zipper 
mediates all bZIP protein-protein interactions made by Meq and has been shown to be vital 
for lymphoma development (Brown et al 2009; Suchodolski et al 2009; Suchodolski et al 
2010). The hydrophobic nature of the leucine core mediates preferential interactions with 
other hydrophobic residues to form stable homodimers or heterodimers (Baxevanis & Vinson 
1993; Fong et al 2004). Leucine zippers primarily interact with other leucine zippers but they 
may also interact with a variety of zinc-finger domains (Lee & Haber 2001; Liu et al 1999). 
The putative CtBP binding domain is also found in the N-terminal region of Meq along with 
a LxCxE motif that potentially interacts with pRB (Parker et al 1996). 
The C-terminus of Meq has been shown to be involved in the activation of target 
genes and because of this is often termed the transactivation domain. Initial investigation 
highlighted this transactivation activity when the Meq C-terminus was fused to the Gal4 
DNA binding domain in order to up-regulate a reporter and in turn this activity was 
significantly reduced with a truncation of the C-terminus (Qian et al 1995a). The Meq C-
terminus is predicted to be primarily composed of random coils although there are several 
regions that potentially comprise a more ordered secondary structure.  
Several proteins have been shown to interact with different regions of the Meq protein 
but it is naïve to suggest that these interactions make up the entire global Meq interactome. 
Ultimately, the identification of novel Meq protein partners will provide additional 
information when unravelling the increasingly complex story of the Meq oncoprotein. 
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3.2 Meq phylogenetic analysis 
Meq has been described as a ‘c-Jun analogue’ (Liu & Kung 2000) but upon first 
impression the leucine zipper domains share few common residues. Although it is clear that 
Meq and c-Jun share several functional characteristics it is important to identify the proteins 
that most closely resemble Meq at the amino acid level in order to make hypotheses as to 
potential novel leucine zipper interactions. This was carried out by aligning the leucine zipper 
domains of all chicken bZIP transcription factors and counting all conserved residues (Table 
3.1). The count was split into four groups: conserved residues at the ‘d’ position; conserved 
residues at the ‘eg’ positions; conserved residues at all other positions ‘abcf’; and the total 
number of conserved residues. The number of conserved residues at the ‘d’ position provides 
little information on the relationship between interacting partners as the hydrophobic core 
simply regulates the stability of leucine zipper interactions. However, the amino acids at 
positions ‘e’ and ‘g’ were aligned as it is these residues that mediate the specificity of a 
leucine zipper interaction. Finally, the alignment of the ‘other’ residues is thought to provide 
little information on the binding specificity of Meq but interestingly it does highlight that the 
Meq protein, and most chicken leucine zipper proteins, contains an asparagine residue at the 
‘a’ position of the second heptad much like most human leucine zipper proteins.  
The alignment shown in Table 3.1 suggests that the functional amino acid residues in 
the Meq leucine zipper domain most closely resemble those found in the BATF3 and BATF 
proteins. Furthermore, the total number of conserved residues provides little significance in 
terms of functional comparison but they do suggest that the Meq leucine zipper is most 
closely related to the BATF3 leucine zipper. Meq shares a total of four residues at positions 
‘e’ and ‘g’ with BATF3 and BATF, three with ATF7 and two with eleven other proteins. 
Although Meq is suggested to be analogous to c-Jun, the leucine zipper region shows very 
little amino acid conservation with a total of only one shared residue at the ‘e’ and ‘g’ 
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positions. In fact, c-Jun has one of the most divergent leucine zippers in the group showing 
very little sequence conservation to Meq or any other protein. Also, Meq seems to be more 
closely related to Fos than Jun which adds weight to the hypothesis that Meq preferentially 
binds Jun (Levy et al 2003) in a similar manner to Fos (Abate & Curran 1990). This analysis 
also confirms that Meq is indeed a true AP-1 family member (Jones et al 1992b) as both 
BATF and BATF3 bind c-Jun in an AP-1 complex. 
This alignment was further used to generate a phylogenetic tree of Meq in comparison 
with the chicken leucine zipper proteins (Figure 3.1). Alignment and subsequent phylogenetic 
analysis of leucine zipper domains and also functional leucine zipper residues (Figure 3.2) 
suggests that Meq is indeed more closely related to the BATF family of transcription factors 
than it is to c-Jun. The basic regions were also aligned and subject to phylogenetic analysis 
(Figure 3.3) which confirms these DNA binding regions of the Meq protein are also most 
closely related to those found in the BATF family. 
From phylogenetic analysis we hypothesise that the Meq leucine zipper is most likely 
to interact with proteins that are known to interact with BATF and BATF3. Table 3.2 shows 
all known BATF and BATF3 interaction mediated by the leucine zipper domains. It is 
important to note that these molecules have been shown to make several other protein-protein 
interactions via a non-leucine zipper context but these interactions are not included. BATF 
interacts most readily with the Jun family of bZIP proteins that include Jun, JunB and JunD 
but a weak interaction with Fos has also been reported (Dorsey et al 1995). Little is known 
about BATF3 but interactions have been reported with both Jun, ATF3 (Dorsey et al 1995) 
and more recently a weak interaction with Meq was identified (Reinke et al 2010). Meq has 
been shown to interact with Jun and weakly with Fos (Levy et al 2003). 
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It is interesting to note that Meq is most closely related to proteins that are known to 
preference the formation of heterodimers. This also fits with the general consensus that, 
although Meq can form functional homodimers (Suchodolski et al 2009; Suchodolski et al 
2010), heterodimers with Jun and other proteins are more readily formed and vital to the 
oncogenic nature of the protein. 
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Table 3.1 Meq and chicken leucine zipper protein alignment. Chicken bZIP 
transcription factor proteins (sequences mined from Ensembl build 46) were aligned with 
Meq leucine zipper using ClustalX. Conserved core residues at the ‘d’ position are 
highlighted in yellow  and functional ‘eg’ residues are shown in dark grey. All other 
conserved residues ‘abcf’ are shown in light grey. Non-conserved residues are not 
highlighted. Counts indicate number of conserved residues at the ‘d’ position; number of 
conserved residues at the ‘eg’ positions; number of conserved residues other all other 
positions; and total number of conserved residues. The register sequence denotes the position 
of each residue within the leucine zipper domain running sequentially from A to G.  
* Denotes a stop codon 
Protein Leucine zipper amino acid sequence D EG Other Total 
REGISTER CDEF GABCDEFGABCDEFGABCDEFGABCDEFGABCDEFGABCDE   
 
 
 
MEQ KQTD YVDKLHEACEELQRANEHLRKEIRDLRTECTSLRVQLACHE   
 
 
BATF3 KQTQ KADKLHEEYESLEQENTSLKKEIGKLTDEMKHLSEVLKDHE 6 4 11 21  
BATF RQTQ KADTLHLESEDLERQNAALRREIKQLTEEMKHFT 4 4 5 14 
ATF7 KRKL WVSSLEKKAEELTTQNIQLSNEVTLLRNEVAQLKQLLLAHK 6 3 6 14 
ATF2 KRKL WVQSLEKKAEDLSSLNGQLQNEVTLLRNEVAQLKQLLLAHK 6 2 5 13 
CREB5 KRKV WVMSLEKKAEELTQTNMQLQNEVSMLKNEVAQLKQLLLTHK 6 1 6 13 
CREB3 RKKI YVDGLENRVAACTAQNHELQKKVQLLQKQNMSLLEQLRKLQ 4 2 6 12 
CREB3L1 KKKE YVECLEKKVETYTTENNELWKKVETLESANRTLLQQLQKLQ 4 2 6 12 
CREB3L2 KKKE YMDSLEKKVENCSNENSELRKKVEVLESTNRTLLQQLQRLQ 4 2 5 12 
FOSL2 RRRE LTEKLQAETEVLEEEKSVLQKEIAELQKEKEKLEFMLVAHS 6 2 5 12 
CREB3L3 KKKE YIDGLESRMSACTAQNQELQRKVLHLEKQNSSLLEQLKKLQ 4 2 5 11 
ATF3 KKKE KTECLQKESEKLETINAELKAQIEELKNEKQHLIYMLNLHR 6 1 4 11 
ATF4 KKRA EQEALSGECRDLEQKNQALKEKADSLSKEIQYLKDLIEEVR 5 1 4 10 
CEBPB ETQH KVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASS 5 1 4 10 
JUN RKLE RIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHV 6 1 2 9 
ATF1 KKKE YVKCLENRVAVLENQNKTLIEELKTLKDLYCHKS 4 2 3 9 
CREB1 KKKE YVKCLENRVAVLENQNKTLIEELKALKDLYCHKS 4 2 3 9 
CREM KKKE YVKCLENRVAVLENQNKTLIEELKALKDLYCHKA 4 2 3 9 
BACH2 RKLD CIQNLECEIRKLVCEKEKLLSERNQLKASMGELLDNFSCLS* 5 0 3 8 
BACH1 RKLD CIQNLESEIEKLQNEKENLLKERNLIL 3 1 4 8 
ATF6 KKKE YMLGLEARLEAALLENEKLKKENSTLKRQLDEVV 2 2 4 8 
PAR-4 DKEE VIGKLKEEIDLLNRDLDDIEDENEQLKQENKTLLKVVGQLT 4 1 1 7 
TEF QITI RAAFLEKENTALRTEVAELRKEVGRCK 3 2 2 7 
HLF QIAI RASFLEKENSALRQEVADLRKELGKCK 3 2 1 6 
MAFF KRVC QKEELQKQKMELEWEVDKLARENAAMR 3 1 2 6 
MAFG KRVT QKEELEKQKAELQQEVEKLASENASMK 3 1 2 6 
MAFK KRVT QKEELERQRVELQQEVEKLARENSSMK 3 1 2 6 
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Figure 3.1 Phylogenetic analysis of Meq and cellular leucine zipper containing 
proteins. The full length leucine zipper residue sequences of all chicken bZIP transcription 
factors were aligned and phylogenetic analysis carried out using treeview function and pair-
wise alignment in ClustalX. Meq groups with the BATF family (red), CREB family members 
group together (blue), ATF7 and CREB5 group together (green) and the MAF family (light 
grey) and TEF/HLF (dark grey) group together. Scale bar is measured as a percentage and bar 
represents 10% divergence. 
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Figure  3.2 Phylogenetic analysis of Meq and cellular functional leucine zipper 
residues. The residues responsible for bZIP dimerisation specificity were aligned and subject 
to phylogenetic analysis using treeview function and pair-wise alignment in ClustalX. Meq 
groups with BATF and BATF3 (red), CREB family member group together (blue), ATF7 and 
CREB5 group together (green) and the MAF (light grey), HLF, TEF and Q5ZMD5 families 
(dark grey) group together. Scale bar is measured as a percentage and bar represents 10% 
divergence. 
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Figure 3.3 Phylogenetic analysis of Meq and cellular DNA binding domains. The 
basic residues responsible for DNA binding were aligned and subject to phylogenetic analysis 
using treeview function and pair-wise alignment in ClustalX. Meq groups with BATF and 
BATF3 (red), CREB and other AP-1 family members group together (blue), ATF7 and 
CREB5 group together (green) and the MAF family (dark grey) group together. Scale bar is 
measured as a percentage and bar represents 10% divergence. 
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Table 3.2 BATF and BATF3 leucine zipper mediated interactions. BATF interacts 
via the leucine zipper domain with all members of the Jun family (Jun, JunB and JunD) and 
weakly with Fos. BATF3 has been shown to interact with both ATF3, Jun and Meq. Meq has 
previously been shown to interact with Jun, Fos and itself. 
 
 
Partner 
DNA 
binding 
Function 
Meq 
partner 
Reference 
BATF 
   
YES (Reinke et al 2010) 
 
Jun TGA[C/G]TCA Repression (AP-1 sites) YES (Williams et al 2001) 
 
JunB TGA[C/G]TCA 
 
YES (Dorsey et al 1995) 
 
JunD TGA[C/G]TCA 
 
YES (Dorsey et al 1995) 
 
Fos 
  
YES (Dorsey et al 1995) 
BATF3 
   
NO (Reinke et al 2010) 
 
ATF3 
  
YES (Dorsey et al 1995) 
 
Jun TGA[C/G]TCA Repression (IL-2 gene) YES (Dorsey et al 1995) 
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3.3 Predicted interactions mediated by the Meq leucine zipper 
The Meq leucine zipper amino acid sequence was aligned with the chicken leucine 
zipper amino acid sequences and a dimerisation likelihood prediction was made using a 
computational base optimized weights method described in (Fong et al 2004) (Table 3.3). 
Favourable and unfavourable electrostatic weights were assigned to each potential residual 
interaction to produce a positive, negative or neutral score for each interaction. The predicted 
interactions were carried out in a pair-wise fashion with the score representing the most 
energetically favourable position for an interaction to occur. From Table 3.1 we can see that 
not only do many of the chicken leucine zipper proteins show a high degree of homology 
with each other but also to the Meq leucine zipper. This however, is not surprising 
considering the conserved nature of leucine zipper domains cross protein and even species.  
Proteins with an assigned base optimized weight of ≥32.8 are considered high 
confidence predicted interactions. Protein interaction predictions with a score ≥32.8 were 
experimentally shown to be correct 92% of the time (Fong et al 2004). A high confidence in 
dimerisation prediction cannot be made for protein scores of <32.8 but proteins that score 
>28 have a significantly greater likelihood of an interaction than those with a score of <28. 
The strongest interactions are predicted between Meq and ATF7, CREB5, ATF2, BATF3, 
Jun, BACH2 and BATF. Although Meq has been shown to interact with Jun, human ATF2, 
human ATF7 and human BATF3, functional studies are yet to be carried out with any protein 
other than Jun. The strongest novel interaction is predicted to be with CREB5. It is also 
interesting to note that known interactions with ATF1 and CREB1 produced scores of >28 
but <32.8. This adds confidence to the predicted novel interactions with CREB3L2, CREB3 
and Par-4. 
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Table 3.3 Meq known and predicted leucine zipper interactions. Listed are known leucine zipper mediated interactions made by Meq. 
‘Yes’ denotes a known interaction; ‘No’ denotes no interaction and ‘Weak’ denotes a weak known interaction.  Meq interactions with human 
and chicken homologs are listed. Predicted interactions are provided with those in blue a strong likelihood interaction, those in green a moderate 
likelihood interaction and those in red a low likelihood interaction. Interaction scores are provided as base optimised weights (Fong et al 2004). 
Protein 
           Known interactions 
         Human                       Chicken 
Predicted 
interactions 
Interaction score References 
MEQ N / A  N / A  Y E S  43.213 
 
BATF3 Y E S  N O  Y E S  40.651 (Reinke et al 2010) 
BATF N O  N O  Y E S  33.090 
 
ATF7 Y E S  N O  Y E S  46.073 (Reinke et al 2010) 
ATF2 Y E S  N O  Y E S  43.514 (Reinke et al 2010) 
CREB5 N O  N O  Y E S  43.650 
 
CREB3 Y E S  NO YES 29.085 (Reinke et al 2010) 
CREB3L1 N O  NO YES 28.887 
 
CREB3L2 N O  NO YES 30.173 
 
FOS W E A K  NO NO 26.017 (Reinke et al 2010) 
CREB3L3 N O  NO NO 26.480 
 
ATF3 Y E S  NO NO 26.416 (Levy et al 2003; Reinke et al 2010) 
ATF4 N O  NO NO 26.589 
 
CEBPB N O  NO NO 26.905 
 
JUN Y E S  Y E S  Y E S  36.993 (Levy et al 2003; Reinke et al 2010) 
ATF1 Y E S  NO YES 29.857 (Levy et al 2003; Reinke et al 2010) 
CREB1 Y E S  NO YES 29.857 (Levy et al 2003; Reinke et al 2010) 
CREM N O  NO NO 27.494 
 
BACH2 N O  NO Y E S  33.478 
 
BACH1 N O  NO NO 24.589 
 
ATF6 W E A K  NO NO 21.583 (Reinke et al 2010) 
PAR-4 N O  NO YES 28.708 
 
TEF N O  NO NO 17.141 
 
HLF N O  NO NO 16.584 
 
MAFF N O  NO NO 10.663 
 
MAFG N O  NO NO 9.141 
 
MAFK N O  NO NO 8.485 
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3.4 Yeast two-hybrid library screen 
The Meq protein has recently been subject to medium scale protein interaction screen 
against human bZIP proteins (Reinke et al 2010). This provided valuable insight into several 
known and novel interactions made by Meq but the main drawback of the study was the use 
of small peptides with corresponding sequences to a pool of leucine zippers found in humans. 
Crucially, this study fails to investigate interaction with full length proteins and furthermore 
fails to confirm these interactions with homologous chicken proteins. In order to investigate 
the ‘global Meq interactome’ we decided to utilise the classical yeast two-hybrid technology 
in order to screen a cDNA library for potential novel partners. It was hoped that this would 
provide a concise overview of Meq interactions and also act to confirm the predicted 
interactions shown in Table 3.3. Meq was used as the ‘bait’ in the Clontech matchmaker III® 
yeast two-hybrid screen against a ‘prey’ HeLa cDNA pre-transformed library. For the 
purpose of this investigation the Meq protein was truncated into two shorter proteins to allow 
for better protein expression and reduced chance of autoactivation to the reporter system. 
Meq was truncated and fused to the GAL4 DNA binding domain to produce two chimeric 
proteins that were named after the amino acid residue composition. Meq
(1-129)
 and Meq
(130-339)
 
were amplified using conventional PCR methods and cloned in frame with the GAL4 DNA 
binding domain present in the pGBKT7 vector. The proteins were tagged with the myc 
epitope and subject to sequence analysis to confirm cloning in the absence of error or frame 
shift. 
 
3.4.1 Protein expression 
The bait proteins of interest were expressed in the yeast cell lines and assayed by 
western blot before carrying out the library mating experiment. A single colony was used in 
the case of both strains to inoculate an SD/-Trp culture before harvesting at two steps during 
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lysis on glass beads with cracking buffer. Samples were subject to western blot with both 
anti-Meq antibody (FD7) and anti-GAL4 antibody.  Meq
(1-129)
 was probed with FD7 as this 
monoclonal Meq antibody recognises the Meq N-terminal whereas Meq
(130-339)
 was probed 
with anti-GAL4 DNA binding domain antibody. The signal produced by western blot for 
both proteins provides adequate evidence for the expression of each protein in the yeast stain 
(Figure 3.4A and B). This allowed the progression of the assay. 
 
3.4.2 Autoactivation assay 
The pGBKT7-Meq
(1-129)
 and pGBKT7-Meq
(130-339)
 vectors were transformed into the 
S. cerevisiae AH109a yeast strain independently where they are able to replicate 
autonomously. Transformation was carried out using the Lithium Acetate assay described in 
chapter two to produce the AH109a-Meq
(1-129)
 and AH109a-Meq
(130-339)
 stains selected on 
SD/–Trp media in the first instance. When incubated with X-α-Gal, Meq(1-129) failed to induce 
the formation of blue colonies whereas the Meq
(130-339)
 construct induced blue colony 
formation after a period of 4 days. Meq
(130-339)
 colonies were re-streaked on triple drop out 
media (SD/-Trp/-Leu/-Ade) containing X-α-Gal and colonies failed to develop. Due to the 
fact that both constructs failed to produce colonies when streaked on the most stringent 
reporter media they passed the autoactivation assay as described by the manufacturer’s 
specification. Although a higher stringency was required to abolish blue colony formation for 
the Meq
(130-339)
 construct this is perhaps not surprising since it has already been demonstrated 
that the Meq C-terminus acts as a transactivation domain when fused to the GAL4 DNA 
binding domain (Qian et al 1995b). 
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3.4.3 Toxicity assay 
Toxicity is measured due to the lethal nature of some proteins to the yeast cell. A 
single colony must initially grow to a size ≥2mm upon transformation after incubation for 4 
days. After AH109a was transformed with both Meq
(1-129)
 and Meq
(130-339)
 colonies grew to a 
size of 2-4mm on SD/-Trp media after this time period. For confirmation that the proteins are 
non toxic to AH109a a single colony was used to inoculate SD/-Trp and incubated overnight. 
Yeast growth was assayed for Meq
(1-129)
 and Meq
(130-339)
 by measuring optical density at 
600nm. Meq
(1-129)
 and Meq
(130-330)
 inoculations produced healthy cultures with an OD600 of 
0.81 and 0.43 respectively. Although AH109a-Meq
(1-129)
 grew significantly faster than 
AH109a-Meq
(130-339)
 both of these values are within the expected range provided by 
Clontech. The slow growth of Meq
(130-339)
 suggests that it is slightly toxic to the harbouring 
AH109a yeast cell. 
 
3.4.4 Yeast mating 
  The pre-transformed HeLa cell cDNA library was subject to serial dilution and 
titration on SD/-Leu media in order to confirm validity. A single vial of pre-transformed 
HeLa cell cDNA library was used for each assay with both vials containing >1X10
7
 colony 
forming units mL
-1
. 
The transformed Meq bait strains were mated with the S. cerevisiae Y19α strain 
containing the HeLa cell cDNA library. This was carried out by incubation for 24 hours with 
slow rotation to allow maximal contact between the yeast strains. Mating was visualised 
using confocal microscopy and confirmed by the presence of clear three-lobed structures seen 
in Figure 3.4C and D. After mating the culture was plated by spreading on quadruple drop out 
media containing X-α-Gal and incubated for 7 days. Positive interacting clones were 
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represented by the formation of blue colonies that began appearing after only 3 days. Yeast 
mating efficiency was measured by serial dilution and titration on SD/-Trp/-Leu drop out 
media. The limiting factor in both mating incubations was the pre-transformed library with a 
total mating efficiency of ≥5% in both cases. This corresponds to the expected mating 
efficiencies provided by the manufacturer. 
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Figure 3.4 Yeast two-hybrid bait protein expression and yeast strain mating. A. 
shows Meq
(1-129)
 expression in the AH109 strain. The first and second extracted fractions are 
immunoblotted with anti-Meq antibody (FD7). B. shows Meq
(130-339)
 expression in the 
AH109 strain and immunblotted with anti-GAL4 antibody. C. and D. show mating events 
characterised by the highlighted three lobed structures in both Meq
(1-129)
 and Meq
(130-339)
 yeast 
two-hybrid screen. Scale bar represents 40µm. 
  
AH109a-Meq
(1-129) 
Y19α-HeLa library 
 
AH109a-Meq
(130-339) 
Y19α-HeLa library 
 
A. B. 
C. D. 
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Bait Autoactivation Library titre 
Mating 
efficiency 
Clones 
screened 
Positive 
clones 
Meq
(1-129)
 NO (DDO) 3X10
7
 mL
-1
 5.3% 4.95X10
6
 46 
Meq
(130-339)
 NO (TDO) 3.6X10
7
 mL
-1
 12.3% 7.48X10
6
 22 
 
Table 3.4 Meq
(1-129)
 and Meq
(130-339)
 yeast two hybrid screen. Meq
(1-129)
 and Meq
(130-
339)
 failed to autoactivate the reporter system under the most stringent growth conditions 
(TDO growth media). HeLa cDNA library titres both exceeded the manufacturer’s 
recommendation (>1X10
7
 mL
-1) and the mating efficiency of both assays was ≥5%. Total 
clones screened were over the expected 1X10
6
 and the resulting positive interacting clone 
counst for Meq
(1-129)
 and Meq
(130-339)
 were 46 and 22 respectively. 
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3.4.5 Yeast two-hybrid clone analysis 
Yeast strains are able to harbour more than one bacterial vector at one time which 
allows the expression of both bait and prey proteins in a single yeast cell. If a direct 
interaction occurs blue colonies form on selective media over a period of 5-7 days. The initial 
24 hour mating event resulted in the formation of 46 positive colonies for the Meq
(1-129)
 bait 
and 22 colonies for the Meq
(130-339)
 bait. Positive clones were assigned a number relating to 
the time post incubation at which a resulting blue colony formed. Meq
(1-129)
 positive 
interacting clones all produced positive colonies within 5 days whereas Meq
(130-339)
 positive 
interacting clones produced colonies within 7 days. All positive colonies were ≥2mm in 
diameter. 
However, the ability of yeast cells to harbour more than one bacterial plasmid also 
poses a problem when identifying positive colonies that contain the ‘bait’ vector and a single 
‘prey’ vector. In order to prevent the analysis of polyclonal ‘prey’ vectors, positive colonies 
were re-streaked on selective media 3-4 times with continual PCR analysis. Several positive 
colonies were lost and classed as false positives during re-streaking due to white colony 
development. Prey clones were isolated from yeast culture and subject to sequence analysis. 
Sequenced clones were then subject to BLAST genome analysis to identify gene names and 
to ascertain whether a homologous partner was found in the chicken genome. Meq
(1-129)
 
interactions are shown in Table 3.5 and Meq
(130-339)
 interactions are shown in Table 3.6. 
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Table 3.5 Meq
(1-129)
 yeast two-hybrid positive interacting clones. Table show all positive clone interactions with Meq
(1-129)
. Clone number 
corresponds to the time in which the clones produced positive colonies and the name indicates the gene name of identified positive clones. 
Compartment relates to the normal cellular localisation of the protein and function relates to the normal cellular process related to the gene. The 
presence of each protein in the chicken genome is also highlighted (Ensembl build 46 was used unless stated otherwise).
 Clone name Compartment Function   Chicken Reference 
1 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
2 Zinc finger BTB-9   N  
3 ATF3 Nucleus; Cytoplasm Transcription factor Y (Hai et al 1999) 
5 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
6 Zinc finger BTB-9   N  
7 RGS16 Plasma membrane Receptor N  
11 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
12 CtBP Nucleus Trans-repressor Y (Chinnadurai 2009) 
14 C3orf21   N  
15 c-Fer Nucleus Tyrosine kinase Y (Greer 2002) 
20 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
21 N4BP1 Nucleus; Cytoplasm E3 ligase inhibitor Y (Oberst et al 2007) 
22 JunD Nucleus Transcription factor N (Meixner et al 2010) 
23 JunD Nucleus Transcription factor N (Meixner et al 2010) 
24 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
25 Par-4 Nucleus; Cytoplasm Pro-apoptosis Y (Shrestha-Bhattarai & Rangnekar 2010) 
26 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
29 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
31 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
32 RACK1 Nucleus; Cytoplasm PKC chaperone Y (Severino et al 2004) 
33 JunD Nucleus Transcription factor N (Meixner et al 2010) 
36 JunB Nucleus Transcription factor N (Piechaczyk & Farras 2008) 
37 Zinc finger BTB-9   N  
39 ATF3 Nucleus; Cytoplasm Transcription factor Y (Hai et al 1999) 
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Table 3.6  Meq
(130-339)
 yeast two-hybrid positive interacting clones. Table show all positive clone interactions with Meq
(130-339)
. Clone 
number corresponds to the time in which the clones produced positive colonies and the name indicates the gene name of identified positive 
clones. Compartment relates to the normal cellular localisation of the protein and function relates to the normal cellular process related to the 
gene. The presence of each protein in the chicken genome is also highlighted (Ensembl build 46 was used unless stated otherwise). 
 Clone name Compartment Function Chicken Reference 
1 Pin1 Nucleus; Cytoplasm cis/trans proline isomerase Y (Lee et al 2011) 
3 PLCD3 Cytoplasm Calcium binding N (Marshall & Caldwell 1992) 
4 PDE1C Cytoplasm 
hydrolysis of the cyclic 
nucleotides cAMP 
N (Rybalkin et al 2003) 
5 LGALS1 Membrane Galectin N (Perillo et al 1998) 
6 Cox11 Mitochondria NADH transfer chain Y (Carr et al 2005) 
7 Flavoprotein A Cytoplasm 
 
Y 
 
8 Flavoprotein A Cytoplasm 
 
Y 
 
12 Flavoprotein A Cytoplasm 
 
Y 
 
13 Metallothionein 2A Nucleus; Cytoplasm 
 
Y (Maghdooni Bagheri et al 2011) 
16 PSAP Mitochondria Lipid binding Y 
 
18 LDHA Cytoplasm Anaerobic glycolysis Y (Toyoda et al 2009) 
22 TBRG4 Cytoplasm; Mitochondria Kinase Y 
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3.4.6 Yeast two-hybrid back screen 
Positive interacting clones were purified from yeast cultures and transformed directly 
back into yeast containing either the Meq bait vectors or the empty bait vector. The screen 
was carried out as per manufacturer’s instructions. The ‘back screen’ was carried out for 
ATF3, Par-4, N4BP1 and RACK1 in the case of the Meq
(1-129)
 bait and Pin1 in the case of the 
Meq
(130-339) 
 bait. Selection was carried out on double amino acid drop-out medium to allow 
colony formation in the empty vector control group to determine whether transformation was 
successful. Quadruple amino acid drop-out medium containing X-α-Gal was used for more 
stringent selection and blue colony formation for positive interactions. The results for the 
back screens are shown in Figure 3.5. 
The Meq
(1-129)
 interactions with ATF3, N4BP1, Par-4 and RACK1 were confirmed 
due to blue colony formation on quadruple drop-out medium containing X-α-Gal. White 
colonies formed on the double drop-out medium containing the empty vector and positive 
interacting clone, indicating a good transformation efficiency. No colonies grew on quadruple 
drop-out medium when transformed with the empty vector and Meq
(1-129)
. The Meq
(130-339)
 
interaction with Pin1 was confirmed due to blue colony formation on quadruple drop-out 
medium containing X-α-Gal. White colonies formed on double drop-out medium plates when 
transformed with the empty vector and Pin1, while no colonies grew on quadruple drop-out 
medium containing the empty vector and Pin1.  
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Figure 3.5 Yeast two-hybrid back screening analysis of positive interactions. The pGBKT7 vector containing the Meq bait was co-transformed 
into the yeast strain AH109a with each positive clone (above). The interaction is confirmed by the growth of blue colonies on quadruple drop-out 
medium (QDO). The negative control vector (pGBKT7 only) was also co-transformed (below) with each positive clone in order to reject the suggestion 
of a false positive but autoactivation of the reporter. This was carried out for Meq
(1-129)
 and Meq
(130-339)
 respectively. 
Meq:ATF3 Meq:RACK1 Meq:Par-4 Meq:N4BP1 Meq:Pin1 
Vector:ATF3 Vector:RACK1 Vector:Par-4 Vector:N4BP1 Vector:Pin1 
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3.5 Meq interactions by LC-MS/MS analysis 
 Direct interactions are were investigated using the classical yeast two-hybrid approach 
described previously but indirect interactions were investigated using an LC-MS/MS 
approach. The Meq protein and the non-oncogenic L-Meq protein were expressed in CEF 
with a HA tag by transduction with a recombinant RCAS virus. Cells were incubated with the 
virus for a period of 4 days before harvesting and subject to western blotting and 
immunofluorescence for confirmation of Meq expression (Figure 3.6A and B). Co-
immunoprecipitation with HA antibody conjugated agarose beads was then carried out for 
Meq, L-Meq and a Meq negative cell lysate. Samples were eluted and run on SDS gel before 
silver staining. Gel slices were prepared from the experimental lanes and subject to trypsin 
digest before analysis on LC-MS/MS. Gel slices and well numbering can be seen in Figure 
3.6C.  
 Co-immunoprecipitation and subsequent LC-MS/MS analysis was carried out in 
duplicate. Interactions were identified with several cellular proteins. However, a large 
majority of these were deemed to be unlikely in the cellular context due to their cellular 
localisation. This is likely to be a result of post cell lysis interactions or non-specific binding.  
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Figure 3.6 Meq and L-Meq co-immunoprecipitation for LC-MS/MS interactions 
analysis. A. RCASMeq and L-Meq was used to over-express each protein in CEF cells 
before western blotting and B. immunofluorescent analysis. C. Meq and L-Meq were co-
immunoprecipitated from RCAS transduced CEF cells after a period of 4 days. Whole cell 
lysates were run in the first three lanes for comparison as loading controls. Alpha numeric 
coordinates relate to well numbers for high throughput digest and LC-MS/MS analysis by the 
proteomics group at IAH, Compton, Berkshire, UK.  
A. C. 
B. 
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3.6 Discussion 
3.6.1 Meq phylogenetic analysis  
 The application of phylogenetic trees in this study provides an excellent method to 
visualise identical amino acid conservation between multiple proteins at a sequential level. 
By no means does this study make claim to the evolutionary significance of these results but 
this would be an extremely interesting direction to take these data. Little is known about 
many of these proteins and sequence alone is not enough to class them as orthologous (a gene 
from a different species related to another by common ancestral DNA sequence) or 
paralogous (a gene duplicated in the genome that has evolved a different function over time) 
so it is important to note that all phylogenetic data in this study can only contribute towards a 
hypothesis at this point.  Alignment and phylogenetic analysis of the Meq leucine zipper 
provided interesting comparisons with the BATF family of bZIP transcription factors. The 
BATF gene (also known as p21SNFT) was originally isolated from a cDNA library prepared 
from Epstein-Barr virus stimulated human B cells (Dorsey et al 1995). Originally described 
as a member of the AP-1 transcription factor family it was shown to interact with c-Jun, 
JunB, JunD and weakly with Fos in order to mediate DNA binding to the AP-1 consensus 
sequence (Dorsey et al 1995). However, unlike AP-1 family members, BATF does not 
contain a transactivation domain and was shown to negatively regulate AP-1 mediated 
transcription and block cellular transformation by Ras and Fos (Echlin et al 2000; Williams et 
al 2001). More recently, BATF has been identified as a vital component required for the 
differentiation of IL 17 producing T helper cells (Martinez & Dong 2009; Schraml et al 2009) 
and so plays a key role in both transformation and the development of the adaptive immune 
system. It has also been observed that the EBV-encoded EBNA2 protein is responsible for 
up-regulating BATF (Johansen et al 2003) which presented possible roles for BATF during 
viral transformation.  
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It is interesting to note that BATF seems to play a key role in a variety of different 
cellular processes, but perhaps more importantly BATF has been shown to be up regulated by 
EBV. Direct comparisons can be made between MDV and EBV but the bZIP proteins 
expressed by each virus are not thought to be analogous. Meq is known to be vital to the 
oncogenic nature of MDV whereas the EBV-encoded BZLF1 protein is more actively 
involved in reactivation of the virus from latency (Speck et al 1997).  
 BATF3 also lacks the transactivation domain present in most AP-1 family 
members and thus is a transcriptional repressor molecule. BATF3 has been shown to 
negatively regulate IL-2 (Iacobelli et al 2000) and MMP-1 (Bower et al 2004). Little else is 
known about this protein but it was also recently described as one of several proteins up-
regulated in the Hodgkin's lymphoma cell line L1236 (Schwering et al 2003). Interestingly 
the human BATF3 leucine zipper was recently shown to interact with the Meq leucine zipper 
domain (Reinke et al 2010) but functional studies are yet to be carried out.  
 
3.6.2 Predicted Meq interactions mediated by the leucine zipper 
 The computational weights method described in chapter two indicates that Meq is 
predicted to most readily interact with ATF7, CREB5, ATF2, BATF3, Jun, BACH2 and 
BATF. Interactions with ATF7, ATF2, BATF3 and Jun have already been established but 
interactions with CREB5, BACH2 and BATF are yet to be identified. These predicted 
interactions provide significant insight into the global Meq interactome due to their high 
throughput nature but it is clear that biochemical evidence is required to back up these in 
silico data. Four of the top seven have already been confirmed as Meq interacting proteins in 
the literature, providing a strong positive control for this in silico approach.  
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It is extremely difficult to hypothesise what the functional significance of interactions 
with cellular leucine zipper containing proteins would be. This is due to the huge variability 
in cellular processes that these proteins take part in. However, it is reasonable to assume that 
leucine zipper interactions with different members of the ATF, CREB, BATF, BACH and 
Jun families have the potential to transactivate or transrepress a huge number of target genes 
as well as carry out non-transcription factor functions such as those related to epigenetics, 
cell cycle regulation or apoptosis. If the primary role of Meq is to act as a transcription factor 
it has the potential to interact with an unprecedented number of protein partners. In fact, only 
the Jun proteins have been shown to potentially interact with more leucine zipper partners 
than Meq. 
The further six proteins that are neither a strong interaction prediction nor a strong 
non-interaction prediction also provide a mixture of known and potentially novel protein 
interactions. Known interactions are made between Meq and ATF1 and CREB1 while 
interactions with CREB3L1, CREB3L2, CREB3, and Par-4 are yet to be identified in the 
literature. These proteins also provide a varied mixture of transcription factors and repressors 
but the incorporation of Par-4 is perhaps the most interesting.  In cancer cells undergoing 
apoptosis Par-4 has been shown to translocate to the nucleus where it up-regulates apoptosis 
(El-Guendy et al 2003). The majority of known Par-4 protein interactions are mediated by the 
leucine zipper domain and it was primarily found to interact with Wilms' tumour suppressor 
(WT1) (Johnstone et al 1996) to result in repression of the anti-apoptotic Bcl-2 protein 
(Cheema et al 2003). A potential interaction with Meq proves extremely interesting due to the 
apoptotic nature of this leucine zipper containing protein. 
In conclusion, predicted interactions with novel leucine zipper containing proteins 
have been supported with the prediction of interactions with known Meq partners. This 
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provides substantial evidence for these novel interactions but it is clear that further 
investigation is necessary to successfully uncover the global Meq interactome. 
 
3.6.3 Yeast two-hybrid screen 
The yeast two-hybrid screen provided an excellent overview of Meq interactions with 
cellular proteins. The screen was carried out using the Clontech matchmaker 3® yeast two-
hybrid system which results in a greatly reduced number of false positive interactions due to 
its quadruple selection method. First generation yeast two-hybrid systems inherently 
produced a large number of false positive interactions due to the selection mechanism. The 
two most prevalent reasons for false positive expression of the reporter system are 
interactions with sequences flanking the Gal4 binding site and those that interact with 
transcription factors bound to the TATA box. This is overcome by the use of the S. cerevisiae 
AH109 yeast strain which contains three reporter genes (ADE2, HIS3 and MEL1) under the 
control of three heterologous Gal4 upstream activation sequences and promoters (James et al 
1996). This allows a range of different selection mechanisms and also the ability to select 
under varying pressures. 
A HeLa cDNA library was chosen to carry out the yeast two-hybrid screen. This was 
in part due to the lack of a viable and compatible chicken cDNA library but also due to the 
apparent shortcomings of the chicken genome annotation. Although a human cDNA library is 
not ideal for this task, the availability of highly efficiency pre-transformed libraries and the 
complete and well annotated nature of the human genome sequence made this the most viable 
option. However, the limitations of using the human genome are clear so careful 
bioinformatics analysis was employed in order to confirm homologous chicken genes after 
the identification of novel protein-protein interactions. 
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Meq
(1-129)
 contains the bZIP region of Meq so it was expected to pull out several 
known leucine zipper interacting proteins. JunB was the most common interacting partner 
found in the whole yeast two-hybrid assay as the Meq
(1-129)
 protein pulled JunB out of the 
HeLa library on nine occasions. The bZIP domain of JunB has been shown to interact with 
Meq in the past but this is the first description of the full length JunB protein interacting with 
the Meq bZIP domain. However, the interaction with JunB may lack physiological 
significance due to the fact that at the point of carrying out this study JunB was, and still is, 
not present in the current annotation of the chicken genome (Ensembl 46). JunD was the 
second most abundant bZIP protein to be pulled out with a total of three hits. This study 
provides the first evidence for Meq interacting with JunD but as, with JunB, it is not present 
in the current annotation of the chicken genome so is potentially not significant. Together the 
Jun proteins make up a third of the proteins isolated from the yeast two-hybrid assay and add 
a built in positive control as they contain the identical leucine zipper to the known Meq 
interacting partner c-Jun. The assay also pulled out CtBP as a Meq interacting partner which 
provides confirmation of this interaction and also adds a non-bZIP positive control to the 
assay. 
 ATF3 was the final bZIP protein to be identified in the yeast two-hybrid assay. An 
interaction with a peptide corresponding to the human and mouse ATF3 leucine zipper has 
been demonstrated previously (Levy et al 2003; Reinke et al 2010) but this is the first account 
of an interaction with the full length ATF3 protein. This is perhaps more interesting than the 
interactions with Jun described above due to the current understanding of ATF3 as a stress 
induced protein that has multiple roles in oncogenesis, cell cycle progression and apoptosis 
(Hai et al 1999). This interaction is investigated further in chapter 5. 
RACK1 was also identified by the Meq
(1-129) 
yeast two hybrid assay. It is an extremely 
diverse protein that has multiple roles in a huge array of cellular processes. Its main function 
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seems to be as a cytoplasmic signalling scaffold protein that binds PKC during catalytic 
processes (Lopez-Bergami et al 2005). RACK1 contains multiple WD40 domains which 
mediate protein-protein interactions (Chen et al 2004; Imai et al 2009) and potentially play a 
key role in the Meq interaction. The interaction with Meq certainly warrants further 
investigation due to the highly conserved nature of RACK1 in all species and it is also 
important to note that Meq has been shown to interact with RACK1 in previous unpublished 
data from the Viral Oncogenesis group, Compton, Berkshire, UK (Personal communication 
with Y. Zhao). 
Nedd-4 binding protein 1 (N4BP1) is an inhibitor of the E3 ubiquitin ligase Itch 
(Oberst et al 2007). This is particularly interesting as Itch is known to be responsible for c-
Jun ubiquitination and its subsequent degradation by the proteasome (Liu 2004). If Meq is 
interacting with N4BP1 in the infected cell it is feasible to hypothesise a reduction in c-Jun 
ubiquitination and degradation thus leading to a net increase in c-Jun molecules. This 
increase in c-Jun has the potential to increase gene transcription, cellular transformation and 
reduce apoptosis (Eferl & Wagner 2003; Shaulian & Karin 2002) and so may play a key role 
in the development of MDV-induced lymphoma. This hypothesis is outlined in Figure 3.7. 
c-FER is a tyrosine kinase that was also shown to interact with Meq
(1-129)
 in the yeast 
two-hybrid screen. c-FER is a member of the non-transmembrane bound tyrosine kinases and 
plays a major role in cell matrix organisation and cell-cell interactions (Greer 2002). It is also 
thought to be involved in the cell cycle due to its similarity to c-FYN (Greer 2002) but this 
characteristic has not been fully investigated. Interestingly the c-FER protein contains five 
coiled coil domains but none of these appear to be ‘true’ leucine zippers. The interaction 
warrants further investigation as a functional interaction has the potential to prove extremely 
important in uncovering a new role for Meq in this kinase cascade. 
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Figure 3.7 The Meq interaction with N4BP1 functional hypothesis. Meq has been 
shown to interact with N4BP1 in the yeast two-hybrid screen. N4BP1 is an inhibitor of the E3 
ligase Itch which targets c-Jun for polyunbiquitination and subsequent degradation by the 
proteasome. The interaction with N4BP1 may play a key role in inhibiting this process and 
thus lead to increased levels of the c-Jun oncoprotein. 
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Prostate apoptosis response-4 (Par-4) is the final and most interesting interacting 
protein that was identified through the Meq
(1-129)
 yeast two-hybrid screen. It is a leucine 
zipper containing protein that is known to be important in the apoptosis of cancer cells 
(Gurumurthy & Rangnekar 2004). Moreover, the chicken Par-4 leucine zipper domain 
contains only a single amino acid substitution compared with the human protein which 
suggests there is a strong possibility of an interaction with chicken Par-4. The Par-4 protein 
was identified in the initial predicted interactions screen as a potential interaction due to a 
score of >28 but <32.8. The Par-4 leucine zipper domain is located at the C-terminus and all 
known interactions are made through this domain (El-Guendy & Rangnekar 2003). 
The Par-4 protein was first identified as one of two novel proteins that were 
upregulated during ionomycin treatment of prostate cancer cells (Sells et al 1994). It has 
since been implicated in many other forms of cancer as well as neurodegenerative disease 
(El-Guendy & Rangnekar 2003). The mechanism by which Par-4 is able to induce apoptosis 
is not fully understood but it is thought to be regulated by several different protein 
interactions and phosphorylation events. The first protein found to interact with Par-4 was the 
Wilms' tumor 1 (WT1) protein. The Par-4/WT1 dimer binds to a region in the Bcl-2 promoter 
and down regulates expression of the pro-survival protein (Cheema et al 2003). It is possible 
that Meq prevents this interaction with WT1 since it is mediated through the Par-4 leucine 
zipper region. An increased level of Bcl-2 has been shown to be a vital mechanism in the 
progression of many cancers (Yip & Reed 2008) and may also contribute to MDV-induced 
oncogenesis. Another important interaction made by Par-4 is with the protein kinase Akt 
which phosphorylates Par-4 in order for it to be sequestered by the 14-3-3 protein in the 
cytoplasm (Goswami et al 2005). However, a mutation at the chicken Par-4 phosphorylation 
site may indicate that Akt1 phosphorylation of Par-4 is not utilised by chicken cancer cells. 
This would allow Par-4 to translocate to the nucleus where it may be sequestered by Meq in 
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MDV-transformed cells. Par-4 is also phosphorylated by PKC which results in decreased NF-
κB activation by the prevention of IKK phosphorylation (Diaz-Meco et al 1996). Since Meq 
is also known to interact with PKC it is also possible that Meq is preventing Par-4 from 
interacting with PKC and so NF-κB activation is increased. NF-κB activation has long been 
associated with cancer cell resistance to apoptosis which highlights the potential implications 
of the interaction with Par-4. Finally, Par-4 has recently been found to interact with the 
THAP1 protein. THAP1 is thought to be a DNA binding transcription factor that recruits Par-
4 to specific promoters to stimulate or inhibit transcriptional activation of genes involved in 
apoptosis (Roussigne et al 2003; Sabogal et al 2010). The apoptotic action of THAP1 is 
mediated by the THAP domain so it may be important in understanding the functional 
significance of the THAP1/Par-4 interaction. Meq contains a predicted THAP domain similar 
to that of THAP1 so it is possible that the functional significance of the Meq/Par-4 interaction 
is mediated by the THAP and SAC domains as well as the leucine zipper domains. Whether 
the Meq/Par-4 interaction is mediated by solely the leucine zipper domain remains to be seen. 
This theory may explain why the shorter and longer forms of the Meq protein (missing the 
predicted THAP domain) are less potent oncoproteins but this remains to be seen.  
Meq
(130-339)
 was found to interact with several proteins in the yeast two-hybrid screen 
but only Pin1 was taken to the back screen. This was due to the fact that Pin1 was identified 
as a positive interacting clone at 5 days post incubation whereas all other clones developed 
colonies at the 7 day threshold. Pin1 is a proline cis/trans isomerase that has been shown to 
catalyse the steric rotation of a proline residue adjacent to a threonine or serine residue (Lee 
et al 2011). A notable target of Pin1 is the c-Jun transcription factor which is known to 
exhibit increased target gene transactivation ability when subject to Pin1 proline cis/trans 
isomerisation. c-Jun contains 6 Pin1 binding sites whereas Meq contains 14 (Figure 3.8). We 
suggest that Pin1 may interact with Meq in a similar manner to c-Jun and the functional 
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significance of this interaction may shed further light on how Meq is able to transactivate and 
transrepress its target genes. 
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Figure 3.8 Pin1 cis-trans isomerase binding sites in the Meq and c-Jun amino acid 
sequence. A. shows the molecular mechanism by which Pin1 catalyses the cis/trans 
orientation of the proline residue. B. shows the c-Jun and Meq amino acid sequence and 
highlights all potential Pin1 binding sites with blue indicating a threonine residue binding site 
and red indicating a serine residue binding site. A total of 6 Pin1 binding sites are found in c-
Jun and 14 in Meq. 
  
A. 
B. 
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 The yeast two-hybrid approach provided a good overview of the global Meq 
interactome but the inherent bias towards genes expressed to a high level in the HeLa cell 
library is a significant downfall. With this in mind it would be extremely interesting to 
develop a chicken lymphocyte cDNA library that is compatible with the yeast two-hybrid 
technology. This would allow the investigation of Meq interactions in the target cell type. 
Also, it would be interesting to repeat the screen in triplicate as the high stringency applied to 
the Clontech® system may reduce the identification of less abundant clones and weaker 
interacting proteins. It has been reported that the LC-MS/MS approach often results in a high 
percentage of false positive interactions as well as indirect interactions. This potentially 
‘muddies the water’ and from our data we fail to see any known protein interactions made by 
Meq. However, the yeast two-hybrid produced interactions with a range of known proteins as 
well as novel proteins. From this it is clear that a direct interactome is within our scope but 
looking further into the indirect interactome will prove to be substantially more laborious and 
potentially less informative in terms of physiological significance.  
 It is clear that the entire Meq interactome is far from complete but we feel a large step 
has been taken towards this goal. The identification of the yeast two-hybrid screen as a sound 
methodology for proceeding further is a significant step in the right direction. This allowed 
the identification of a group of novel protein-protein interactions made by Meq all of which 
warrant further investigation.    
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4 Meq interacts with Prostate apoptosis response 4 
4.1 Introduction 
 In chapter three it was shown that Meq can interact with a group of known proteins 
such as CtBP1 and two members of the Jun family.  Importantly however, interactions of 
Meq with a number of novel proteins were also revealed. The yeast two-hybrid screen proved 
to be a powerful technique when identifying novel protein-protein interactions.  
The most interesting and potentially significant of the interactions found by yeast two-
hybrid screen was with the pro-apoptotic protein Prostate apoptosis response 4 (Par-4). As 
described previously, Par-4 is an extremely powerful pro-apoptotic protein that has been 
shown to fulfil significant roles in several canonical cellular pathways. Most interestingly 
when over expressed in cancer cells it has been shown to induce rapid apoptosis (El-Guendy 
& Rangnekar 2003) and has recently been shown to act as an extracellular apoptotic 
signalling molecule (Shrestha-Bhattarai & Rangnekar 2010). This exciting finding sparked a 
general consensus that Par-4 may prove to be a viable target for cancer therapy (Azmi et al 
2010; Butler & Rangnekar 2003). Drug design and peptide treatment are suggested to be in 
the research stages of development but it is clear that a lack of a crystal structure has hindered 
the production of any such treatments.  
Interactions made by Par-4 take place through the coiled-coil region that harbours a 
distinct leucine zipper domain toward the C-terminus of the protein (Rangnekar 1998). This 
domain does not contain a basic DNA binding region and so is not thought to interact directly 
with DNA. However, Par-4 has been shown to interact with other DNA binding proteins such 
as WT1 in order to occupy the Bcl-2 promoter and prevent expression of this pro-survival 
protein (Cheema et al 2003). Many other interactions have been shown to be vital to the 
function of Par-4 and therefore, an interaction with Meq would provide interesting insights 
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into the potential role for Meq and other AP-1 proteins in the function of Par-4 during 
apoptosis and cancer. 
 
4.2 Prostate apoptosis response-4  
 The yeast two-hybrid screen identified human Par-4 as a Meq protein partner. 
Interacting clone number 25 developed a positive signal after a period of 4 days and was 
subsequently isolated from the mated yeast stain. Sequencing and BLAST analysis confirmed 
the clone to be a truncated form of the human Par-4 gene. Furthermore, the region of Meq 
shown to interact with Par-4 was between N-terminal residues 1-129 whereas the C-terminus 
failed to identify Par-4 as a partner. The Par-4 clone identified by the yeast-two hybrid assay 
did not contain the full length open reading frame but contained only residues 185-340 which 
account for approximately 40% of the functional SAC domain and 100% of the leucine 
zipper domain found at the Par-4 C-terminus (Figure 4.1). This narrowed down the 
interacting domain in the Par-4 protein since it is only possible for residues 185-340 to be 
responsible for the interaction. 
 From the yeast two-hybrid data we can suggest that amino acid residues 1-129 and 
185-340 in Meq and Par-4 respectively are sufficient for a direct interaction to take place. 
The interacting region in Meq contains the leucine zipper domain and, since Par-4 has been 
previously shown to interact with leucine zipper proteins, it is reasonable to hypothesise that 
the interaction is mediated by the leucine zipper of each protein. 
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Figure 4.1 Yeast two-hybrid clone 25 corresponds to the Par-4 open reading frame. 
The full length Par-4 protein contains two distinct domains (the selective for apoptosis in 
cancer cells (SAC) domain and the leucine zipper (LZ) domain). Positive interacting clone 25 
was isolated and sequenced to confirm it as a partial clone of the Par-4 open reading frame. 
The sequence codes for residues 185-340 and harbours ~40% of the SAC domain and 100% 
of the LZ domain. 
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4.3 Chicken Par-4 cloning 
The Par-4 gene and coding sequence is poorly annotated in the chicken genome and 
so traditional cloning techniques were not successful when trying to amplify the coding 
region. However, an EST clone was identified at the 3’ end of the open reading frame by in 
silico translation of the sequence and alignment with the chicken Par-4 C-terminus. The 
alignment also showed high homology to the human sequence and so was used to design a 
reverse primer set for amplification of the whole sequence by 5’ RACE. However, this 
approach only allowed the amplification of a truncated chicken Par-4 clone but one that was 
larger than the human clone identified in the yeast two-hybrid assay. It is hypothesised that 
~125 residues (375 bp) are missing from the sequence due to comparison with the human 
Par-4 gene but those residues have been shown to account for the redundant N-terminal 
region. Although, this region has been shown to be dispensable for the apoptotic function of 
Par-4 we cannot say for sure that it is truly non-functional. It is disadvantageous to translate a 
protein sequence that is not used so it is important that further investigation and 
experimentation be implemented to clone the full length chicken Par-4 gene as a priority for 
further work. 
 Total RNA was isolated from CEF cells in order to carry out 5’ RACE amplification 
of chicken Par-4. The result of the 5’ RACE can be seen in Figure 4.2A. The PCR product at 
~450bp is a result of 5’ RACE amplification with specific nested chicken Par-4 primers and 
nested adapter primers. The expected band was ~900bp which would indicate full length Par-
4 amplification but this was not the case. Furthermore, the 5’ RACE was repeated and 
produced the same length product. The product produced by 5’ RACE was sequenced and 
used to design primers for traditional cloning of the truncated chicken Par-4 open reading 
frame with and without HA epitope tagging (Figure 4.2B). 
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 The chicken Par-4 coding region was sequenced and subject to in silico translation to 
allow critical review of the peptide sequence in comparison to orthologues from human, rat 
and mouse (Figure 4.3). The human Par-4 protein is well studied and can be divided into two 
functional domains (El-Guendy et al 2003; Rangnekar 1998). The Selective for apoptosis in 
cancer cells domain (SAC) has been shown to be vital for the pro-apoptotic function of the 
protein. When aligning the human, rat, mouse and chicken peptide sequences we can see that 
the SAC domain is highly conserved. The level of conservation is 97% with human, rat and 
mouse but perhaps most significantly the T
155
 PKA phosphorylation site is conserved across 
all species. The S
249
 Akt phosphotylation site is not conserved in chickens. However, the 
serine/threonine substitution in the chicken Par-4 peptide sequence may not prove significant 
as Akt is known to be a serine/threonine kinase (Bellacosa et al 1991). The chicken Par-4 
leucine zipper is 98% conserved with the human Par-4 leucine zipper but this is reduced to 
95% in the rat and mouse. The non-functional linker sequence between the SAC domain and 
the leucine zipper domain contains 96 amino acid residues that are less conserved between 
the species. The chicken Par-4 linker sequence is 45% conserved with human Par-4, 46% 
conserved with mouse Par-4 and 42% conserved with rat Par-4. This indicates that this region 
is under less selective pressure due to the non-functional nature and has been allowed to 
diverge evolutionarily. This however does not appear to be the case for the functional SAC 
and leucine zipper domains which indicates that these regions are required to contribute to the 
function of Par-4 across species. 
 Given the high levels of conservation between the Par-4 sequences in different species 
it seems counterintuitive that we were unable to clone the full length coding region. However, 
given that this conservation drops significantly in the non-functional ‘linker’ region between 
the SAC domain and the leucine zipper it is perhaps not a surprise that we were unable to 
amplify the potentially highly divergent non-functional N-terminus. 
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Figure 4.2 Chicken Par-4 PCR amplification and cloning. A. 5’ RACE of the chicken 
Par-4 gene. Total RNA was isolated from CEF cells and used as a template for 5’ RACE of 
chicken Par-4. 5’ adapter ligation was carried out with calf alkaline phosphatase (CIP) and 
tobacco pyrophosphatase (TAP) negative controls as well as the experimental sample. 
Amplification with the outer RACE primer resulted in a product of ~450bp in size (expected 
size of full length Par-4 was ~900bp). B. Amplification of the Par-4
(125-340)
 and Par-4
(125-340)
 
tagged with HA epitope coding region by conventional PCR techniques using primers 
designed as a result of sequence obtained from 5’ RACE. DNA ladders represent NEB 2Log. 
A. B. 
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Figure 4.3 Chicken Par-4 amino acid sequence and alignment. The chicken Par-4 coding region was cloned and sequenced to produce a 
truncated clone encoding amino acid residues ~125-340. Alignment of the chicken Par-4 amino acid sequence with the human, rat and mouse 
sequences was carried out using ClustalX. The total chicken Par-4 peptide sequence is 74% conserved with the human sequence. The blue region 
depicts the nuclear localisation signal that is 100% conserved. The green residues indicate phosphorylation sites and the red residues represent 
the core leucine residues in the leucine zipper domain. The leucine zipper domain is 98% conserved and the SAC domain is 97% conserved 
between species. Stars indicate conserved residues. 
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4.4 Par-4 expression in chicken cells 
The human Par-4 protein is found in a variety of tissue and cell types. Expression at 
the protein level has been shown to vary in many different cancers, and this differential 
expression is suggested to be linked to an increased or decreased survival rate (Bojarska-
Junak et al 2011; Mendez-Lopez et al 2010). It is also clear that an increased level of Par-4 
expression has the ability to result in the trigger of apoptosis in cancer cells (El-Guendy & 
Rangnekar 2003). Chicken Par-4 expression has yet to be investigated at the RNA or protein 
level and it was not clear if a suitable antibody could be found to cross react with the chicken 
protein due to the variable level of conservation across the protein sequence.  
Chicken Par-4 was cloned by 5’ RACE using total RNA from CEF cells as a template. 
Several fibroblast cell lines were assayed for Par-4 expression at the protein level (Figure 
4.4). The human HeLa cell line contains a high level of Par-4 although it is not clear if this is 
a result of higher antibody specificity or higher protein concentration. CEF cells contain a 
moderate level of Par-4 when compared with HeLa cells but the transformed CEF cell line 
DF-1 contains no Par-4.  
Although the level of protein in fibroblasts appears interesting, the expression in 
lymphocytes is more biologically relevant in a virological sense. A selection of MDV 
transformed cell lines (produced by L. Smith, IAH, Compton, Berks, UK) were harvested, 
protein was extracted for western blot analysis and total RNA isolated for the production of 
cDNA to be utilised in a semi-quantitative PCR assay to indicate the presence of the message 
transcript. Figure 4.4 shows that the Par-4 protein is absent from all MDV cell lines apart 
from MSB-1 (Akiyama & Kato 1974) where a low level can be detected. The analysis of the 
transcript levels correlate with the protein levels with MSB-1 cDNA containing the most Par-
4 transcript. However, the transcript is also present in the MDV transformed 226(s) cell line 
and the ALV transformed cell line AVOL-1.  
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Figure 4.4 Par-4 protein and mRNA expression in chicken cell lines. A. Par-4 
expression by western immunoblot (IB) analysis of HeLa, CEF and DF-1 cells (Ab Par-4 
Santa Cruz). Human Par-4 is expressed at high levels in HeLa cells and chicken Par-4 is 
expressed at lower levels in CEF cells. DF-1 cells contain no Par-4 at the protein level. 
CtBP1 expression was assayed as a loading control. B. shows MDV cell lines assayed by 
western immunoblot (above) for Par-4 protein expression and RT-PCR (below) for Par-4 
gene transcription levels. MSB-1 cells express Par-4 at the protein level but it is absent from 
all other cell lines. MSB-1 cells contain the highest level of Par-4 transcript but it is also 
present at low levels in 226(s) and AVOL-1 cells. GAPDH expression was assayed for 
endogenous control. 
A. B. 
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4.5 Par-4 protein expression in tissue 
Previous Par-4 expression studies are limited but protein and mRNA levels have been 
investigated in rats (Boghaert et al 1997). This study highlights the ubiquitous expression of 
the Par-4 protein and mRNA across a tissue panel. The highest levels of Par-4 protein were 
found in the brain, kidney, lung and testes but levels were also detected in the spleen, 
prostate, muscle and liver. The only tissue that did not contain Par-4 was heart. However, 
Par-4 mRNA was found in all tissue types to a similar degree with a slight reduction in the 
levels found in heart tissue. This highlights the potential for Par-4 gene expression in a 
particular tissue, in this case the heart, with protein expression being limited or abolished. 
A tissue panel was taken from a 33 week old specific-pathogen-free Rhode Island Red 
chicken in order to investigate the level of Par-4 protein expression in chicken tissues. 
Chicken tissue samples were homogenised and lysed in SDS loading buffer before being 
subject to western blot analysis. Figure 4.5 shows that the chicken tissue samples taken 
contain a similar level of Par-4 protein with the exception of the liver which contains slightly 
more than the spleen, lung and kidney. This pattern is similar to that seen in the rat study 
(Boghaert et al 1997) and highlights the presence of the Par-4 protein in several of the most 
prominently MDV-affected organs in the chicken. 
The feather follicle epithelium is also known to play a key role in the MDV life cycle 
by facilitating the shedding of the virus into the environment. The pulp was squeezed from 
the interior of the shaft of pinfeathers plucked from line 6 and line P chickens.  The pulp was 
homogenised and lysed in SDS loading buffer before being subject to western blot analysis 
for Par-4 protein expression. We see from Figure 4.5 that both samples contain the Par-4 
protein. However, the levels are considerably lower than those found in HeLa cells. 
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4.6 Par-4 protein expression in splenocytes 
 The spleen is thought to be a pivotal lymphoid organ for the development and spread 
of MDV by infection, transformation and systemic spread of CD4
+
 T-cells. Figure 4.5 shows 
that the Par-4 protein is expressed in the spleen at relatively low levels when compared with 
HeLa cells. This was further investigated by fractionating the spleen into the lymphoid cell 
sub-sets (Figure 4.6). A spleen was harvested from an adult Rhode Island Red chicken post 
infection with RB-1B strain of MDV-1.  Splenocytes were purified by gradient centrifugation 
over Histopaque, and cells were separated into CD4
+
, CD8
+
, B-cells and macrophages by 
Automacs cell separation. The lymphocyte cell fractions were then subject to western blot 
analysis to assay for the presence of the Par-4 protein. Figure 4.6 shows that although the 
total chicken spleen sample contains a low level of the Par-4 protein it is not seen in the 
lymphocyte fractions isolated by Automacs. 
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Figure 4.5 Par-4 protein expression in a chicken tissue panel. A. Liver, spleen, lung 
and kidney samples were harvested from a 33 week old Rhode Island Red chicken. The 
samples were homogenised and subject to western blot analysis to investigate Par-4 protein 
expression. The liver contains the highest levels of Par-4 with the levels in the spleen and 
lung being slightly lower. Par-4 levels in the kidney were reduced further but still present. 
HeLa cell lysate was used as a loading control. B. Feather follicle epithelium (FFE) pulp was 
extracted from line 6 and line P chickens and subject to western blot analysis. Par-4 protein is 
present in both samples but at low levels in comparison to HeLa cells. Line 6 FFE pulp 
contains significantly more Par-4 protein than line P. CtBP1 was expression for loading 
control. 
A. B. 
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Figure 4.6 Par-4 protein expression in chicken splenic lymphocytes. A whole spleen 
was harvested from a Rhode Island Red chicken infected with RB-1B strain of MDV.  CD4
+
, 
CD8
+
, macrophages (Ø) and B-cells were isolated by Automacs separation. Lymphocyte sub-
sets were subject to western blot analysis for Par-4 protein expression. Whole splenocyte 
sample contains low levels of the Par-4 protein but CD4
+
, CD8
+
, Ø and B-cells do not contain 
the Par-4 protein.  
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4.7 Par-4 cellular localisation  
Par-4 is known to be localised to the cytoplasm in normal cells by sequestration by 
the 14-3-3 family members but upon over-expression or cell transformation it translocates to 
the nucleus and induces apoptosis (El-Guendy et al 2003). However, although we have 
shown that the chicken Par-4 protein exhibits a high level of conservation to the mammalian 
protein and can be identified in many of the same tissues, the physiological function and 
localisation is not known. This was primarily investigated by identifying and cloning the 
chicken Par-4 gene by 5’ RACE which highlighted the potential for analogous functionality 
due to the presence of the selective for apoptosis in cancer cells domain and the leucine 
zipper, both of which have been shown to play a part in apoptosis. This clone only contains 
residues from ~125-340 which contain the only observed functional regions in the protein 
and when over expressed in the Par-4 negative DF-1 cell line the protein is clearly located in 
the cell nucleus (Figure 4.7). Furthermore, at 24 hours post transfection of the Par-4 clone, 
clear apoptotic cell morphology was observed (Figure 4.7) which indicates an analogous 
function of the chicken and mammalian Par-4 proteins. Over-expression of chicken Par-4 was 
localised entirely to the nucleus as expected due to the presence of the nuclear localisation 
signal found in the selective for apoptosis in cancer cells domain and resulted in classical 
apoptotic cell morphology. Apoptotic phenotypes such as nuclear blebbing and chromatin 
condensation are highlighted in Figure 4.7.  
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Figure 4.7 The partial chicken Par-4 protein localises to the cell nucleus and induces 
apoptosis in DF-1 cells. DF-1 cells were transfected with the chicken Par-4 gene cloned in 
figure 4.2 and tagged with the HA epitope. Par-4 is shown in green and the nuclear 
environment is shown in blue by DAPI staining. The top three panels show nuclear 
condensation by ~90% and Par-4 localising to the nuclear compartment. Scale bar equal to 
5μm. The bottom three panels show blebbing events taking place in the cell nucleus and Par-
4 is localised to this region. Scale bar equal to 10μm. 
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4.8 Meq and Par-4 co-localise in the cell nucleus 
As a transcription factor Meq is known to occupy the cell nucleus (Liu et al 1997) but 
it has also been identified in the nucleolus (Liu et al 1997) and even the cytoplasm during 
synthesis stage of the cell cycle for interaction with CDK2 (Liu et al 1999). However, in our 
experience the Meq protein is always absent from the nucleolus so it is possible that this 
observation requires revision. From Figure 4.7 we have shown that ectopic Par-4 is also 
present in the cell nucleus and exhibits the hypothesised apoptotic function seen in the 
mammalian protein. In order to investigate the localisation of Par-4 in the presence of Meq, 
DF-1 cells were co-transfected with eukaryotic expression vectors containing the Meq and 
Par-4 open reading frames and fixed after 24 hours for co-immunofluorescence analysis and 
confocal microscopy. Figure 4.8 shows that upon overexpression the Meq and Par-4 proteins 
occupy the same nuclear environment and also co-localise to occupy a region close enough to 
produce a merged colour that in turn suggests the possibility of an interaction. 
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Figure 4.8 Meq and Par-4 co-localise in the cell nucleus. In the top panel DF-1 cells 
were co-transfected with Meq and chicken Par-4 expression constructs and 24 hours post 
transfection were fixed and subject to immunofluorescence. Par-4 is shown in green, Meq 
shown in red and the merged panel shows co-localisation indicated by yellow regions within 
the nucleus. Scale bar represents 20 µm. The bottom panel represents the same transfection 
experiment but shows a DF-1 cell nucleus at higher magnification. Scale bar represents 10 
µm. 
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4.9 Meq interacts with Par-4 
 Par-4 was identified as a novel Meq interacting protein by yeast two-hybrid screen in 
chapter three. Here it was also demonstrated the N-terminal region of Meq and the C-terminal 
region of Par-4 are required for the interaction due to the truncated Meq bait and truncated 
Par-4 prey. However, the yeast two-hybrid screen was carried out using HeLa cell cDNA as 
the prey library so further investigation with the chicken Par-4 protein was required. After 
cloning and sequencing the chicken Par-4 open reading frame we saw that the residue 
conservation in the functional domains is very high (Figure 4.3). This is particularly true for 
the leucine zipper region of the protein which shows 98% sequence conservation to the 
human protein. This led to the initial hypothesis that Meq interacts with Par-4 through the 
leucine zipper domain of each protein. The interaction was first mapped using the leucine 
zipper helical wheel method and shows the potential for an interaction by the presence of 
favourable electrostatic interactions. The Meq interaction with Par-4 is predicted to make 
four favourable electrostatic interactions whereas the known Meq interaction with c-Jun only 
makes three favourable interactions (Figure 4.9). 
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Figure 4.9 Meq helical wheel leucine zipper interaction. Top panel: Meq interacts with 
c-jun via three favourable electrostatic interactions (green dashed lines). The leucine zipper 
helices begin at the ‘A’ heptad and run through a single full turn in the right handed α-helix 
of the domain. Residues at positions ‘G’ and ‘E’ mediate the specificity of the leucine zipper 
interaction. Bottom panel: The Meq interaction with the Par-4 leucine zipper is predicted to 
make four favourable electrostatic interactions. Positively charged residues are shown in red 
and negatively charged residues are shown in blue (neutral residues in black). 
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 Further biochemical investigation was carried out by co-immunoprecipitation of the 
Meq and Par-4 proteins from total lysates of cells co-transfected with eukaryotic expression 
vectors containing the Meq and Par-4 open reading frames (Par-4 containing the HA epitope 
tag). The proteins were then co-immunoprecipitated as a complex and subject to western blot 
analysis. Furthermore, the Meq
BZIP
 mutant was co-transfected with Par-4 and co-
immunoprecipitation carried out in order to investigate whether the interaction was mediated 
through the leucine zipper domain (Meq
BZIP
 mutant contains alanine residues in place of the 
leucine zipper core residues in order to disrupt interactions mediated by the domain). 
 The co-immunoprecipitation of both proteins was carried out with the application of 
both Meq and HA antibodies indicating a protein-protein interaction between the two proteins 
(Figure 4.10). Meq was used to pull out Par-4 from a total cell lysate and correspondingly 
Par-4 was used to pull out Meq from a total cell lysate. Furthermore, this was not the case 
with the Meq
BZIP
 mutant indicating that the interaction is mediated via the leucine zipper 
domain. These data along with the yeast two-hybrid data indicates that Meq is able to interact 
directly with the human and chicken Par-4 proteins. We were unable to co-immunoprecipitate 
endogenous levels of Par-4 and Meq from MSB-1 cells. 
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Figure 4.10 Par-4 interacts with Meq but not the Meq
BZIP
 mutant. The co-
immunoprecipitation of Meq and Par-4 was carried out by co-transfection into DF-1 cells and 
pulling out the protein complex with both Meq and HA (Par-4) antibodies. A. Shows co-
immunoprecipitation of Par-4 using the Meq protein but not Meq
BZIP
 and B. shows the co-
immunoprecipitation of Meq but not Meq
BZIP
 using the Par-4 protein. Loading controls were 
taken from 10% of total cell lysate. Immunoprecipitations were carried out with anti-tubulin 
antibodies for negative control. 
A. B. 
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4.10 Meq reduces Par-4 mediated apoptosis 
 Although the mechanisms by which Par-4 induces apoptosis are not fully understood 
we have shown that the chicken Par-4 protein acts in a similar way to mammalian Par-4 by 
translocating to the cell nucleus and up-regulating cell death (Figure 4.7). Further 
investigations were carried out in order to quantify this and identify a physiological role for 
Meq in the process. This was carried out by transfecting the Par-4 protein alone or with Meq 
into the DF-1 and PC-3 cell lines before staining for apoptotic cells with an antibody against 
the early apoptotic marker Annexin-V. 
 Figures 4.11 and 4.12 show that Meq transfection has little to no effect on apoptosis 
when compared with the mock transfection. Par-4 transfection produces a significant up-
regulation of apoptosis that is rescued by the co-transfection of Meq. This is shown in both 
DF-1 cells (p<0.05) and PC-3 cells (p<0.05). The upper panels in Figures 4.11 and 4.12 show 
the extent of Annexin-V staining. 
 Par-4 mediated apoptosis was also investigated using the PARP-1 cleavage western 
blot assay. The PARP-1 protein acts as a DNA damage and repair sensor that is cleaved and 
rendered non-functional by caspase-3 during early apoptosis (Soldani & Scovassi 2002). This 
cleavage event is widely employed as a marker for apoptosis by western blot analysis. The 
PARP-1 cleavage assay was carried out in order to confirm the results of the Annexin-V 
study in Figures 4.11 and 4.12. PC-3 cells were transfected with a constant concentration of 
Par-4 and an increasing level of Meq in order to visualise a reduction in PARP-1 cleavage as 
the Meq concentration increased. However, when an increased concentration of Meq was 
transfected into PC-3 cells that are ectopically expressing Par-4 a change in PARP-1 cleavage 
was not observed (Figure 4.13). Furthermore, no PARP-1 cleavage was seen in the cells 
containing only ectopic levels of Par-4 which is contrary to the apoptotic cell morphology 
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seen in Figure 4.7 and the Annexin-V assay seen in Figures 4.11 and 4.12. This indicates that 
further investigation is required in order to optimise the technique. 
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Figure 4.11 Meq decreases Par-4 mediated apoptosis in DF-1 cells. DF-1 cells were 
transfected in triplicate with a mock vector, Meq alone, Par-4 alone or Meq and Par-4. Cells 
were harvested after 24 hours and half were subject to Annexin-V staining and the remaining 
cells were lysed and subject to western blot analysis. A. shows immunofluorescent staining of 
annexin-v positive cells (green). B. shows total number of positive cells that were counted in 
triplicate as a percentage of total cells. C. shows western blot analysis as a transfection 
control. (Error bars represent S.E.M). 
  
A. 
B. C. 
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Figure 4.12 Meq decreases Par-4 mediated apoptosis in PC-3 cells. PC-3 cells were 
transfected in triplicate with a mock vector, Meq alone, Par-4 alone or Meq and Par-4. Cells 
were harvested after 24 hours and half were subject to Annexin-V staining and the remaining 
cells were lysed and subject to western blot analysis. A. shows immune fluorescent staining 
of annexin-v positive cells (green). B. shows positive cells were counted in triplicate as a 
percentage of total cells. C. shows western blot analysis as a transfection control. (Error bars 
represent S.E.M). 
 
A. 
B. C. 
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Figure 4.13 Par-4 mediated PARP-1 cleavage in PC-3 cells. PC-3 cells were co-
transfected with a stable concentration of Par-4 (1μg) and an increasing concentration of Meq 
(0 - 1μg). Samples were lysed in SDS loading buffer 16 hours post transfection and subject to 
PARP-1 western blot analysis. Mock transfection shows only native PARP-1 and all titrations 
show only native PARP-1 (no cleavage events). Endogenous levels of Par-4 were assayed for 
loading control. 
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4.11 Discussion 
4.11.1 Prostate apoptosis response-4 
The yeast two-hybrid screen identified the C-terminus of human Par-4 as an 
interacting partner with the N-terminus of Meq. Each of these respective truncations contains 
a distinct leucine zipper domain. This allowed the formulation of a clear hypothesis as to 
which domains in each protein are responsible for the interaction. The functional core of the 
Par-4 leucine zipper was paired with the Meq leucine zipper sequence and an interaction 
hypothesis was made in chapter three. However, this interaction was further investigated due 
to the potential significance of this interaction.  
 The Par-4 leucine zipper sequence was aligned in native form with the Meq leucine 
zipper to provide an indication as to potential hydrophobic and charged interactions. This can 
be seen in Figure 4.9 and clearly shows four potentially favourable charged interactions as 
well as a distinct hydrophobic core. When compared with the known Meq leucine zipper 
interaction with c-Jun we see that three favourable charged interactions are adequate to 
produce a viable leucine zipper dimerisation event. The theoretical and experimental 
evidence show that Meq and Par-4 directly interact and furthermore, this interaction is 
potentially mediated by the leucine zipper domain of each protein.  
 Meq is known to make several non-leucine zipper interactions, most notable of which 
would be of that with CtBP1 (Brown et al 2006) and p53 (Deng et al 2010). However, the 
majority of known and predicted interactions are thought to take place at the leucine zipper 
domain. These interactions are thought to mediate a change in DNA consensus sequence 
recognition but since Par-4 does not act to directly bind DNA this hypothesis is perhaps 
unlikely for the Meq/Par-4 dimer. The Par-4 protein makes all known interactions through the 
leucine zipper domain but primarily interacts with zinc-finger containing proteins. These 
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interactions are widely studied and are involved in a variety of cellular mechanisms. The only 
other known transcription factor that interacts with Par-4 is the WT1 factor that acts with Par-
4 not to transactivate gene activity but to transrepress. Specifically, the pro-survival Bcl-2 
gene promoter is occupied and the gene is subsequently repressed in order to facilitate the 
upregulation of apoptosis (Cheema et al 2003). 
 This begs the question whether Meq and Par-4 are acting together for the benefit of 
the virus or whether Par-4 is a cellular target that must be sequestered by Meq in order to 
hinder its vital pro-apoptotic function. 
 
4.11.2 Chicken Par-4 cloning 
The chicken Par-4 gene is not correctly annotated in either the ensemble or NCBI 
database. This is due to a poor sequencing read or ‘gap’ in the genome that incorporates the 
5’ end of the gene and the promoter region. The 3’ end of the chicken Par-4 gene shows high 
homology to the human and mouse sequence when translated. An EST clone was mined from 
the BBSRC chicken EST database that matched this sequence to confirm that this region was 
correctly annotated. Primers were designed inside this known region of the transcript in order 
to confirm its presence in CEF total RNA. CEF cells were confirmed to contain the Par-4 
transcript and as such were used as a template for the 5’ RACE approach. 
 The 5’ RACE was carried out with the expectation of amplification of the full length 
Par-4 transcript but this was not the case. A shorter product resulted from both the primary 
and repeat 5’ RACE which corresponds to a region coding for the final ~215 amino acid 
residues of the Par-4 protein. Considering that both assays were carried out independently 
degradation of total RNA was not likely to be the cause of the unexpected product size. It is 
however possible that the RACE PCR was amplifying an abundant splice product of Par-4 
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gene transcription. Although this is a potential cause for the identification of ‘short’ Par-4 a 
splice variant of this nature is not known in other species. This however does not preclude 
this hypothesis as a possibility.  
 The Par-4 sequence that was identified by the 5’ RACE assay was translated in silico 
in order to confirm the amplification of the true Par-4 transcript. Alignment with the human, 
mouse and rat transcripts confirm that the transcript amplified by 5’ RACE has a high level of 
residue conservation and is confirmed to be the chicken Par-4 orthologue. The short chicken 
Par-4 transcript contains both functional domains present in the human Par-4 protein. The 
SAC domain found in the middle of the peptide chain is highly conserved to a level of 97%. 
This suggests that the SAC domain that is conserved in the chicken peptide chain maintains 
the function identified in the mammalian orthologues. The leucine zipper is also conserved to 
a degree of 98% which suggests that the interactions made by the chicken Par-4 orthologue 
are maintained and as the two residue substitutions do not alter the functional leucine zipper 
residue configuration we hypothesised that the chicken Par-4 protein will interact with the 
Meq protein in a similar manner to the human clone identified in the yeast two-hybrid screen. 
 Since the Par-4 gene is poorly annotated in the chicken genome we can assume that 
this is the first in-depth analysis and subsequent cloning of the chicken Par-4 transcript. 
Furthermore, we hypothesised that the chicken Par-4 protein acts as a functional orthologue 
to the human protein and maintain the hypothesised leucine zipper interaction with Meq. 
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4.11.3 Par-4 expression in chicken cells 
Par-4 is known to be expressed in many human cell lines including HeLa, HEK 293T 
and PC-3 cells. Although Par-4 protein expression is well documented in human, mouse and 
rat cells the expression profile in chicken cells is not known. The Par-4 antibody was tested 
with lysate from CEF and DF-1 cells in the first instance by western blot. This was to confirm 
the recognition of the correct size protein when compared with the human Par-4 protein in 
HeLa cell lysate. Western blot analysis of CEF cell lysate confirmed expression of Par-4 by 
development of a band at the same molecular weight as the band identified in HeLa cell 
lysate. This not only confirmed the antibody to be viable for recognition of the chicken Par-4 
protein but also shows that CEF cells contain a low level of Par-4 in comparison to HeLa 
cells. However, it is important to note that this apparent change in expression may also be due 
to the Par-4 antibody exhibiting a reduced avidity to the chicken Par-4 protein. Conversely, 
DF-1 cells were found to contain no endogenous Par-4. This is interesting due to the fact that 
DF-1 cells are an immortalized chicken embryo fibroblast cell line. This would suggest that 
the transformation process may have played a role in the negative regulation of Par-4. This 
would of course be extremely advantageous for the survival of DF-1 cells as in human cancer 
cells the over expression of Par-4 would likely induce apoptosis. This down regulation of 
Par-4 could be due to epigenetic regulation, cell protein profile change or otherwise but this 
remains to be seen and perhaps requires further investigation. 
 MDV is known to infect the cells of the immune system and so the splenic cells from 
an infected Rhode Island Red chicken were investigated for Par-4 protein expression. The 
infected spleen was used in order to incorporate infected cells that express the Meq 
oncoprotein. This in turn would help uncover whether Par-4 is expressed in the same cells at 
the same time as Meq. The whole splenocyte population was subject to western blot analysis 
and shows a low level of Par-4 protein expression but when fractionated into the CD8
+
, 
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CD4
+
, macrophages and B-cells we fail to see Par-4 expression in any of these cell types. 
This is surprising as we do see a low level of Par-4 expressed in the whole splenocyte 
fraction so this suggests that the Par-4 expressing cells are of different cell type to those 
traditionally involved in MDV infection. The residual Par-4 could also be due to the 
inevitable isolation of red blood cells and other contaminating fractions with the splenocyte 
fraction. However, considering that we are far from understanding the full story of MDV 
infection, life cycle and transformation we cannot rule out a functional consequence to this 
interaction in the spleen or other lymphoid tissue. 
 
4.11.4 Par-4 expression in chicken tissue 
Par-4 protein expression in tissue has been extensively investigated in human and rat 
(Boghaert et al 1997). This investigation showed protein expression in a large variety of 
tissues including kidney, brain, liver, lung, spleen, prostate and the testes. We went on to 
investigate tissue samples and confirm a similar expression pattern with highest levels found 
in the liver and lower levels in the kidney, spleen and lung. A similar expression pattern in 
rat, human and chicken suggests a potentially functionally analogous role for Par-4 in each 
species.  
 Furthermore, Par-4 was found by western blot in the feather follicle epithelium of 
chicken lines that are both resistant and susceptible to MDV-mediated oncogenesis. The 
feather pulp was harvested but it is likely that several other cell types were incorporated due 
to the structure of the feather and also in part the crude harvest technique. This requires 
further investigation by immunofluorescence or even by laser microdisection and subsequent 
mass spectrometry approaches in order to confirm the cell type that harbours Par-4 in the 
feather follicle.  
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 The feather follicle is a site of lytic infection which begs the question whether the 
Meq interaction with Par-4 is important in transformation or lytic infection. It is known that a 
high level of cell death occurs during lytic infection and it would be interesting to determine 
whether this results in, or is a result of, Par-4 expression. Also, it would be important to 
ascertain whether the Meq interaction with Par-4 is a function that is advantageous to the 
virus or whether it is a cellular defence mechanism that increases the level of cell death 
during lytic infection or transformation. Either way, it is clear that further investigation is 
required and the development of chicken specific reagents including antibodies would be 
highly advantageous. 
 
4.11.5 Par-4 cellular localisation 
It is clear from the literature that Par-4 localises in the cytoplasm of non-apoptotic 
cells as it is sequestered by a member of the 14-3-3 protein family (Goswami et al 2005). 
However, in cancer cells undergoing apoptosis it has been shown to be overexpressed and as 
a result of this it translocates to the nucleus. This is where Par-4 can exert its apoptotic effect 
by binding WT1 and suppressing the Bcl-2 promoter as well as suppressing the upstream 
NFκB pathway by interacting and sequestering PKC in order to prevent the phosphorylation 
of IKK (Chang et al 2002b; Diaz-Meco et al 1996). We have seen that several human and 
chicken cell types express Par-4 but it is not known where this Par-4 is localised in the cell. 
From the literature we know that endogenous levels of mammalian Par-4 reside in the 
cytoplasm however it is not known whether this is the case for chicken cells. Although the 
available antibodies proved to be viable for western blot analysis, they were not detectable in 
immunofluorescence tests. This proved to be a significant hindrance when trying to 
investigate Par-4 localisation by confocal microscopy. However, as mentioned above it is 
known that Par-4 is often overexpressed to result in its functional apoptotic nuclear 
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localisation. We took advantage of this by overexpressing Par-4 in chicken cells and tagging 
with the HA epitope for antibody recognition. We see that Par-4 is present in the cell nucleus 
when ectopically expressed as expected. We hypothesised that this is due to the highly 
conserved nuclear localisation signal in the chicken protein. We also see that when 
overexpressed the Par-4 protein exerts the predicted apoptotic effect on DF-1 cells. After 
transfection we can not only see the Par-4 protein localised in the cell nucleus, but also the 
classical signs of apoptosis such as nuclear blebbing and chromatin condensation. This was 
also as hypothesised due to the highly conserved selective for apoptosis in cancer cells 
domain. It is known from previous studies that Meq is localised in the cell nucleus so we 
hypothesised that the interaction takes place in the nucleus and is reliant on nuclear 
translocation of Par-4. 
 Further investigation was carried out to study the potential for co-localisation of Meq 
and Par-4 in the cell nucleus by immunofluorescence tests. This was carried out by DF-1 co-
transfection using eukaryotic expression vectors containing both open reading frames before 
immune staining and visualisation by confocal microscopy. We showed that upon co-
transfection not only do we see co-localisation (Figure 4.7) in the nucleus, but also a 
reduction in the apoptotic phenotype seen in Figure 4.7. This suggested that the interaction 
with Meq reduces or slows the rate of apoptosis mediated by Par-4. Further investigation is 
required to study endogenous levels of Par-4 but the production of a viable chicken specific 
antibody would be advantageous.  
 
4.11.6 Par-4 leucine zipper 
We hypothesised that Par-4 and Meq interact via the leucine zipper. This hypothesis 
was established because of the alignment of the two leucine zipper domains and the predicted 
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favourable electrostatic interactions between charged residue side chains. We compared the 
Meq/Jun interaction with that of the predicted Meq/Par-4 interaction and found that Meq/Jun 
has only three favourable interactions whereas the Meq/Par-4 interaction has four. This added 
further strength to the hypothesis that these molecules interact via the leucine zipper domains. 
This also produces interesting insight into the potential for mutations in either leucine zipper 
to abolish the specific interaction but this potentially leads to significant alterations in the 
unknown function and specificity of the leucine zipper.  
 
4.11.7 Meq and Par-4 interact via the leucine zipper 
Initially we showed the interaction of Meq and Par-4 using the yeast two-hybrid 
system. This was further confirmed by predicted interactions and co-localisation in the cell 
nucleus. We then confirmed the interaction by a co-immunoprecipitaion assay whereby Meq 
and Par-4 are over expressed and co-immunoprecipitated with both the Meq and HA (Par-4) 
antibody. We went on to investigate the properties of the Meq
BZIP
 mutant lacking a viable 
leucine zipper and showed that this does not co-immunoprecipitate with Par-4. This 
suggested that the Meq leucine zipper domain is essential for the interaction to take place. We 
failed to co-immunoprecipitate the endogeneous Par-4 protein with Meq and hypothesise that 
this is due to a low abundance of Par-4 protein in most cell types. 
 
4.11.8 Meq and Par-4 during apoptosis 
The co-localisation of Meq and Par-4 in the cell nucleus is clear and we also see cells 
containing both Meq and Par-4 do not exhibit such dramatic apoptotic phenotypes as those 
containing Par-4 alone. When visualising this effect by confocal microscopy, the apoptosis 
was not completely halted by the presence of Meq but looked to be reduced.  
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 Although we see a reduction in the apoptotic phenotype when Par-4 is co-transfected 
with Meq we went on to quantify this using an Annexin-V assay. Annexin-V is a highly 
abundant phospholipid that is exposed to the cell surface upon early apoptotic events. Cells 
containing either Par-4 alone or Par-4 and Meq were stained with anti-Annexin-V antibody 
and positive cells counted. The data suggests a small but significant rise in apoptosis after 
transfection with Par-4 alone but this seems to be reduced when co-transfected with Meq. 
This was carried out in both DF-1 and PC-3 cells. The Annexin-V assay suggests that Meq 
can slow or reduce the rate of apoptosis mediated by ectopic Par-4 expression. 
 Further clarification of the reduced or slowed rate of apoptosis was carried out by 
PARP-1 cleavage assay. This was carried out by transient transfection of Meq into PC-3 cells 
overexpressing Par-4. At 16 hours post transfection we see no PARP-1 cleavage with Par-4 
alone and this is maintained through the transient Meq transfection. However, further study 
should include a PARP-1 cleavage assay of later time points in order to fully investigate the 
potential for apoptotic regulation by Meq. These data suggests that any change in Par-4 
mediated apoptosis regulated by Meq is likely to be small and perhaps not significant. 
However, this certainly warrants further investigation perhaps with the application of live cell 
imaging of apoptotic events in order to visualise Meq and Par-4 over a time lapse period. It is 
also important to optimise the PARP-1 cleavage assay as this is classed as the ‘gold standard’ 
in apoptotic studies.  
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5 Meq interacts with Activating Transcription Factor 3 
5.1  Introduction 
The Meq leucine zipper has been shown to interact with the leucine zipper found in 
the mouse and human activating transcription factor-3 (ATF3) protein (Levy et al 2003; 
Reinke et al 2010). However, this study fails to shed light on the interaction between Meq 
and chicken ATF3 and lacks an investigation into the potential significance of this 
interaction. This is surprising due to the clear biological importance of the ATF3 protein 
during the development of cancer cells (Yin et al 2008). ATF3 is a product of the ATF3 gene 
and is primarily thought to be a stress associated protein (Hai et al 1999) and potentially plays 
a major, yet undefined role in cell proliferation (Tamura et al 2005), cell cycle regulation (Lu 
et al 2006) and apoptosis (Hartman et al 2004; Huang et al 2008; Jiang et al 2010; Nobori et 
al 2002). As a basic leucine zipper transcription factor, ATF3 is able to influence these 
processes by specifically targeting genes for transactivation (Filen et al 2010) by 
heterodimerisation and, more frequently, transcriptional repression (Yin et al 2008) by 
homodimerisation. ATF3 is able to target these genes through binding conserved consensus 
sequences such as CRE, TRE and AP-1 sites located in the promoters of target genes. The 
mechanism by which ATF3 is able to transactivate and transrepress gene transcription is not 
fully understood and, although it is reliant on protein partners, it is clear that this requires 
further investigation. Several viral proteins have also been shown to interact with ATF3 as a 
potential method for regulating its action on cell cycle regulators CDC2 and cyclin E2 
(Hagiya et al 2011).   
 The majority of protein interactions with ATF3 take place through the basic leucine 
zipper region which mediates interactions with several other leucine zipper and zinc finger 
containing proteins, perhaps the most prominent of which is c-Jun. ATF3 is also expressed as 
a splice variant (ATF3Δ) that has so far solely been linked to transactivation activity due to 
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the potential for sequestering regulatory co-factors from the native ATF3 protein (Hai et al 
1999). ATF3 also interacts with several non-leucine zipper containing proteins such as p53 in 
order to regulate genome stability (Yan & Boyd 2006). 
 
5.2 Cloning chicken ATF3 
In this study we have identified the full length clone of human ATF3 as an interacting 
partner with the Meq N-terminus. The full length ATF3 clone was isolated twice from the 
panel of positive Meq interacting clones in the yeast two-hybrid assay described in chapter 
three and was only 1 of 4 clones that were identified more than once (JunB (9 times), JunD (3 
times) and Zinc finger BTB-9 (3 times)). In order to confirm the interaction in the yeast 
system, the ATF3 clone was re-transformed with either Meq or the empty prey vector. The 
interaction with Meq was confirmed by the development of blue colonies in the experimental 
sample.  
The chicken ATF3 amino acid sequence was identified using the gallus gallus genome 
assembly (Ensemble 46) and NCBI predicted annotation (XM_419429) and aligned with 
the human, mouse and rat amino acid sequence (Figure 5.1). These sequences were 
aligned in order to confirm the chicken clone was orthologous to that of the human clone. 
However, it is clear that although sequence conservation suggests orthologous function it 
is not possible to confirm orthologous or paralogous function without functional data. 
Alignment of the amino acid sequence confirms that 83% of residues are conserved 
identically between the four sequences. It was also found that 94% of residues are 
conserved identically between the leucine zipper domains and 96% of residues are 
conserved identically between the residues that comprise the DNA binding domain 
(Figure 5.1). This suggests that the interacting partners of all ATF3 orthologues are 
potentially the same and also the DNA target consensus sequence is likely to be 
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conserved. The high level of conservation between the leucine zipper domains indicates 
that the chicken ATF3 protein is likely to interact with the Meq N-terminus as with the 
human and mouse isoform. It is also important to take note of the high level of 
conservation between the domains responsible for transactivation. The two transactivation 
domains show levels of conservation at 75% and 96% respectively which indicates that 
the chicken orthologue has the same ability to transactivate target genes as the human 
protein. However, the transrepression domain only exhibits identical conservation to 62% 
which indicates that the chicken ATF3 protein is less likely to transrepress target genes in 
the same manner as the human protein. However, it is possible that target genes in the 
chicken are also slightly divergent and since the mechanisms by which ATF3 is able to 
regulate gene expression are far from fully understood, it is only possible to make a 
hypothesis as to the function. In conclusion, from the alignment we can see that the 
chicken ATF3 protein is potentially functionally homologous to human ATF3 in many 
respects.  
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Figure 5.1 Alignment of ATF3 protein homologs. The alignment of human, mouse, rat and chicken ATF3 protein sequences. Residues in 
green are involved in gene activation, residues in red are involved in gene repression, residues in light blue comprise the DNA binding domain 
and residues in dark blue comprise the leucine zipper domain (core leucine residues are highlighted in white). Chicken ATF3 residues in the 
leucine zipper domain are 94% conserved with the human sequence and residues in the DNA binding domain are 96% conserved. 
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5.3 ATF3 expression in chicken cells 
 The ATF3 open reading frame was amplified from cDNA isolated from CEF cells and 
sequenced to confirm the annotation investigated in Figure 5.1. ATF3 was also found in 
cDNA isolated from MSB-1 cells so it is clear that the transcript is present in at least one of 
the MDV-transformed cell lines as well as a primary fibroblast cell type. However, several 
other regularly used MDV-transformed cell lines were investigated for their levels of the 
ATF3 transcription in order to confirm that it is ubiquitously transcribed in MDV-transformed 
lymphocytes (Figure 5.2B). We can see that the ATF3 transcript is present in all cell lines but 
the level of expression varies significantly. The transcript is more highly expressed in the 
226(s) and ALV-transformed cell line AVOL-1 than other cell lines. Furthermore, we went 
on to investigate the ATF3 protein expression levels in these same cell lines and surprisingly 
we found a lack of ATF3 protein in all MDV-transformed cell lines. This however was not 
the case for the non-MDV cell line AVOL-1.  
 In order to confirm the activity of the ATF3 antibody the chicken clone was 
transfected into DF-1 cells and subject to western blot analysis with the anti-human ATF3 
antibody acquired (Figure 5.2A). Figure 5.2 clearly demonstrates that chicken ATF3 is not 
present in non-transfected DF-1 cells whereas a clear band at the expected molecular weight 
of 23 kDa is observed in the transfected sample. This indicates that the human antibody 
acquired for chicken ATF3 protein detection cross reacts with the chicken protein. 
 ATF3 protein expression has long been linked to cellular stress including heat shock 
(Murray et al 2004) and so the MDV-transformed cell line MSB-1 was subject to heat shock 
in order to investigate the expression of ATF3 in stressed chicken cells (Figure 5.2C). Cells 
were subject to 43ºC heat shock for 8 hours and recovered for 1 or 2 hours at 38.5ºC before 
lysing in SDS loading buffer and being subject to western blot analysis for ATF3 expression. 
However, heat shock failed to induce ATF3 protein expression at all time points observed.  
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Figure 5.2 ATF3 antibody test and expression profile in MDV-transformed cell lines. 
A. DF-1 cells were transfected with a eukaryotic expression vector containing the chicken 
ATF3 open reading frame. Cells were harvested and subject to western blot analysis for the 
ATF3 protein. Transfected DF-1 cells contain a band at 23 kDa and untransfected cells do 
not. B. MDV-transformed cell lines were harvested and total protein subject to western 
blotting for the ATF3 protein (above). MDV cell lines do not contain the ATF3 protein at 
high enough levels to detect by western blot. The non-MDV transformed cell line AVOL-1 
does contain ATF3. Loading was confirmed by CtBP1 expression. Total RNA was isolated 
from each cell line and reverse transcribed into cDNA for detection of the ATF3 transcript. 
The ATF3 transcript was most highly abundant in 226(s) and AVOL-1 but present in all cell 
lines investigated. GAPDH expression was assayed for a loading control. C. MSB-1 cells 
were heat shocked at 43ºC for 8 hours and either not recovered, recovered at 38.5ºC for 1 
hour or recovered for 2 hours. Cells were lysed in SDS loading buffer and subject to western 
blot for ATF3. Expression of ATF3 was not up-regulated by heat shock. Loading control was 
chicken ATF3 transfected DF-1 cell lysate.   
  
A. B. C. 
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5.4 MDV infection results in increased ATF3 gene expression 
 ATF3 has been shown to be a stress induced molecule that is up-regulated by many 
different stress conditions and factors (Hai et al 1999). Interestingly ATF3 expression has 
been shown to be regulated by viral infection (Hwang et al 2007; Zhao et al 2003) but 
regulation by herpesvirus infection is yet to be investigated. In this investigation CEF cells 
were infected with either the RB-1B strain of MDV or RB-1BΔMeq virus and total RNA 
harvested every 24 hours for the total duration of 120 hours. Total RNA was used to produce 
cDNA and this was in turn used as a template for a specific ATF3 PCR in order to quantify 
the ATF3 transcript levels during MDV infection. We can see from Figure 5.3 that the ATF3 
transcript level remains low in both infection events until between 24 hours and 48 hours post 
infection. Transcript levels then begin to increase to a peak at the last two time points (96 
hours and 120 hours). This increase in ATF3 transcript is confirmed by the relatively stable 
level of amplification of GAPDH. This data suggests that the ATF3 gene is up-regulated upon 
infection by MDV and this up-regulation is seen equally by infection with both wild type RB-
1B and the mutant RB-1BΔMeq. 
 
  
157 
 
 
Figure 5.3 ATF3 transcript levels increase upon MDV infection. CEF cells were 
infected with 200pfu RB-1B or RB-1BΔMeq and total RNA harvested after 8 hours, 24 hours 
and every 24 hours thereafter. Total RNA was subject to RT-PCR and specific PCR 
amplification of ATF3. Levels of ATF3 transcript are shown to remain low until 24-48 hours 
in both sample infections before increasing. Loading control shows similar levels of GAPDH 
in all samples. 
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5.5 ATF3 expression in feather follicle epithelium 
 The chicken ATF3 protein is not expressed in the panel of MDV-transformed cell 
lines investigated in Figure 5.2B. However, we have much to learn regarding the MDV life 
cycle and it is possible that Meq and ATF3 interact in another cell type involved in the 
process of transformation or lytic infection. MDV proteins have been shown to be expressed 
in the feather follicle epithelium (Gimeno et al 2005). So we investigated the potential for 
ATF3 expression in the cell types associated with the feather follicle. First we investigated 
the potential for ATF3 protein expression in the feather pulp (Figure 5.4). This was carried 
out by extracting the feather follicle pulp and lysing in SDS loading buffer before western 
blot analysis. From Figure 5.4 we see that the ATF3 protein is expressed in moderate levels 
in the feather follicle pulp but to investigate this further we utilised skin samples harvested 
from RB-1B infected chickens. Samples were tested by immunofluorescence analysis using 
antibodies against the MDV protein pp38 (Meq is only visible at very low levels in the 
feather follicle epithelium) and ATF3 to see if the same cells harboured MDV and ATF3 at 
the same time. We see from Figure 5.4 that pp38 is heavily expressed at the feather follicle 
epithelium as previously described but also the expression of ATF3 is seen. Furthermore, 
from Figure 5.4 we can see that not only are pp38 and ATF3 expressed in the same cell type 
but also in the same cell. This confirms that ATF3 protein expression does occur in the same 
cells that are infected by MDV.  
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Figure 5.4 Chicken ATF3 is expressed at the feather follicle epithelium. A. Feather 
pulp was harvested from RB-1B infected chickens and subject to western blot analysis for 
ATF3 expression. The ATF3 protein is expressed in both line 6 and line P. B. Skin samples 
were taken from RB-1B infected chickens and subjected to immunofluorescence and 
confocal microscopy. ATF3 (green) localised to the feather follicle epithelium and Keratin 
(red) localised to the feather sheath (DAPI in blue). Scale bar equal to 200μm. C. The upper 
panel shows infected feather follicle as above. ATF3 (green) expressed at the feather follicle 
epithelium and pp38 (red) in the same cell type. Scale bar equal to 75μm. The lower panel 
shows the same sample as the upper panel but at higher magnification. Scale bar equal to 
75μm. 
A. B. 
C. 
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5.6 Chicken ATF3 co-localises with Meq 
 As a transcription factor endogenous levels of human ATF3 localise to the cell 
nucleus. We hypothesise that chicken ATF3 is also found in the nucleus but furthermore it 
co-localises with Meq in order to facilitate the interaction with Meq. We show that in DF-1 
cells transfected with a Meq expression vector very low levels of endogenous ATF3 co-
localise with Meq in the cell nucleus (Figure 5.5) and moreover, when Meq and ATF3 
expression vectors are co-transfected into DF-1 cells we also see co-localisation which 
suggests the proteins occupy a close enough physical location in the cell to facilitate an 
interaction. 
When overexpressed, we see that chicken ATF3 diffuses though the entire cell and 
clear nuclear localisation is lost in a high proportion of cells. This may be an over-expression 
phenotype but interestingly, when Meq is co-expressed with ATF3 this seems to induce a 
nuclear translocation and abolishes almost all non-nuclear ectopic expression. This can be 
seen clearly in Figure 5.6. It was possible to count cells that contained diffuse ATF3 and 
ATF3 present in the nucleus only and analyse these data graphically. We show that ATF3 is 
present solely in the nucleus of only 55% of cells when transfected alone. This is increased 
significantly when Meq is co-expressed, and a shift to nuclear localisation of ATF3 is seen 
(p<0.005). This is further confirmed by ATF3 co-expression with the Meq
BZIP
 mutant that is 
unable to form stable leucine zipper mediated interactions. This mutant proves unable to 
facilitate the nuclear translocate which suggests that the translocalisation event may be 
facilitated though a direct interaction. 
  
161 
 
 
 
Figure 5.5 ATF3 co-localises with Meq in the cell nucleus. DF-1 cells were transfected 
with the Meq expression vector and subject to immunofluorescence with anti-Meq and anti-
ATF3 for endogenous localisation of ATF3 protein. Meq is shown in green and ATF3 in red. 
Co-localisation of Meq and endogenous ATF3 is indicated by yellow (top). Scale bar equal to 
20μm. DF-1 cells co-transfected with Meq and ATF3 expression vectors and assayed as 
above. Meq and ATF3 co-localisation as indicated by the yellow merge panel (middle). Scale 
bar equal to 10μm. DF-1 cells co transfected with Meq and ATF3 tagged with HA (bottom). 
Scale bar equal to 20μm. 
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Figure 5.6 ATF3 localisation in DF-1 cells. A. Immunofluorescence confocal analysis of 
DF-1 cells transfected with ATF3, Meq and Meq
BZIP
 mutant. When expressed alone ATF3 
(red) is found in a diffuse localisation after 24 hours. Meq (green) was transfected and 
localises to the nucleus. When co-transfected the diffuse localisation of ATF3 is reduced and 
it translocated to the nucleus but when the Meq
BZIP
 mutant (green) was co-transfected with 
ATF3 this nuclear translocalisation fails to take place. B. Count of cells with ATF3 in the 
nucleus only (black) or diffuse (white). A significant increase in nuclear expression is seen 
when ATF3 is co-transfected with Meq. This translocalisation is not seen when co-
transfected with Meq
BZIP
. Values represent total percentage of cells counted. C. Meq 
localisation was assayed as before and plotted as a percentage of total cells. Meq and the 
Meq
BZIP
 mutant are largely present in the nucleus of the cell as expected. Transfections and 
co-transfections were carried out in triplicate and error bars represent S.E.M. 
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5.7 Meq interacts with ATF3 via the Meq leucine zipper domain  
The Meq N-terminus was found to interact with the full length human ATF3 protein 
during the yeast two-hybrid screen described in chapter three. From the presence of a leucine 
zipper domain in both proteins we hypothesise that the interaction is likely to be mediated via 
this domain in each protein. Primarily, the interaction was confirmed in the yeast system by 
back screening against Meq and an empty bait vector but the interaction was further studied 
biochemically by co-immunoprecipitation (Figure 5.7). Meq and chicken ATF3 with a HA 
epitope tag were co-expressed in DF-1 cells before ATF3 was immunoprecipitated by 
immobilisation on HA antibody conjugated agarose beads. Interacting protein partners were 
pulled out of the whole cell lysate and subjected to western blot analysis for Meq. We see 
from Figure 5.7 that Meq is pulled out of a whole cell lysate by the immunoprecipitation of 
ATF3 by HA antibody affinity. However, when DF-1 cells were co-transfected with the 
Meq
BZIP
 mutant and ATF3 the Meq
BZIP
 mutant failed to be immunoprecipitated with ATF3. 
This indicates that the Meq leucine zipper domain is essential for the interaction with ATF3. 
The co-immunoprecipitation assay was repeated using the Meq protein to pull out ATF3 from 
a whole cell lysate. We show that Meq and not the Meq
BZIP
 mutant can purify ATF3 from a 
whole cell lysate.  This co-immunoprecipitation assay in conjunction with the yeast two-
hybrid screen confirms that Meq and ATF3 can interact directly but furthermore, the integrity 
of the Meq leucine zipper domain is essential for the interaction to take place. 
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Figure 5.7 ATF3 interacts with Meq but not the Meq
BZIP
 mutant. The co-
immunoprecipitation of Meq and ATF3 was carried out by co-transfection into DF-1 cells 
and pulling out the protein complex with both Meq and HA (ATF3) antibodies. A. Shows co-
immunoprecipitation of ATF3 using the Meq protein but not Meq
BZIP
 and B. shows the co-
immunoprecipitation of Meq but not Meq
BZIP
 using the ATF3 protein. Loading controls were 
taken from 10% of total cell lysate and anti-tubulin was used as a negative IgG 
immunoprecipitation control for co-immunoprecipitation.   
  
A. B. 
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5.8 Identification of ATF3 binding sites in the MDV genome 
 The MDV genome contains over 70 predicted open reading frames and 13 non-coding 
microRNA transcripts. This begs the question whether ATF3 is able to interact with the 
MDV genome and if so which genes or transcripts are affected. By scanning the MDV 
genome we were able to identify 4 potential ATF3 binding sites from DNA binding 
consensus sequences identified in the literature. These sites have been plotted in Figure 5.8 
and have the potential to regulate several MDV encoded genes. However, since at this point 
we do not know the target sequence of the Meq/ATF3 dimer it is not known whether ATF3 is 
likely to interact with these regions.  
 
5.9 MDV-encoded and host gene regulation by Meq and ATF3 
 Primarily, the promoter region of glycoprotein I was cloned from the RB-1B BAC 
virus and inserted into a firefly luciferase reporter construct. This construct was co-
transfected with the renilla luciferase control vector and Meq, Meq
BZIP
 or ATF3 expression 
vectors. This initial investigation of the MDV glycoprotein I promoter shows a significant up-
regulation by the co-expression of Meq and ATF3 (Figure 5.9). Furthermore, upon 
transfection with ATF3 and the Meq
BZIP
 mutant this increase in expression is not seen. This 
indicates that the Meq and ATF3 dimer has the potential to regulate the MDV glycoprotein I 
promoter region. 
 This was further investigated by the application of RT-PCR in order to show a 
difference in gene expression between infected and non-infected cells (Figure 5.10). CEF 
cells were infected with RB-1B strain of MDV or RB-1BΔMeq and total RNA harvested at 
24 hour time points until 120 hours post infection. Total RNA was reverse transcribed into 
cDNA and transcript levels were ascertained by specific PCR for MDV encoded 
Glycoprotein I, UL21 and UL42. Several ATF3 known cellular targets (Cyclin D1 and 
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SNAI2) were also assayed in order to investigate whether the rise in ATF3 seen in Figure 5.3 
has an effect on host gene transcription. No difference in host or MDV-encoded gene 
transcript levels was detected with levels of both Cyclin D1 and SNAI2 remaining the same 
over the course of infection and the levels of MDV-encoded Glycoprotein I, UL21 and UL42 
increased over the course of infection. However, no difference was seen between RB-1B and 
RB-1BΔMeq infection. 
 Further investigation of host gene transcription was carried out by co-transfection of 
DF-1 cells with Meq and ATF3 expression vectors before harvesting for total RNA isolation 
and cDNA production. cDNA was then subject to qRT-PCR by Taqman analysis for Cyclin 
D1 and SNAI2 gene transcription investigation (Figure 5.11). However, as in Figure 5.10 no 
significant difference in gene transcription was observed.  
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Figure 5.8 ATF3 binding sites in the MDV genome. Potential ATF3 binding sequences 
are noted with the genomic location in brackets. Genes located on the positive strand are 
shown in red and genes located on the negative strand are shown in blue. Gene lengths are 
not to scale. 
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Figure 5.9 Meq and ATF3 up-regulate the MDV glycoprotein I promoter region. A. 
DF-1 cells were co-transfected with the glycoprotein I promoter firefly luciferase expression 
vector along with the renilla control and a combination of Meq, Meq
BZIP
 and ATF3 
expression vectors. Meq alone increased the expression of the luciferase reporter whereas 
Meq
BZIP
 and ATF3 did not. When Meq and ATF3 were co-transfected a significant (p<0.05) 
up-regulation was detected. This up-regulation was also significantly different from the 
Meq
BZIP
 co-transfection with ATF3 (p<0.005). Negative control promoter (empty firefly 
luciferase construct) is shown in red (left hand column) and positive control promoter (SV40 
driven firefly luciferase construct) is shown in black. Error bars represent S.E.M. B. Cell 
lysates were also taken for western blot analysis. This confirms that Meq, Meq
BZIP
 and ATF3 
are expressed at similar levels. 
 
  
A. B. 
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Figure 5.10 Host and MDV-encoded gene transcript expression after MDV infection. 
CEF cells were infected with 200pfu RB-1B or RB-1BΔMeq and total RNA harvested after 8 
hours, 24 hours and every 24 hours thereafter. Total RNA was subject to RT-PCR and 
specific PCR amplification of Glycoprotein I, UL21, UL42, Cyclin D1 and SNAI2. No 
difference in host and MDV-encoded gene transcription between RB-1B and RB-1BΔMeq 
infection is seen. MDV-encoded genes (Glycoprotein I, UL21 and UL42) increase over time 
and host genes (Cyclin D1 and SNAI2) remain level. Loading control shows similar levels of 
GAPDH in all samples. 
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Figure 5.11 qRT-PCR analysis of cellular ATF3 targets. A. DF-1 cells were transfected 
with either an empty expression vector, Meq, MeqBZIP, ATF3 or co-transfected with Meq + 
ATF3 or MeqBZIP + ATF3. Cells were harvested for total RNA isolation after 48 hours and 
subject to specific qRT-PCR for Cyclin D1 and B. SNAI2 expression. No significant change 
in transcript levels was detected after Meq and ATF3 transfection. Error bars represent 
S.E.M.  
A. B. 
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5.10 Discussion 
5.10.1 Chicken ATF3 
Chicken ATF3 is well annotated in the chicken genome (NCBI accession: 
XM_419429) and a classical cloning approach was adopted to amplify the coding sequence. 
This produced a fragment of expected size and sequence to allow cloning of chicken ATF3 
into a range of expression vectors for further analysis. This was then used as a positive 
control for antibodies as the ATF3 protein is expressed at low levels in most cell types. To 
our knowledge this is the first time chicken ATF3 has been cloned and so we can confirm the 
chicken annotation in Ensembl is correct. 
 
5.10.2 ATF3 expression in chicken cells 
We show that the ATF3 protein is either not expressed or expressed at very low levels 
in MDV-transformed cell lines but we see a low level of expression in the ALV-transformed 
cell line AVOL-1. This suggests that Meq interaction with ATF3 may not be important for 
MDV-induced transformation. As a stress induced product it has been shown that ATF3 can 
be induced after heat shock and so we subjected the MDV cell line MSB-1 to heat shock but 
again failed to see expression of ATF3. This is particularly interesting since we see moderate 
levels of ATF3 transcript in all MDV transformed cell lines investigated in Figure 5.2. The 
production of mRNA but not protein is puzzling but perhaps not completely unexpected since 
the current understanding is contrived about the relationship between transcript and protein 
levels in general. This suggests a mechanism is in place for regulating the translation of the 
ATF3 protein. The cell uses many different mechanisms for regulating protein expression and 
having studied the ATF3 3’ UTR we suggest this regulation is unlikely due to the presence of 
an MDV-encoded microRNA. 
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 It was hypothesised that ATF3 protein expression would be altered after MDV 
infection and so CEF wells were infected and ATF3 transcript levels investigated at several 
time points. As hypothesised, levels of ATF3 transcript increased as MDV infection 
progressed. It is thought that this is due to the stress and ultimately cell death that CEF cells 
undergo after MDV infection. This increase in ATF3 transcription is also seen after infection 
with coxsackie virus (Hwang et al 2007) or adenovirus (Zhao et al 2003) but we believe this 
is the first account of ATF3 gene transcription up-regulation by a herpes virus. 
  
5.10.3 ATF3 in the feather follicle epithelium 
Western blot confirms the presence of the ATF3 protein at the feather follicle and 
feather pulp. This is perhaps not surprising since this region is highly associated with 
apoptosis and growth. Immunofluorescence and confocal microscopy confirm this expression 
and show ATF3 to be localised mainly to the epidermis of the feather follicle. Furthermore, 
we show that ATF3 is present in the same cell type and even the same cell as MDV by 
staining to detect the lytic cell antigen pp38. This provides strong evidence that ATF3 is 
expressed in the same cell type as MDV and so potentially interacts with Meq in vivo. We 
also see a high level of ATF3 in the feather follicle muscle but we fail to see MDV in these 
cell types. This suggests a potential role for the Meq interaction with ATF3 in lytic 
replication at the feather follicle. Since it is thought that ATF3 acts as a transactivating 
protein when present as a heterodimer it is reasonable to suggest that when bound to Meq it 
has the potential to up-regulate anti-apoptotic or pro-survival proteins. This however remains 
to be seen and requires further investigation. 
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5.10.4 Chicken ATF3 co-localises with Meq 
We go on to show that chicken ATF3 is recognised by the commercial mouse ATF3 
antibody by immunofluorescence and confocal microscopy. When ATF3 is co-trasnfected 
with Meq we see co-localisation in the cell nucleus. This is confirmed by tagging the ATF3 
protein with the HA epitope and visualising as above. We see the same expression pattern but 
furthermore, when we transfect Meq alone into DF-1 cells we see a low number of cells 
expressing ATF3 but were able to visualise co-localisation between Meq and the endogenous 
ATF3 protein. This is significant since the levels of ATF3 in a cell type may be low but 
individual cells can be under different stresses than the majority of the cell population which 
allows for investigation at a single cell level. From this we can confirm that Meq co-localises 
with endogenous ATF3 and so is in close enough proximity to interact directly. 
 When investigating the co-localisation of Meq and ATF3 it was noticed that when 
transfected alone ATF3 was present in the entire cellular compartment. This is likely to be an 
overexpression phenotype since ATF3 is a well known transcription activator and repressor. 
However, when ATF3 is co-transfected with Meq we see a dramatic translocalisation to the 
nucleus. This suggests further that ATF3 is interacting with Meq since Meq seems to be 
sequestering the overexpressed ATF3 protein to the nucleus. 
 
5.10.5 Meq interacts with chicken ATF3 
Primarily we showed using the yeast two-hybrid system that Meq and ATF3 interact. 
This however was not confirmed by predicted interactions via the leucine zipper domain of 
each protein. However, Meq and endogenous ATF3 co-localise in the cell nucleus and Meq 
has been shown to interact with the human and mouse ATF3 leucine zipper. We then went on 
to show that the interaction takes place, by utilising a co-immunoprecipitaion assay whereby 
Meq and ATF3 are over expressed and co-immunoprecipitated with both the Meq and HA 
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(ATF3) antibody. We went on to investigate the properties of the Meq
BZIP
 mutant lacking a 
viable leucine zipper and showed that this does not co-immunoprecipitate with ATF3. This 
suggests that the Meq leucine zipper domain is essential for the interaction to take place. We 
did not co-immunoprecipitate the endogenous ATF3 protein with Meq due to the low levels 
of ATF3 present in most cell types.  
Since the interaction with ATF3 takes place via the leucine zipper it is reasonable to 
suggest that Meq may alter the function of ATF3 and perhaps mediate the binding of the 
dimer to a different consensus sequence. On the other hand the interaction may abolish the 
DNA binding of ATF3 completely but perhaps most likely is that Meq and ATF3 acts in a 
similar way to c-Jun and ATF3 since Meq is known to interact with AP-1 sites in a similar 
manner to c-Jun. 
 
5.10.6 ATF3 in the MDV genome 
Several potential ATF3 binding sites were located in the MDV genome. Since ATF3 
is known to bind a variety of consensus sequences at both low and high affinities this was not 
unexpected. These MDV promoter regions were cloned and analysed using a luciferase 
reporter assay but only the MDV glycoprotein I showed increased activity in the presence of 
both Meq and ATF3. This proved interesting since glycoprotein I is an essential antigen 
expressed by MDV (Schumacher et al 2001) in lytic replication. Since we have already 
identified ATF3 in the feather follicle epithelium we hypothesised that Meq and ATF3 play a 
key role in the expression of glycoprotein I during lytic infection at the feather follicle 
epithelium. 
 However, although we see an up-regulation of firefly luciferase after Meq and ATF3 
transfection we fail to see a difference in glycoprotein I expression in CEF infected with 
either the RB-1B wild-type virus or the RB-1BΔMeq virus. This suggests that Meq does not 
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play a role in glycoprotein I expression in CEF at least but it remains to be seen whether these 
proteins act together in the feather follicle epithelium in order to up-regulate this essential 
MDV antigen. 
 
5.10.7 ATF3 and the host genome 
We have shown that Meq and ATF3 have the potential to target the MDV 
glycoprotein I but ATF3 is known to target several human genes for both transactivation and 
transrepression (Allan et al 2001; Yan et al 2011). These targets with known ATF3 binding 
sites were investigated in the chicken genome to find that only SNAI2 and Cyclin D1 are 
maintained in the chicken genome. The promoter regions of these targets in the chicken 
genome are poorly annotated so the same luciferase reporter assay was not possible for these 
cellular targets. Primers were designed against these targets and RB-1B and RB-1BΔMeq 
infected CEF were assayed for a change in these potential target transcript levels. No change 
was seen but this is perhaps due to the low levels of endogenous ATF3 in the CEF cells.  
As viral infection is a complex mechanism and we are simply interested in the Meq 
and ATF3 proteins we carried out a range of transfections of both Meq, Meq
BZIP
 and ATF3. 
However, we still failed to see a change in SNAI2 or Cyclin D1 levels. From this we can 
suggest that Meq and ATF3 do not target these cellular genes and it is clear that further work 
is required to investigate the potential cellular targets of Meq and ATF3. 
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6 General Discussion, further work, and conclusions 
6.1 Discussion and further work 
 The Meq oncoprotein has previously been shown to interact with several important 
cellular factors but this area of study has been neglected since the identification of CtBP1 as a 
pivotal functional partner. We know from genetic manipulation that Meq mediated hetero and 
homodimers are essential in the neoplastic nature of the disease (Brown et al 2009; 
Suchodolski et al 2009; Suchodolski et al 2010) but little is known regarding these bZIP 
protein partners. The pro-oncogenic mechanisms behind MDV infection are not yet fully 
understood and uncovering novel protein-protein interactions made by the viral oncoprotein 
Meq can only provide further insights into this increasingly complex story. With the 
application of a global protein-protein interaction study as well as phylogenetic analysis we 
have succeeded in learning more about this bZIP transcription factor and identifying a panel 
of novel interactions. This has ultimately introduced a new understanding of the MDV-
encoded oncoprotein Meq.  
 Initially we highlight the interesting possibility that c-Jun may not be the most closely 
related protein to Meq. The present understanding is that Meq is a c-Jun analogue but 
evidence presented in this thesis suggests that Meq is more closely related to the BATF 
family of transcription factors by evolution if not physiological function. We show that the 
functional residues in the Meq leucine zipper, the non-functional residues in the leucine 
zipper, the DNA binding domain and the protein as a whole are most closely related to the 
BATF family and so we hypothesise that Meq is analogous to BATF and not c-Jun. BATF is 
a small family of bZIP transcription factors that does not feature heavily in the literature. This 
is surprising since the information we do have about these proteins is particularly relevant to 
the story of cancer development as a whole. This along with the apparent lack of reagents for 
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the chicken BATF proteins would prove the largest stumbling block for initial investigation 
into this hypothesis but the importance and relevance of the study would certainly warrant 
future work.  
 The yeast two-hybrid screen was employed in order to provide a global view of the 
Meq interactome. This proved to be an extremely powerful approach that provided a large 
panel of novel Meq interacting proteins. However, the design of the yeast two-hybrid screen 
also provided a built in positive control mechanism by the identification of known Meq 
protein partners. We were successfully able to pull out a range of proteins that have 
previously been shown to interact with Meq in order to confirm the viability of the assay. 
Leucine zipper interactions with JunD and JunB featured heavily in the protein panel but also 
the non-leucine zipper interaction with CtBP1 was identified. However, the most significant 
interactions identified by yeast two-hybrid were those with novel partners Par-4, ATF3, 
N4BP1, RACK1 and Pin1. 
 This study is the first example of the powerful pro-apoptotic protein Par-4 interacting 
directly with a viral oncoprotein. This discovery creates the opportunity to hypothesise on the 
physiological function of this interaction, but also provides further insight into the potential 
for other oncogenic viruses to utilise a similar mechanism in order to counter the pro-
apoptotic effects of Par-4. We know from the literature that the apoptotic function of Par-4 is 
indirectly mediated by the EBV-encoded LMP1 protein (Lee et al 2009) but this is the first 
suggestion that a viral oncoprotein can interact directly and potentially moderate the Par-4 
function. It is clear that further work is required in order to provide conclusive evidence for a 
physiologically relevant interaction but the evidence presented in this study highlights the 
potential for an extremely important role for this interaction during virus induced neoplasia.  
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 We show that Par-4 protein expression is limited in MDV-infected cells but this is by 
no means a reason for dismissing the interaction as not biologically relevant. Primarily, the 
mechanism by which MDV infection results in cellular transformation is far from being fully 
understood. Furthermore, the huge array of cellular interactions thought to be pivotal for 
MDV spread and accumulation have not yet been mapped. Finally, the mechanism by which 
lytic MDV infection persists in the feather follicle epithelium and other tissues has not yet 
been elucidated. It is clear that the understanding of MDV infection and oncogenesis has 
improved dramatically in recent years but it is still the case that there is much to learn 
regarding both the infection model as a whole and the molecular principles that underpin it. 
With this in mind it would be naïve to suggest the Meq interaction with Par-4 is not 
biologically relevant but should only serve to increase the appetite for further understanding 
of this natural disease model. 
 From Figure 1.7 we can see how Par-4 is able to interact with WT1 in order to occupy 
the Bcl-2 promoter region and thus prevent expression of the pro-survival protein. This is one 
molecular mechanism by which we can see that the evolution of an interaction with Meq 
would potentially benefit MDV-induced oncogenesis. The expression of Bcl-2 has long since 
been related to cell survival and cancer (Yip & Reed 2008). However, Par-4 is able to 
infiltrate this mechanism and by binding the WT1 protein, which directly interacts with the 
Bcl-2 promoter, can abolish Bcl-2 protein expression. It is not clear however if this process 
takes place in the chicken but the sequestration of Par-4 from the Bcl-2 promoter in vivo 
certainly has the potential to play a pivotal role in cellular transformation due to the pro-
survival nature of Bcl-2. 
 The majority of Par-4 interactions with its known protein partners are mediated by the 
leucine zipper domain. The nature of this domain dictates that only a single interacting 
partner can bind at one point in time. This highlights the potential for protein sequestration as 
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suggested above by the removal of Par-4 from WT1 and the Bcl-2 promoter simply because 
the two proteins compete for the same binding domain. This could also prove to be 
interesting when introducing Meq into the other known Par-4 mediated apoptotic cascades. 
Figure 1.8 describes the mechanism by which Par-4 interacts with protein kinase C in order to 
prevent the phosphorylation and activation of the NFκB complex. This in turn prevents the 
pro-survival action of NFκB and, by mechanisms that are not fully understood, allows Par-4 
to exert its apoptotic effect. However, the sequestration of Par-4 by Meq in much the same 
way that the human ubiquitin binding protein p62 does, would provide an extremely 
advantageous mechanism by which the virus could prevent cell death. The Par-4 protein can 
be visualised in the cellular apoptotic pathways context using Ingenuity Pathway Analysis. In 
Figure 6.1 we can see the potential consequence of Par-4 sequestration by Meq. 
 We can see a potentially significant biological role for the Meq interaction with Par-4 
but it is clear that further work is required in order to improve our understanding. The 
primary concern was the difficulty encountered when attempting to clone the full length 
chicken Par-4 gene. We attempted several 5’ RACE amplifications of the gene but a 
truncated sequence output resulted from both assays. This was potentially due to the 
amplification of a short transcript splice variant but, since a protein of equal molecular weight 
to that of human Par-4 is detected by western blot in chicken cells, this is unlikely. Further 
optimisation of the 5’ RACE assay or potentially a new generation high throughput method to 
sequence the ‘gap’ in the chicken genome would prove advantageous.  
 We identified an antibody that detects the chicken Par-4 protein in immunoblotting 
assays but we have as yet not identified an antibody that detects the native form of the protein 
in immunofluorescence assays. This proved to be problematic when investigating 
endogenous levels of Par-4 at a single cell level so over expression studies were adopted in 
order to shed light on the pro-apoptotic nature of the chicken Par-4 protein. We see that when 
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chicken Par-4 is ectopically expressed the cell undergoes dramatic apoptotic morphological 
change, but further studies with the application of chicken-specific antibodies and gene 
silencing tools could be powerful in determining the functional significance of the chicken 
Par-4 protein. 
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Figure 6.1 Par-4 and apoptosis pathway analysis. Ingenuity Pathway analysis was used 
to integrate the Par-4 protein into the apoptotic pathways of the cell. Solid lines represent 
direct protein-protein interactions, dashed lines represent indirect interactions and arrow 
direction represents regulation. Par-4 is represented by PAWR.  
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 We demonstrated that Meq interacts with Par-4 directly with the application of yeast 
two-hybrid screening and further showed that the Meq leucine zipper domain is essential for 
the interaction to take place by mutational analysis. Although such dramatic mutations to the 
leucine zipper domains are useful in understanding the biochemical aspects of the interaction 
they would certainly not be as useful when looking into the physiological significance of the 
interaction. This aspect of the further investigation would prove to be extremely complex due 
to the nature of both leucine zipper domains. Meq makes many interactions through this 
domain and each of them relies on different functional residues to direct these dimerisation 
events. It is true that selective single residue alteration may have the ability to disrupt the 
leucine zipper interaction between Meq and Par-4, although the effect of such mutations on 
other leucine zipper mediated interactions cannot be ruled out. However, even if a single 
residual mutation does not disrupt any other known interactions, we are still far from 
identifying the global Meq leucine zipper interactome. This introduces the problem of 
disrupting any as yet unknown leucine zipper interactions that may prove to be vital for the 
action of Meq as an oncoprotein. Considering the importance of Meq to the virus and its 
oncogenic nature we conclude that this direction of investigation would be premature and 
could potentially give misleading conclusions. 
 Perhaps more important is the continuation of the investigation into Par-4 mediated 
apoptosis in the presence of Meq. In the fourth chapter of this thesis we investigate the 
potential for Meq disrupting the apoptotic function of Par-4. We see that there is a reduced 
level of apoptosis when examined microscopically but fail to see conclusive evidence when 
assaying for apoptotic markers. It is clear that further study is required to bolster this 
hypothesis and, with the recent application of live cell imaging in the laboratory, this would 
be an exciting direction to take with this study. Several live cell imaging reagents have 
recently been introduced to the scientific market and, along with the application of 
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fluorescent protein tags to both Meq and Par-4, it would be possible to visualise Par-4 
mediated apoptosis in the presence and absence of Meq in real time. This would provide an 
extremely interesting approach to visualising the dynamics of Meq and Par-4 in relation to 
apoptosis in an individual cell rather than a cell population as used by the classical PARP-1 
cleavage and DNA fragmentation assays. 
 In conclusion, we have identified the extremely powerful pro-apoptotic protein Par-4 
as a Meq protein partner. This is not only the first example of a viral oncoprotein directly 
interacting with Par-4 but it is also the first member of the AP-1 transcription factor family to 
make a Par-4 heterodimer. The biological significance of this interaction is as yet unresolved 
but the significance of this finding to the field is evident as this novel protein-protein 
interaction provides not only the potential for an exciting advance in MD virology but also 
cell biology as a whole. 
 The Meq N-terminus was shown to interact with the full length ATF3 protein by yeast 
two-hybrid screening. We decided to look further into this interaction as Meq has been shown 
to interact with a human and mouse peptide chain corresponding to the ATF3 leucine zipper 
but full length ATF3 and, ultimately, chicken ATF3 experiments are lacking. To our 
knowledge this study is not only the first account of chicken ATF3 cloning but also the first 
suggestion that the chicken ATF3 protein can interact with Meq. We go on to investigate the 
expression of chicken ATF3 in a variety of cell types before finally exploring cellular 
localisation of chicken ATF3 and the potential biological consequence of its interaction with 
Meq.  
The cloning of the chicken ATF3 gene was straightforward due to the full annotation 
of the gene sequence available on the Ensembl genome browsing website. A classical PCR 
amplification approach was utilised which confirmed the coding sequence and aided cloning 
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into a variety of expression vectors with and without epitope tags. The full gene sequence 
annotation also allowed for investigation into transcript levels in chicken cells by PCR and 
the identification of a human ATF3 antibody that cross reacts with the chicken ATF3 protein 
allowed for protein expression analysis. Furthermore, we hypothesise that as transcription 
factors the Meq and ATF3 complex interacts with the MDV genome, host genome or both in 
order to regulate gene transcription.  
ATF3 protein expression was not seen in MDV-transformed cell lines but, as we 
suggest with Par-4, this does not necessarily label this interaction as not biologically 
significant. As we discuss above, the cellular and molecular pathways by which MDV 
infection results in cancer and virus spread are far from fully understood. This illustrates the 
potential for the Meq and ATF3 proteins to be present in the same cell type at the same time. 
We also show that the ATF3 protein is present in the feather follicle epithelium of infected 
chickens but, furthermore, it is present in the nucleus of single infected cells that also express 
the MDV-encoded pp38 antigen. This shows that ATF3 can be expressed by single cells 
infected with MDV and highlights the potential for a direct interaction with the Meq 
oncoprotein in vivo. 
Furthermore, we show that Meq can co-localise in the cell nucleus with endogenous 
chicken ATF3 when expressed in DF-1 cells. Although, expression of the ATF3 protein is not 
seen in a DF-1 population by immunoblotting, we see a small percentage (<1%) of ATF3 
positive cells by immunofluorescence assays. These cells are likely to be present at different 
cell cycle stages or under different stresses to the majority of the population and so harbour 
the ATF3 protein, and it would be interesting to shed further light on this phenomenon. 
In this thesis we also identify several potential targets for Meq and ATF3 but they 
failed to be regulated by the complex in CEF and DF-1 cells. However, it is clear that this 
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requires further investigation in vivo.  With the application of DNA binding assays including 
high throughput ChIP sequencing we hypothesise that Meq and ATF3 interact with a large 
number of promoter regions in the host cell genome. We also highlight the possibility for the 
Meq and ATF3 dimer to interact with the MDV genome at the glycoprotein I (gI) promoter 
region and potentially upregulate gI expression. We hypothesise this since the gI antigen is 
required for MDV lytic replication and it is reasonable to suggest that another pivotal virally 
encoded protein such as Meq is involved in its regulation. However, the difficulty in AP-1 
binding site mining comes in the diverse range of proteins that can interact with them and the 
significant number of sequence variations. Demonstration of the interaction of Meq with the 
gI promoter can be carried out be gel shift analysis but in vivo assays would be required by 
ChIP analysis as described above. Moreover, the application of RNAi against Meq or ATF3 
would be an extremely powerful technique along with the mutational analysis of the gI 
promoter AP-1 binding site within the MDV genome by site directed BAC mutagenesis. 
As mentioned previously, a complete examination of the global Meq interactome 
would benefit from analysis of both direct and indirect interactions. The yeast two-hybrid 
screen would ideally be carried out in comparison with LC-MS/MS technology. We utilised 
this technique in chapter three but failed to identify any known protein interactions (Meq 
homodimer was not identified) as a built in technical control to the system. It is interesting 
that other similar studies have also failed to identify Meq in the MS spectra (Buza & Burgess 
2007), suggesting technical issues exist such as a lack of sufficient trypsin cleavage sites in 
the Meq peptide chain. Thus further investigation making use of alternative proteomics 
approaches could be carried out to provide a better picture of the global Meq interactome. 
The current technology would allow for a quantitative account of the Meq protein complex in 
the cell using quantitative proteomics. Methods such as SILAC (Mann 2006) and others such 
as label-free proteomics (Zhu et al 2010) allow for the relative quantification of protein 
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molecules in a sample and, from this, a hypothesis can be made regarding the composition of 
different Meq protein complexes present inside the cell.  
In conclusion to this thesis we can say that both chicken Par-4 and ATF3 interact 
directly with Meq. Furthermore, these interactions are mediated via the Meq leucine zipper 
regions and are abolished by the disruption of this domain. We show that Meq and Par-4 co-
localise in the cell nucleus when ectopically expressed and that Par-4 is not present in most 
MDV-transformed lymphocyte cell lines. However, Par-4 is expressed in the feather follicle 
epithelium of infected chickens. We go on to further investigate the interaction between Meq 
and chicken ATF3 by identifying the co-localisation of Meq and endogenous ATF3 in the 
cell nucleus and further expression at the feather follicle epithelium of infected chickens. 
Here we show that ATF3 is expressed in individual MDV infected cells but it is clear that 
further investigation is required in order to uncover the physiological significance of this 
localised potential interaction. With the application of laser microdissection and 
immunofluorescence assays this could be taken further to incorporate the analysis of the 
MDV and the host cell proteome in infected feather follicle epithelial cells. However, the 
main finding of this work is the identification of novel interacting partners of the MDV-
encoded oncoprotein Meq by application of a yeast two-hybrid screen. Further confirmation 
of these interactions and incorporating a variety of techniques to crack the global Meq 
interactome are of the highest priority for future investigations. 
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6.2 Summary of results 
6.2.1 Chapter 3 Global Meq interactome 
 In chapter three we suggested that Meq is evolutionarily analogous to BATF and not 
c-Jun as previously thought. We demonstrated this by bioinformatic sequence analysis as 
well as phylogenetics. We went on to subject the Meq protein to a global scale protein-
protein interaction study using the yeast two-hybrid system and identified a group of known 
and novel protein partners. The Meq N-terminus was shown to make known interactions with 
JunD, JunB and CtBP1 and novel interactions with Par-4, ATF3, RACK1 and N4BP1. The 
Meq C-terminus was shown to interact with the novel Pin1 protein but not with any known 
proteins.  
 
6.2.2 Chapter 4 Meq interacts with Prostate apoptosis response-4 
 The chicken Par-4 gene was cloned from RNA isolated from CEF followed by 
5’RACE and shows significant homology to the human, mouse and rat genes at the functional 
SAC and leucine zipper domains. We demonstrated that the chicken Par-4 protein is likely to 
be functionally orthologous to the human protein by the induction of apoptosis as a result of 
over expression studies. We went on to confirm the interaction with Meq and furthermore, 
show that this interaction is mediated by the Meq leucine zipper domain. Ectopic expression 
of each protein results in co-localisation in the cell nucleus but endogenous levels of Par-4 
are found in a limited panel of MDV-transformed cells. Finally, we suggest a potential role 
for Meq in the disruption of the pro-apoptotic nature of Par-4 but this requires further 
investigation.   
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6.2.3 Chapter 5 Meq interacts with Activating transcription factor-3 
 The chicken ATF3 gene was cloned from cDNA isolated from CEF by traditional 
cloning techniques. By co-immunoprecipitation we were able to confirm that Meq interacts 
with the full length chicken ATF3 protein and, furthermore, we show that the interaction is 
mediated by the Meq leucine zipper domain. Meq co-localises with both endogenous and 
ectopically expressed ATF3 in the cell nucleus but endogenous ATF3 is detected in only a 
limited panel of MDV-transformed cells. However, we show that endogenous levels of ATF3 
are present in the feather follicle epithelium of infected birds and, moreover, ATF3 is 
expressed in cells expressing the MDV-encoded antigen pp38. Finally, we go on to suggest 
that Meq and ATF3 potentially regulate the expression of the MDV-encoded gI antigen but it 
is clear that this requires further investigation.  
  
6.3 Concluding remarks 
 With the development of new generation technologies available to protein 
biochemists, the global Meq interactome is within reach. It is clear that several key issues 
should be addressed in the immediate future in order to aid in this ultimate goal. The 
resolution of the Meq crystal structure would prove to be an interesting step in the right 
direction but would clearly require the application of proteomics techniques and perhaps 
collaborative efforts to achieve. This thesis has uncovered several novel Meq protein partners 
but it is clear that we are yet to fully understand the molecular mechanisms behind the MDV-
encoded oncoprotein. We provide the first account of interactions with Par-4, ATF3, RACK1, 
N4BP1 and Pin1 but it is likely that Meq interacts with a vast array of proteins and it is 
imperative that these interactions are uncovered. The goal of this thesis was achieved by the 
identification of these proteins but much additional work is required in order to identify the 
multiple molecular pathways resulting from the global Meq interactome.  
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Appendix I 
Tissue culture 
 DF-1 cell growth medium 
  Dulbecco's Modified Eagle Medium     89mL 
  Fetal Bovine Serum       10mL 
  Sodium Pyruvate (0.5M)      1mL 
 MDV transformed cell line growth medium 
  Roswell Park Memorial Institute medium 1640   79mL 
  Fetal Bovine Serum       10mL 
  Tryptose Phosphate Broth      10mL 
  Sodium Pyruvate (0.5M)      1mL 
  2-Mercaptoethanol (0.25M)      100µl 
 HeLa cell growth medium 
  Dulbecco's Modified Eagle Medium     89mL 
  Fetal Bovine Serum       10mL 
  Sodium Pyruvate (1M)      1mL 
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PC-3 cell growth medium 
Roswell Park Memorial Institute medium 1640   89mL 
  Fetal Bovine Serum       10mL 
  Sodium Pyruvate (0.5M)      1mL 
 Chicken Embryo Fibroblast growth medium 
Tryptose Phosphate Broth      50mL 
199 medium (10X)       50mL 
  New-born calf Serum       10mL 
  Sodium Bicarbonate (7.5%)      43.5mL 
  L-Glutamine        5mL 
  dH20         380mL 
 Chicken Embryo Fibroblast maintenance medium  
199 medium (10X)       10mL 
  Fetal Bovine Serum       5mL 
L-Glutamine        1mL 
  dH20         76mL 
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Yeast cell culture 
 YPDA liquid medium 
  YPD         50g 
  L-adenine hemisulphate (0.2%)     15mL  
  dH2O         to 1L 
2X YPDA liquid medium 
  YPD         100g 
  L-adenine hemisulphate (0.2%)     15mL  
dH2O         to 1L  
0.5X YPDA liquid medium 
YPD         25g 
  L-adenine hemisulphate (0.2%)     15mL  
dH2O         to 1L 
 YPDA agar 
YPD agar        70g 
  L-adenine hemisulphate (0.2%)     15mL  
dH2O         to 1L 
 SD/-Trp liquid medium 
  Minimal synthetic defined base     26.7g 
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  -Trp dropout supplement      0.74g 
dH2O         to 1L 
SD/-Trp agar 
Minimal synthetic defined agar     46.7g 
  -Trp dropout supplement      0.74g 
dH2O         to 1L 
SD/-Leu liquid medium 
  Minimal synthetic defined base     26.7g 
  -Leu dropout supplement      0.69g 
dH2O         to 1L 
SD/-Leu agar 
Minimal synthetic defined agar     46.7g 
  -Leu dropout supplement      0.69g 
dH2O         to 1L 
SD/-Leu/-Trp liquid medium (DDO) 
Minimal synthetic defined media      
 26.7g 
  -Leu/-Trp dropout supplement     0.64g 
dH2O         to 1L 
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SD/-Leu/-Trp agar (DDO) 
Minimal synthetic defined agar     46.7g 
  -Leu/-Trp dropout supplement     0.64g 
dH2O         to 1L 
SD/-His/-Leu/-Leu liquid medium (TDO) 
Minimal synthetic defined media     26.7g 
  -His/-Leu/-Trp dropout supplement     0.62g 
dH2O         to 1L 
SD/-His/-Leu/-Leu agar (TDO) 
Minimal synthetic defined agar      46.7g 
  -His/-Leu/-Trp dropout supplement     0.62g 
dH2O         to 1L 
SD/-Ade/-His/-Leu/-Trp liquid medium (QDO) 
Minimal synthetic defined media     26.7g 
  -Ade/-His/-Leu/-Trp dropout supplement    0.60g 
dH2O         to 1L 
SD/-Ade/-His/-Leu/-Trp agar 
Minimal synthetic defined agar      46.7g 
  -Ade/-His/-Leu/-Trp dropout supplement    0.60g 
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dH2O         to 1L 
X-α-Gal 
 X-α-Gal        0.04g 
 dH2O         10mL 
1.1X TE/LiAc 
 10X TE        1.1mL 
 1M LiAc         1.1mL 
 dH2O         to 10mL 
PEG/LiAc 
 PEG 3350 (50% w/v)       8mL 
 10X TE        1mL 
 1M LiAc        1mL 
Cracking buffer stock 
 Urea         8M 
 SDS         5%(v/v) 
 Tris-HCl (pH 6.8)       40mM 
 EDTA         0.1mM 
 Bromophenol blue       0.04g 
 dH2O         to 100mL 
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Cracking buffer complete 
 Cracking buffer stock       1mL 
 β-mercaptoethanol       10μl 
 phenyl-methyl-sulphonyl-fluoride     50μl 
 Proteinase inhibitor cocktail      1X 
 
Bacterial cell culture 
 Liquid Lysogeny Broth 
  Tryptone        10g  
  Yeast extract        5g 
  NaCl         10g 
  dH2O         1L 
 Solid Lysogeny Broth 
  Lysogeny Broth 
  Agar         1%(w/v) 
 Super optimal recovery broth 
  Bacto-trptone        20g 
  Bacto-yeast extract       5g 
  NaCl (8.65mM)       0.5g 
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  KCl (2.5mM)        0.186g 
  dH20         1L 
 Antibodies 
  Ampicillin        100µg/mL 
  Kanamycin        50µg/mL 
  Puromycin        1µg/mL 
Protein analysis 
 PBSa 
  NaCl         8g 
  KCl         0.2g 
  Na2HPO4        1.44g 
  KH2PO4        0.24g 
  dH2O         to 1L 
 BupH
TM 
  
Tris-HCl (pH 7.2)       25mM 
  NaCl         150mM 
 Non-reducing loading buffer 
  Tris-HCl (pH 6.8)       300mM 
  SDS         5%(v/v) 
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  Glycerol        50%(v/v) 
  Lane marker tracking dye (Pierce)     1X 
 2X SDS loading buffer 
  Tris-HCl (pH 6.8)       100mM 
  Glycerol        20%(v/v) 
  SDS         1%(v/v) 
  Bromophenol Blue       0.05%(v/v) 
  β-mercaptoethanol       1%(v/v) 
Proteinase inhibitor cocktail 
 One tablet of EDTA-free proteinase inhibitor cocktail (Roche) in 2mL dH2O. 
Radioimmunoprecipitation (RIPA) buffer 
 Tris-HCl        50mM 
 NaCl         150mM 
 SDS         0.1%(v/v) 
 Triton X-100        1%(v/v) 
 Proteinase inhibitor cocktail      1X 
Co-immunoprecipitation lysis buffer 
 Tris-HCl (pH 8.0)       50mM 
 NaCl         150mM 
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 Glycerol        10%(v/v) 
 Triton X-100        0.5%(v/v) 
 Proteinase inhibitor cocktail      1X 
GST lysis buffer 
Tris-HCl (pH 8.0)       50mM 
 NaCl         150mM 
 Glycerol        10%(v/v) 
 NP-40         1%(v/v) 
 Proteinase inhibitor cocktail      1X 
Western Blot Running buffer 
 NuPAGE MES SDS running buffer     20mL 
 dH20         480mL 
Western Blot Wash buffer 
 Tween-20        0.05%(v/v) 
 PBSa         to 1L 
Western Blot Blocking buffer 
 Dried milk powder (Marvel)      5%(w/v) 
 Tween-20        0.05%(v/v) 
 PBSa         to 1L 
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Western Blot Membrane stripping buffer 
 SDS         2%(v/v) 
 Tris-HCl (pH 6.8)       62.5mM 
 β-mercaptoethanol       0.01%(v/v) 
Coomassie brilliant blue de-stain solution 
 Methanol        50%(v/v) 
 Acetic Acid        12.5%(v/v) 
  dH20         37.5%(v/v) 
4% Paraformaldehyde fixing solution 
 Paraformaldehyde       4g 
 HCl         100mM 
 PBSa (10X)        10mL 
 NaOH         1mL 
 dH2O         to 100mL 
Acetone tissue fixing solution 
 Acetone        50%(v/v) 
 Methanol        50%(v/v) 
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Nucleic acid analysis 
 TBE (10X) 
  Tris        890mM 
  Boric Acid       890mM 
  EDTA (pH 8.0)      40mM 
 TE 
  Tris-HCl (pH 7.5)      100mM 
  EDTA (pH 8.0)      500mM 
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Appendix II 
pGBKT7 
pGBKT7 is produced by Clontech and used for bait protein-GAL4 DNA binding 
domain chimeric protein production and expression in yeast cells. Compatible yeast strains: 
Y187(a), Y190(a), SFY526(a), CG1945(a), HF7c(a), or AH109(a). 
pcDNA3.1(+) 
 pcDNA3.1(+) is produced by Invitrogen and used primarily as a eukaryotic 
expression vector driven by CMV promoter. Compatible E. coli strains: TOP10F´, 
DH5α™-T1R and TOP10. 
pGEMT-Easy 
 pGEMT-Easy is produced by Promega and used as a sub cloning vector containing X-
Gal blue/white reporter. Compatible E. coli strains recommended: JM109 
pGEX-6P-1 
 pGEX-6P-1 is produced by GE Healthcare and used as a prokaryotic expression 
vector resulting in chimeric expression of protein of interest with GST tag. GST epitope is 
cleavable with the application of PreScission protease (GE Healthcare). Compatible E. coli 
strains recommended: Rosseta and BL21 (D3) 
pGL3-basic 
 pGL3-basic is produced by Promega and used as a firefly luciferase reporter vector 
for promoter activity.  
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pGL3-promoter 
 pGL3-promoter is produced by Promega and used as a firefly luciferase positive 
control for the pGL3-basic vector. Contains the SV40 promoter. 
pRTS-1-tomato 
 pRTS-1-tomato was obtained from A. Brown, Imperial College London, UK. It 
contains a tetracyclin inducible bi-directional promoter. 
RCAS(A) 
 RCAS(A) was obtained from S. Hughes, National Cancer Institute, MD, USA. The 
vector is derived from the Rous Sarcoma Virus and acts as retroviral eukaryotic expression 
vectors. 
pGBKT7Meq
(1-129) 
 pGBKT7Meq
(1-129)
 was produced to carry out the yeast two-hybrid screen. The Meq 
open reading frame was truncated at the leucine zipper domain using standard cloning 
techniques to insert the N-terminus (387 bp) into the yeast expression vector using 
endonuclease restriction sites EcoRI and BamHI. 
pGBKT7Meq
(130-339) 
pGBKT7Meq
(130-339)
 was produced to carry out the yeast two-hybrid screen. The Meq 
open reading frame was truncated at the leucine zipper domain using standard cloning 
techniques to insert the C-terminus (627 bp) into the yeast expression vector using 
endonuclease restriction sites EcoRI and BamHI. 
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pcDNA3.1Meq 
pcDNA3.1Meq was isolated from a stock produced by A. Brown, Imperial College 
London, UK. Insert contains the wild-type Meq open reading frame from the RB-1B virus. 
pcDNA3.1MeqHA 
 pcDNA3.1MeqHA was produced by standard PCR techniques. HA epitope primers 
were designed at the N-terminus and pcDNA3.1Meq was used as a template for PCR. HindIII 
and EcoRI restriction sites were used for cloning into pcDNA3.1.  
pcDNA3.1Meq
BZIP 
pcDNA3.1Meq
BZIP
 was isolated from a stock produced by A. Brown, Imperial 
College London, UK. Insert contains the wild-type Meq open reading frame from the RB-1B 
strain of MDV-1 with point mutations in the leucine zipper domain. Mutations result in the 
translation of an alanine residue in place of each core leucine residue in the leucine zipper 
domain, thus rendering the leucine zipper non-viable. 
RCAS(A)MeqHA 
 RCAS(A)MeqHA was produced for use in co-immunoprecipitation and LC-MS/MS 
investigation of Meq protein-protein interactions. Standard PCR and cloning techniques were 
adopted using the pcDNA3.1MeqHA as a template. Endonuclease restriction sites ClaI and 
SpeI were used for cloning into RCAS(A). 
RCAS(A)Meq
BZIP
 
RCAS(A)Meq
BZIP 
was produced using the pcDNA3.1Meq
BZIP
 construct as a template 
for standard PCR amplification. Thereafter, classical cloning techniques were adopted using 
endonuclease restriction sites ClaI and SpeI for cloning into RCAS(A). 
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RCAS(A)L-MeqHA 
RCAS(A)L-MeqHA was produced for use in co-immunoprecipitation and LC-
MS/MS investigation of L-Meq protein-protein interactions. Standard PCR and cloning 
techniques were adopted and HA epitope primers were used for addition at the N-terminus. 
Endonuclease restriction sites ClaI and SpeI were used for cloning into RCAS(A). 
pGEX-6P-1Meq 
pGEX-6P-1Meq was produced in order to express Meq in a bacterial system for 
further use in assays such as gel shift analysis. Standard PCR and cloning techniques were 
adopted using the pcDNA3.1Meq vector as a template. Endonuclease restriction sites EcoRI 
and BamHI were used for cloning into pGEX-6P-1. 
pcDNA3.1Par-4
(125-340)
HA 
pcDNA3.1Par-4
(125-340)
HA was produced for expression and interaction studies. The 
partial Par-4 sequence was identified using 5’ RACE followed by design of primers and 
standard PCR amplification. The open reading frame was inserted into the pcDNA3.1 vector 
with and without a HA epitope tag using endonuclease restriction sites EcoRI and BamHI. 
pGEX-6P-1Par-4
(125-340) 
pGEX-6P-1 Par-4
(125-340)
 was produced in order to express chicken Par-4 in a bacterial 
system for further use in assays such as GST pull-down. Standard PCR and cloning 
techniques were adopted using pcDNA3.1Par-4
(125-340)
 as a template. Endonuclease restriction 
sites EcoRI and BamHI were used for cloning into pGEX-6P-1. 
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pRTS-Meq+Par-4
(125-340)
HA 
 pRTS-Meq+Par-4
(125-340)
HA was produced using standard PCR and cloning 
techniques. pRTS-1-tomato was used as a backbone and the tetracycline inducible tomato 
gene was removed and replaced with chicken Par-4
(125-340) 
using BglIII and AscI. The full 
length Meq gene was cloned into the bi-directional SfiI locus. 
pcDNA3.1ATF3 
 Chicken ATF3 was amplified from MSB-1 cDNA using standard PCR techniques and 
cloned into pcDNA3.1 using the EcoRI and BamHI restriction sites. 
pcDNA3.1ATF3HA 
 pcDNA3.1ATF3 was used as a template to amplify ATF3 with a N-terminal HA 
epitope tag by standard PCR techniques. The ATF3HA product was then cloned into 
pcDNA3.1 using the EcoRI and BamHI restriction sites. 
pGEX-6P-1ATF3 
pcDNA3.1ATF3 was used as a template to amplify ATF3 by standard PCR 
techniques. The ATF3 product was then cloned into pEX-6P-1 using the EcoRI and BamHI 
restriction sites. 
pGL3MDVGIprom 
 The MDV-1 glycoprotein I promoter region was amplified using standard PCR 
techniques using the pRB-1B bacterial artificial chromosome produced by L. Petherbridge, 
IAH, Berks, UK as a template. The resulting product was cloned into pGL3 basic using the 
XhoI and BglII restriction sites. 
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pcDNA3.1Pin1 
 Chicken Pin1 was amplified from cDNA isolated from MSB-1 cell cDNA using 
standard PCR techniques. The resulting fragment was then cloned into pcDNA3.1 using the 
EcoRI and BamHI restriction sites. 
pcDNA3.1Pin1HA 
Chicken Pin1 was amplified with an N-terminal HA tag using standard PCR 
techniques. The product was inserted into the pcDNA3.1 backbone using the EcoRI and 
BamHI restriction sites. 
 
 
